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Abstract 
Chronic heart failure (CHF) is a debilitating condition with a poor prognosis. 
Remodelling of the alveolar capillary membrane (ACM) protects against pulmonary 
oedema, but also results in dyspnoea and a worsened prognosis. Systemic inflammation 
associated with CHF contributes to the pathophysiology and mortality of the syndrome. 
Monocyte chemoattractant protein (MCP)-1, a CC chemokine, is elevated in patients with 
CHF and associated with increased mortality. Also, deficiencies in the bone 
morphogentic protein receptor (BMPR) signalling contribute to the pathophysiology of 
vascular remodelling in pulmonary arterial hypertension (PAH), and similar changes are 
seen in CHF. 
The mechanisms underlying lung remodelling and inflammation in CHF are not 
known. This thesis investigated the contribution of the pulmonary endothelium to 
inflammation and ACM remodelling in CHF. 
We hypothesised that pulmonary venous hypertension (PVH) in CHF imparts 
mechanical strain at the ACM stimulating the release of mediators, contributing to lung 
remodelling. To model PVH cyclic mechanical strain (CMS) was applied to monolayers 
of human lung microvascular endothelial cells (HLMVEC) and to an endothelial cell line 
(EaHy 926). MCP-1 was identified as a stretch-induced inflammatory mediator whose 
induction was dependent on activation of the extracellular signal-related kinase (ERK 
1/2) pathway. Supernatants from stretched compared to non-stretched cells increased 
fibroblast and pulmonary smooth muscle cell proliferation, and fibroblast differentiation. 
Bone morphogenetic protein (BMP)-9 stimulated pulmonary arterial endothelial cells to 
release endothelin-1 (ET-1) in a Smad-independent, p38MAPK-dependent, manner.  
In a rodent heart failure model, animals subjected to left coronary artery ligation 
had increased levels of MCP-1 in whole lung, serum and bronchoalveolar lavage. 
Animals treated with gene therapy (SERCA2a) demonstrated functional rescue with 
attenuated release of MCP-1 and ET-1.  
These data support a role for pulmonary ECs in inflammation and remodelling in 
CHF. Increased understanding of lung remodelling may lead to improved management of 
dyspnoea for CHF sufferers. (Words 299) 
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1. Chapter 1: Introduction 
1.1. Left ventricular failure- the clinical burden 
The burden of chronic heart failure (CHF) is rising owing to an increased incidence 
of, and improved survival after, myocardial infarction (Cowie et al. 1999; Tunstall-Pedoe 
et al. 1999). In the UK the estimated incidence of CHF is 66,000/year or 1-2 per 
1000/year of those aged over 25: between 20-53% occur as a consequence of myocardial 
infarction (MI) (Cowie et al. 1999; Lacey and Tabberer 2005). It was estimated that in 
2000 there were up to a half million people in the UK with CHF secondary to MI (Lacey 
and Tabberer 2005). This represents a considerable financial burden of between £181 and 
£453 million per year (0.4% - 1% of total NHS budget), which is expected to rise 
(Bonneux et al. 1994; Kelly 1997; McMurray and Stewart 2002). The burden is similar in 
other developed countries: of the entire adult American population, 2.5% (approximately 
5.3 million men and women) suffer from CHF at a cost of $35 to $60 billion per year 
(Rosamond et al. 2008). The 5 year survival of CHF is approximately 40-50% (Croft et 
al. 1999). CHF is associated with a poor quality of life, more so than for other chronic 
medical conditions, including diabetes and arthritis (Hobbs et al. 2002).  
Dyspnoea is a common and debilitating symptom, 37% of CHF patients had 
shortness of breath on moderate exertion or at rest and over half of those with severe CHF 
(New York Heart Association (NYHA) grade III-IV) would swap years of life for an 
improvement in symptoms (Lewis et al. 2001; Hobbs et al. 2002). Seventy percent of the 
total CHF health care cost is attributable to dypnoea, accounting for about 2% of the total 
health care expenditure (Stewart 2005).  
1.2. Lung remodelling in chronic heart failure 
Pulmonary venous hypertension (PVH) and oedema are not the only causes of 
dyspnoea. Patients with CHF have reduced pulmonary microvascular permeability and 
gas transfer, (Naum et al. 1992; Mettauer et al. 1999) that persisted after effective 
treatment of pulmonary oedema, suggesting a structural abnormality of the alveolar-
capillary membrane (ACM) (Agostoni et al. 2000). Impairment in ACM conductance is 
associated with limited exercise capacity and a worsened prognosis (Puri et al. 1995; 
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Guazzi et al. 2002).  Fibrotic changes in the pulmonary circulation (vascular remodelling) 
and alveolar walls (structural remodelling) contribute to functional limitation by reducing 
lung compliance and diffusing capacity (Gehlbach and Geppert 2004). Structural 
remodelling of the lungs in CHF is characterized by proliferation of myofibroblasts with 
excess collagen and reticulin deposition in alveolar septae (Jasmin et al. 2003; Kingsbury 
et al. 2003). Changes are not always apparent under light microscopy, but are reflected in 
increased dry lung weights without a change in wet to dry weight ratios, suggesting 
parenchymal remodelling in the absence of pulmonary oedema (Dixon et al. 2009). 
Vascular remodelling increases pulmonary vascular resistance (PVR) and 
pulmonary hypertension (PAH) is a consequence.  Over time, the classic changes of the 
distal pulmonary vasculature are seen, including medial hypertrophy, intimal proliferation 
and fibrosis, and adventitial changes. Increased right ventricular (RV) systolic pressure is 
an independent predictor of short and long term survival and predicts post-operative RV 
failure following heart transplant (Kirklin et al. 1988; Kjaergaard et al. 2007). The 
development of PAH in CHF is not, however, uniform or well understood with some 
patients developing vasodilator sensitive PAH, whilst others have irreversible disease 
(Gehlbach and Geppert 2004).  
1.3. Pathophysiology of structural remodelling of the lung 
The mechanisms underlying the structural remodelling of the ACM in response to 
increased pressure are poorly understood. PAH secondary to CHF is “post-capillary” and 
hence rises in left atrial pressure (LAP) will impart a back-pressure, causing the 
pulmonary veins and the microvasculature to distend. This affects the ACM in two ways: 
firstly, acutely increased pressure causes physical disruption of the tissues and cells 
(stress failure), and secondly, mechanical strain is converted into chemical signals 
(mechanotransduction) resulting in activation of proinflammatory, mitogenic and 
fibrogenic pathways. 
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1.3.1. Physiology of the alveolar capillary membrane 
The structure of the ACM reflects its physiological roles: 
a. To allow gas exchange between blood and alveolar air 
b. To provide a barrier regulating fluid and solute flux into the 
alveolus from the blood and interstitium 
c. To promote active fluid clearance from the alveolar lumen to the 
interstitial space 
To facilitate these functions the ACM is composed of three layers: the alveolar 
epithelium, the capillary endothelium and the lamina densa lying between the two. Due to 
the composition of the interstitium the ACM is asymmetrical, having a thinner side that is 
predominantly involved in gas diffusion, and a thicker side that is principally responsible 
for the control of fluid flux and ACM permeability. This latter layer is comprised of a real 
basement membrane lying between the epithelial and endothelial cells (EC). Alveolar 
epithelial cells are less permeable than their neighbouring capillary EC, but have an 
important role in ion transport at the alveolus, and the removal of fluid. Two types of 
epithelial cells are resident in the alveolus: Type I cells represent 90% of the total alveolar 
surface and in addition to providing mechanical support have roles in water and ion 
transport, host defence and tumour suppression (Dahlin et al. 2004). Type II cells (AT2) 
predominantly secrete surfactant and are able to differentiate into type I cells after 
alveolar injury. Capillary tight junctions provide cell-cell adhesion and maintain barrier 
function.  
Fibroblasts, spindle-shaped mesenchymal-derived cells, play essential roles in the 
regulation of extracellular matrix (ECM). This includes maintenance of ECM fluid 
volume and pressure properties, as well as regulating its composition (McAnulty 2007). 
Fibroblasts constantly synthesise and degrade components of the ECM, and synthesise a 
variety of compounds including collagens, fibronectin, reticulin and proteoglycans 
(McAnulty 2007). One mechanism by which they regulate control is the production of 
matrix-degrading matrix metalloproteinases (MMPs) as well as tissue inhibitors of MMPs 
(TIMPs). Fibroblast numbers increase in response to injury with the release of local 
mediators including: endothelin-1 (ET-1), monocyte chemoattractant protein (MCP)-1 
and interleukin-6 (IL-6) (Ross et al. 2010). Fibroblast precursors may be local, such as 
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resident mesenchymal stem cells; distant, from bone marrow-derived fibrocytes that 
circulate in the blood stream; or by the differentiation of local epithelial cells: epithelial 
mesenchymal transition (EMT) (McAnulty 2007; Willis and Borok 2007; Laurent et al. 
2008). Hence, the various types of fibroblast in the lung parenchyma play key roles in 
alveolar homeostasis, wound repair and the pathophysiology of disease. 
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Figure 1.1 Diagrammatic representations of 
the normal human alveolus (A) and the 
interactions between cells of the alveolar-
capillary membrane (B) 
The cellular contacts made by the central 
interstitial fibroblast are numbered 
AL- airspace; CL- capillary lumen 
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1.3.2. Physical disruption- stress failure   
Pulmonary transmural pressures in excess of 24mmHg may cause reversible 
disruption of the ACM (West 2000). Pulmonary arterial wedge pressures in excess of 
20mmHg may be achieved in normal healthy individuals in response to exercise, but also 
after MI (Wagner et al. 1986). Physical stress leads to high permeability pulmonary 
oedema, decompartmentalisation of mediators and extravasation of red blood cells. A 
significant proportion of the fluid is absorbed by the extravascular spaces, particularly the 
thicker portion of the ACM.  In the short term these ultrastructural changes are fully 
reversible (Elliott et al. 1992). Collagen IV, the major component of the lamina densa, 
provides mechanical strength to the ACM which facilitates the restoration of structure 
when capillary pressure returns to normal (West 2000). In response to continued physical 
stress from raised LAP, the ACM is strengthened by increased deposition of collagen IV 
(i.e. lung remodelling) leading to protection against pulmonary oedema seen in patients 
with CHF or long standing mitral stenosis (Townsley et al. 1995). Although this 
thickening is protective against higher LAP, the resulting increased resistance across the 
ACM impairs gas transfer resulting in dyspnoea.  
1.3.3. Mechanical activation of cellular pathways 
Physical forces, such as shear and stretch, play an important role in physiological 
processes and homeostasis in the vasculature (Chien 2007). These effects are mediated by 
the sensing of such forces and their conversion into biochemical signals- 
mechanotransduction. Mechanical strain applied to monolayers of EC results in 
upregulation of, amongst others, cytokines (Interleukin-8 (IL-8), IL-6, cell surface 
molecules (intercellular adhesion molecule (ICAM)-1 and P-Selectin), and ET-1, 
although the responses of human lung microvascular endothelial cells (HLMVEC) have 
been largely ignored. (Okada et al. 1998; Cheng et al. 2001; Sasamoto et al. 2005).   
Isolated-perfused rat lung preparations allow alterations in pulmonary venous (PV) 
pressure without the effects of altering flow. Raising PV pressure increased nitric oxide 
(NO) production in a time dependent manner (Kuebler et al. 2003). Second messenger 
responses were seen when PV pressure was increased by only 4mmHg, suggesting that 
the pulmonary microvasculature is sensitive to mechanical strain (Kuebler and Kuppe 
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2002; Chien 2007). All components of the ACM potentially play a role in 
mechanotransduction and remodelling: 
• The endothelium is the immediate upstream target of raised LAP and will 
therefore be directly exposed to increased PV pressures.  
• The epithelium, comprised of alveolar type 1 and type 2 (AT1 & 2) cells 
will be exposed to the spill over of mediators as a result of stress failure, 
can be injured by recurrent episodes of pulmonary oedema and its resident 
cells are thought to be important sensors of mechanical strain in other 
disease processes, including ventilator induced lung injury (VILI).  
• Interstitial cells, such as fibroblasts and pericytes are also integral in the 
structural skeleton of the lung and as such are likely to sense tensile strain 
at the ACM secondary to raised LAP (Stenmark et al. 2002).  
Here, the effects of mechanical strain on endothelial cells will be studied, but the 
relative importance of the various cellular constituents of the ACM has not been 
established.  
1.3.4. Fibrogenesis at the alveolar capillary membrane 
ECM deposition causes thickening of the ACM in CHF which may protect against 
pulmonary oedema, but decreased lung compliance, increased diffusion distances and 
impaired gas transfer contribute to dyspnoea. The exact mechanism for these changes is 
unclear, but many potential fibrogenic mediators are found in increased levels in CHF.  
Pulmonary fibrosis and airway remodelling secondary to other pulmonary 
pathologies are mediated by transforming growth factor-beta (TGF-β), ET-1 and 
connective tissue growth factor (CTGF), amongst others. Table A.1 (Appendix A) 
summarises mediators that are increased in CHF patients with potential 
pathophysiological roles in other causes of pulmonary fibrosis.  
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1.3.4.1. Potential fibrogenic mediators in chronic heart failure:  
Endothelin-1  
Increased ET-1 activity contributes to vascular remodelling in pulmonary arterial 
hypertension and CHF (Cody et al. 1992). ET-1 is implicated in the pathophysiology of 
pulmonary fibrosis (reviewed (Ross et al. 2010)) and increased expression and release of 
ET-1 is seen in the lungs of both humans and animal models with pulmonary fibrosis 
(Uguccioni et al. 1995; Park et al. 1997; Mutsaers et al. 1998; Shahar et al. 1999). ET-1 
is a fibrogenic mediator: activation of the endothelin A receptor (ETAR), the predominant 
receptor subtype, on human fibroblasts stimulates collagen 1 synthesis and breakdown, 
whilst the endothelin B receptor (ETBR) stimulates synthesis (Guarda et al. 1993; Shi-
Wen et al. 2004; Horstmeyer et al. 2005). Furthermore, ET-1 induces alveolar EMT via 
the production of TGF-. ET-1 is released by EC subjected to mechanical strain and as 
such is a potential candidate in the pathophysiology of pulmonary venous hypertension 
(PVH) induced AMC fibrogenesis (Cheng et al. 2001). The biology of ET-1 in discussed 
later (chapter 1.x). 
Recently, however, bosentan, a dual endothelin receptor antagonist (ETRA) did not 
improve pulmonary structural remodelling at 5-6 weeks post MI (Jiang et al. 2010). This 
suggests that either dual receptor antagonism is not beneficial in CHF, ET-1 confers some 
benefit or ET-1 is not solely important in the pathophysiology of this disease (Jiang et al. 
2010). 
1.3.4.2. Connective Tissue Growth Factor 
CTGF is a secreted ECM-associated growth factor involved in multiple cellular 
events, including synthesis of ECM and proliferation of fibroblasts (Hishikawa et al. 
1999; Shimo et al. 1999). CTGF gene expression is increased in CHF lung and localised 
to alveolar macrophages (Ahmed et al. 2007).  
1.3.4.3. Interleukin-6 (IL-6) 
IL-6 stimulates proliferation and inhibits apoptosis of fibroblasts from patients with 
idiopathic pulmonary fibrosis (Moodley et al. 2003; Moodley et al. 2003). Elevated IL-6 
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levels occur in serum of CHF patients, correlating with lower functional class, worsening 
left ventricular (LV) function and poorer prognosis (Tsutamoto et al. 1995; Lommi et al. 
1997; Raymond et al. 2001). IL-6 expression is localised to the endothelium in lungs of 
animals with CHF (Gaertner et al. 2003).  
1.3.4.4. Monocyte chemoattractant protein (MCP)-1 
Chemokines co-operate with profibrotic cytokines in the development of fibrosis by 
recruiting myofibroblasts, macrophages and other cells to the site of injury. MCP-1 levels 
are increased in animal models of pulmonary fibrosis and in lung tissue and 
bronchoalveolar lavage (BAL) fluid of patients with varying forms of pulmonary fibrosis 
(Smith et al. 1995; Suga et al. 1999). MCP-1 promoted vascular smooth muscle cell 
(VSMC) proliferation and migration via the autocrine production of vascular endothelial 
growth factor (VEGF) and lung fibroblasts increase collagen production in response to 
MCP-1 via autocrine production of TGF- (Gharaee-Kermani et al. 1996; Parenti et al. 
2004). MCP-1 signals via its receptor CCR2. CCR2 -/-mice have less fibrosis in a 
bleomycin model of pulmonary fibrosis, with less -smooth muscle actin (SMA) 
expression, a blunted response to TGF- and reduced MMP-2 and MMP-9 levels 
(Gharaee-Kermani et al. 2003; Okuma et al. 2004). Furthermore, transfection of a mutant 
MCP-1 gene into skeletal muscle of mice exposed to intratracheal bleomycin reduced 
pulmonary fibrosis. This effect was only seen in animals in which the mutant gene was 
transfected at 10-14 days after bleomycin instillation, but not earlier, suggesting that 
MCP-1 has a role in the progression of fibrosis, but not in early lung inflammation 
(Inoshima et al. 2004). 
MCP-1 levels were elevated in the serum of patients with CHF, the source of which 
is not clear (Aukrust et al. 1998). It is therefore possible that endothelium-derived MCP-1 
is an active mediator of lung remodelling in CHF. 
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1.4. Chronic heart failure and vascular remodelling 
In CHF the pulmonary arteries exhibit intimal fibrosis, and medial hypertrophy with 
muscularisation of the small arterioles: i.e. vascular remodelling analogous to the 
classical changes seen in idiopathic PAH. It is unclear how these changes develop, but 
several potential stimuli exist: chronic strain of the pulmonary veins and pulmonary 
microvasculature (PMV), chronic hypoxia and in situ thrombosis. In the majority, 
vascular remodelling occurs alongside deterioration in the left ventricular function, but in 
a proportion of patients the remodelling is out of proportion to the LV failure. Why this 
occurs is unclear, but given that the vascular changes seen are similar to those of 
idiopathic PAH, it is possible that similar mechanisms are occurring. 
 
1.4.1. Pathophysiology of vascular remodelling in chronic heart failure 
The pathophysiology underlying pulmonary vascular remodelling specific to PAH 
secondary to CHF is not understood. The vessel changes mimic those seen in idiopathic 
and other forms of PAH, but differences exist that suggest a possible difference in 
pathophysiology (Lee et al. 1998).  Furthermore, therapies with proven benefit in 
idiopathic PAH have not translated to improved outcomes in CHF (table 1.1) (Rich and 
McLaughlin 2003; McMurray et al. 2007). 
 
1.4.1.1. Endothelin-1 and pulmonary vascular remodelling 
Elevated ET-1 levels in lungs and plasma of patients with idiopathic PAH play a 
crucial role in vascular remodelling and development of pulmonary hypertension 
(Kirchengast and Munter 1999). ET-1 acts on pulmonary artery smooth muscle cells 
(PASMC) causing vasoconstriction and cellular proliferation, primarily via ETAR 
(Bonvallet et al. 1993; Zamora et al. 1993).  It is therefore likely that it is also a 
significant contributor to the pathophysiology of CHF related vascular remodelling, but 
therapeutic benefits of ETRA have been less pronounced in this group of patients. 
Initially it was considered that the poor results were due to the dual blockade of ETAR 
and ETBR, potentially because ETBR is responsible for ET-1 clearance and, hence 
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antagonism would inhibit this (Dupuis et al. 1998). Subsequent trials of selective ETAR 
antagonists have also been disappointing (table 1.1) (Rich and McLaughlin 2003; 
McMurray et al. 2007; Kirkby et al. 2008). Consequently either elevated ET-1 levels 
must confer some benefit, in the lung or elsewhere, or other molecules and processes are 
also important. 
Table 1.1 Summary of the trials of endothelin receptor antagonists in pulmonary hypertension and 
acute and chronic heart failure (from Rich (Rich and McLaughlin 2003)) 
Bosentan is a mixed ETAR and ETBR antagonist. All others are selective ETAR antagonists 
 
1.4.1.2. Bone morphogenetic proteins (BMP) and their receptors (BMPR) 
Bone morphogenetic proteins (BMP) are growth factors that play a crucial role 
during embryonic development, skeletal development and cell fate determination (Zeng et 
al. 2010). They form the largest subgroup of the TGF- superfamily and elicit their 
cellular effects through specific serine/threonine kinase receptors. Interest in their role in 
vascular remodelling in PAH has been driven by the discovery that heterozygous germ 
line mutations were present in the gene encoding for the type 2 BMP receptor (BMPR2) 
in families with PAH (Deng et al. 2000; Lane et al. 2000). Subsequently mutations in the 
BMPR2 gene have been found in approximately 80% of cases of familial PAH (Machado 
et al. 2006). Importantly however, there is often markedly reduced genetic penetrance in 
families with PAH, suggesting that a “second-hit” is required to induce clinical disease.  
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Normal signalling of BMPs through BMPR2 activates an associated type 1 receptor 
(BMPR1a or 1b), with subsequent phosphorylation of downstream signalling molecules 
termed Smads (Mothers Against Decapentaplegic Homolog proteins) (figure 1.2). Whilst 
BMPR1/2 signal through receptor Smads (R-Smads) 1, 5 and 8, TGF- signals through 
Smads 2 and 3. Both then utilise a common (co)-Smad, Smad-4, to form a complex that 
translocates to the nucleus to alter gene expression (figure 1.2). Smad regulated genes are 
known to play significant roles in the maintenance and repair of adult tissues by 
controlling growth, differentiation and apoptosis of a wide range of cells (Kawabata et al. 
1998; Miyazono et al. 2005; David et al. 2008). In addition, phosphorylated Smads 1 and 
5 are inhibitory to Smads 2 and 3 and vice versa. It is therefore thought that a loss of 
BMPR function critically alters the control of BMP-regulated genes in PASMC and 
pulmonary arterial endothelial cells (PAEC) disrupting the balance of BMP-TGF- 
signalling. These changes predisopse to the development of pulmonary vascular 
remodelling (Davies and Morrell 2008). 
Abbreviations: TGF-- transforming growth factor-;BMP- bone morphogenetic protein; BMPR- BMP 
receptor; TR- TGF- receptor 
 
A decrease in BMPR1a expression occurs in the lungs of patients with CHF, 
possibly secondary to increased levels of angiopoeitin-1 (Ang-1) (Du et al. 2003). This 
Figure 1.2 Schematic representation of TGF- and BMP signalling through Smad pathways 
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may provide the predisposition to vascular remodelling in CHF, with other stimuli (for 
example: mechanical strain, immune activation or recurrent stress failure) providing the 
“second-hit”. 
 
1.5. Inflammation in heart failure 
Heart failure is a pro-inflammatory state. Tumour necrosis factor alpha (TNF-) 
was first shown to be raised in the serum of patients with CHF (Levine et al. 1990) and 
since, several studies have presented a role for immune mechanisms in the pathogenesis 
of CHF (reviewed (Mari et al. 2002); table A.1- Appendix A). Proinflammatory cytokines 
(e.g. IL-6, TNF-) are involved in cardiac depression and progression of heart failure, but 
chemokines (IL-8, MCP-1), adhesion molecules (ICAM-1), NO and ET-1 are also 
thought to be relevant to the pathogenesis (Aukrust et al. 2001; Aukrust et al. 2004). 
Levels of both cytokines, such as IL-6, and chemokines, such as MCP-1 are raised in 
CHF and correlate with disease progression and outcome (Aukrust et al. 1998; Damas et 
al. 2000). These increases occur independent of the aetiology of CHF, suggesting a 
potential common pathogenic pathway (Gullestad and Aukrust 2005).  
It is still unclear what the origin of immune activation in CHF is. Two main 
hypotheses predominate: firstly it is proposed that an inflammatory response results from 
the translocation of bacteria and their cell wall components across an oedematous gut 
wall. Alternatively, it is suggested that inflammatory mediators are released directly by 
the infarcted myocardium: TNF- is released by the failing myocardium, but not by the 
normal heart (Torre-Amione et al. 1996). It is likely that neither is wholly responsible and 
other factors, such as hypoxia, contribute. The lung is a potential alternative source of 
inflammatory mediators and table A.2 (Appendix A) summarises pertinent animal studies 
of inflammatory mediators in the lung in CHF. IL-6 and MCP-1 gene expression are 
increased in lungs of animals with experimentally induced CHF, with IL-6 localised to 
the endothelium (Gaertner et al. 2003). Furthermore, mechanical strain is a potent inducer 
of inflammation in other pathologies, such as ventilator associated lung injury (VALI). 
EC have been repeatedly shown to be mechanosensitive and HLMVEC increase 
metalloproteinase expression in response to mechanical strain (Haseneen et al. 2003). 
Other endothelial cells also release MCP-1, ICAM-1 and IL-8 in response to CMS (Wung 
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et al. 1997; Cheng et al. 1998). It is therefore possible that, as the direct upstream target 
of raised LAP in heart failure, the pulmonary microvasculature is exposed to high levels 
of mechanical strain that leads to the production of inflammatory mediators.  
The pathogenic role of cytokines and chemokines in CHF is also not completely 
understood, but is likely to be multifactoral (figure 1.3). In addition to the well 
established role of chemokines in the recruitment of leucocytes, they also regulate cardiac 
fibrosis, angiogenesis and cardiomyocyte apoptosis (Koch et al. 1992; Luster 1998). The 
diversity of cytokines and chemokines and their range of functions might explain why 
initial clinical trials concentrating on anti-TNF- therapy have been neutral or potentially 
detrimental (Lisman et al. 2002; Louis et al. 2002).  
Abbreviations: CHF – chronic heart failure; EC- endothelial cell; LV- left ventricle; RV- right ventricle; IL-
6- ilterleukin-6; TNF- tumour necrosis factor; MCP- monocyte chemoattractant protein; ET-1 endothelin-1. 
1.5.1. Monocyte chemoattractant protein-1 and heart failure 
MCP-1 is implicated in many aspects of cardiovascular disease. Given the 
extensive work into the role of MCP-1, there is little literature describing its specific 
effect on the lung in heart failure. To review its role in all aspects of cardiovascular 
disease is outside the scope of this work, but an excellent overview has been recently 
Figure 1.3 Schematic representation of the pathogenic role of various mediators in chronic heart 
failure (CHF)  
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written (Niu and Kolattukudy 2009). Instead the aspects of the function of MCP-1 in CHF 
that might pertain to the lung will be reviewed. 
MCP-1 has roles in heart failure in both the acute and chronic phases. It is 
responsible for mononuclear cell recruitment into the ischaemic myocardium in the first 5 
hours of reperfusion (Birdsall et al. 1997). Polymorphisms in the CCR2, the receptor 
through which MCP-1 acts, play a role in determining the incidence and severity of CHF 
after MI in humans (Ortlepp et al. 2003). Neutralising antibodies to MCP-1 and anti-
MCP-1 gene therapy decreased infarct size, reduced LV dilatation and preserved cardiac 
function in mice (Ono et al. 1999; Hayashidani et al. 2003). Transgenic mice over-
expressing MCP-1 in the myocardium develop increased LV mass and ventricular 
dysfunction, with homozygotes only surviving to half the age of heterozygotes 
(Kolattukudy et al. 1998). The myocardium of these mice not only showed infiltrating 
monocytes/macrophages, but also thrombotic occlusive arteriolar vasculopathy (strikingly 
similar to that seen in PAH), cardiomyocyte degeneration and cardiac fibrosis (Niu and 
Kolattukudy 2009). Post MI however, MCP-1 also had a protective role, preventing 
hypoxia induced myocyte death in vitro and reducing infarct size following ischaemia-
reperfusion in vivo, possibly via MCP-1 stimulated TNF- release (Tarzami et al. 2002; 
Martire et al. 2003). Transgenic MCP-1 over-expressing mice have reduced infarct area 
and scar formation, with less LV dysfunction after MI (Morimoto et al. 2006). These 
changes were associated with increased myocardial IL-6 expression and myofibroblast 
accumulation. MCP-1 and IL-6 were shown to act by synergistically activating the signal 
transducer and activator of transcription-3 (STAT-3) pathway. MCP-1 null mice and 
genetic deletion of CCR2 resulted in decreased cytokine expression, less LV remodelling 
and decreased myofibroblast accumulation. Together these data suggest MCP-1 plays an 
important role over time in cardiac injury, providing early protection and later facilitating 
tissue repair and remodelling (Niu and Kolattukudy 2009). 
In addition to the crucial role in monocyte recruitment, MCP-1 is able to exert its 
actions via the other major cell types in the heart. MCP-1 stimulated cardiac myocytes 
and VSMC to release MMPs, which regulate ECM turn-over, an effect that was not 
confined to the lung (Yamamoto et al. 2000; Niu and Kolattukudy 2009). By stimulating 
macrophages to release TGF, MCP-1 is able to promote the production of ECM (Wolf et 
al. 2002; Frangogiannis et al. 2007). Furthermore, MCP-1 may be involved in the 
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recruitment and differentiation of bone-marrow-derived fibrocytes (fibroblast precursors) 
(Haudek et al. 2006; Morimoto et al. 2006). 
Aside from work indicating elevated MCP-1 expression in lungs of rodents with 
CHF, the effects on the lungs of altering MCP-1 levels, be it pharmacologically or 
genetically, are not known. MCP-1 inhibition attenuated the development of PAH in an 
inflammatory model (monocrolatine). Similarly anti-MCP-1 therapy or absence of CCR2 
attenuated bleomycin induced lung fibrosis (Ikeda et al. 2002; Gharaee-Kermani et al. 
2003; Inoshima et al. 2004). The changes seen at the ACM in heart failure involve 
deposition of ECM components and increased inflammation. Inhibition of MCP-1 may 
therefore be an attractive therapeutic target. 
1.5.2. Interleukin-6 in heart failure 
As noted above (chapter 1.3.4.2) IL-6 plasma levels are elevated in CHF (table 
A.1, Appendix A) and have been associated with worse functional class and hospital 
mortality. IL-6 plasma levels are increased early in patients with left ventricular 
dysfunction prior to the development of the CHF syndrome, and are an independent 
predictor of mortality (Deswal et al. 2001; Raymond et al. 2001). The exact mechanism 
through which it exerts its deleterious effects is unknown, but cardiac myocytes express 
the receptor glycoprotein 130 (gp130) and through this IL-6 stimulates LV hypertrophy 
(Kunisada et al. 1996; Yamauchi-Takihara et al. 1996). In contrast, over-expression of 
leukaemic inhibitory factor, an IL-6 related cytokine, post MI improved LV function and 
reduced LV dilatation (Berry et al. 2004). The role of IL-6 is complicated and may be 
pro- and anti-inflammatory. In addition to its production in ischaemic cardiac myocytes, 
elevated IL-6 gene expression is localised to the pulmonary microvascular endothelium 
and plasma levels increase across the lung in CHF (Kaneko et al. 1997; Gwechenberger 
et al. 1999; Mabuchi et al. 2002; Gaertner et al. 2003; Tonnessen et al. 2003).  
Interestingly, the “step-up” in IL-6 levels across the lung is not seen in PAH, suggesting 
different pathophysiological mechanisms are occurring (Selimovic et al. 2009). 
Consequently the lung might be a significant contributor to elevated IL-6 levels in CHF 
and it may play a role in the pathophysiology of the changes seen at the ACM. 
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1.6. Mechanotransduction in endothelial cells – mediators of 
mechanical sensation and intra-cellular signalling 
1.6.1. Introduction 
The field of mechanobiology has been driven by a search for specialized 
mechanotransducer molecules that change their chemical activity state when they are 
mechanically distorted, and thereby convert mechanical into biochemical energy. 
However, the function of virtually every molecule could potentially be altered by 
mechanical strain because all bioactive molecules move between extended and contracted 
forms and rearranged internal domains. The more difficult challenge is to explain how 
forces that are transmitted through living organs and across multiple size scales are 
converted into biochemical alterations through specific transduction molecules, rather 
than altering the activities of all cellular components. 
The mechanical forces applied to various organs differ. For example, the vascular 
endothelium is normally subjected to laminar flow but cell behaviour is fundamentally 
altered by the loss of laminar flow and by the sensation of disrupted flow. The work 
addressing shear stress is vast (reviewed-(Lehoux et al. 2006)) and is outside the scope of 
this thesis, in which mechanical strain will be primarily addressed. Similarly, the inner ear 
is specifically adapted to sense sound owing in part to the presence of hair cells that sit 
between two specialized membranes of extra-cellular matrix; one of which is oscillated 
by sound waves that have passed through the middle ear and the other which is stiff. Very 
simply, deformations applied to the hair cells are transduced into depolarisation of 
auditory nerves by stretch-sensitive ion channels (Ingber 2006). The auditory system 
exhibits an important principle of mechanosensation, namely that tissues and cells require 
a degree of stiffness in order to sense mechanical strain {Ingber, 2006 #757}.  
The cells of the ACM will experience strain from two directions: cyclic strain of 
the alveolar walls throughout the normal respiratory cycle, and cyclical pressure waves at 
the endothelium secondary to contractions of the right ventricle. In the lung the residual 
filling pressure that remains after expiration is responsible for tensing and stiffening the 
matrix that surrounds each alveolus, and for resisting surface tension forces acting on the 
epithelium; this balance of forces stabilizes the alveoli in an open form (Stamenovic 
1990). Expiration and inspiration impose complex micromechanical forces in the lung 
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parenchyma, including lengthening and compression of alveolar walls with corresponding 
effects on collagen fibers (Suki et al. 2005).  
The rest of this discussion of mechanotransduction will concentrate on the forces 
transmitted to an endothelial cell in an over-distended capillary – that is a cell that is 
anchored to matrix whose surface area changes with pressure. The effects of cyclic 
distension imparted to the ACM by ventilation will not be considered, although they are 
likely to be similar to the cyclic strain imparted by raised left atrial pressure. 
1.6.2. Tensegrity 
Tensegrity is a building principle that was first described by the architect Fuller 
and defined as structures that stabilize their shape by continuous tension or ‘tensional 
integrity’ rather than by continuous compression as in for example a stone arch (Fuller 
1961). Eukaryotic cells contain an intricate molecular framework, the cytoskeleton, 
composed of microfilaments, microtubules and intermediate filaments. The cellular 
tensegrity model proposes that the whole cell is a pre-stressed structure, resulting from a 
balance between forces generated by contractile microfilaments and intermediate 
filaments, and resisted by interconnected structural elements that resist compression, most 
notably, microtubules and focal adhesions to the ECM (Ingber 2003). Supporting this 
model are observations using magnetic twisting cytometry to stress transmembrane 
receptors. Stressing acetylated-low density lipoprotein or histocompatibility antigens was 
associated with minimal resistance, but when β1 integrins were similarly stressed the 
cells responded by increasing their stiffness in direct proportion to the applied stress. 
Importantly, the integrin-dependent stiffening response was inhibited by disrupting 
microfilaments, microtubules or intermediate filaments, and completely prevented by 
disrupting all three at once (Wang et al. 1993).  
1.6.3. Extracellular matrix to integrin to cytoskeletal pathways 
The adhesion machinery of cells consists of specialised contact sites or focal 
adhesions, formed by transmembrane receptors associated with the cytoskeleton. These 
sites serve as local anchors, linking cells to the ECM or to their neighbours, in a way that 
supports the assembly of tissues with specific structural and mechanical properties. 
Recent studies have established that at these sites, cells can not only sense the chemical 
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properties of external surfaces (e.g. the presence of diverse ECM ligands and cell–cell 
adhesion molecules), but also a variety of mechanical cues, such as mechanical forces 
(stresses) and deformations (strains). The latter include global tension generated within 
the tissue, external mechanical perturbation, shear stress and intracellular forces applied 
to the adhesion sites by the cell's own contractile system. 
Focal adhesions are large (several microns long), polarised adhesion sites 
associated at their proximal ends with contractile actin filaments - stress fibres. Focal 
adhesions usually evolve from focal complexes and small (less than a micron) adhesions 
that are continuously turned over under protruding lamellipodia (Zaidel-Bar et al. 2003). 
Their formation depends either on ‘natural’ matrix proteins, or on RGD (arginine-glycine-
aspartate) peptides that bind different integrins, mainly 51 and v3. Integrins are cell 
surface receptors, consisting of an alpha (α) and a beta (β) subunit that recognise as 
ligands components of the ECM. Integrins influence cell adhesion, spreading and 
migration as well as fundamental responses to the immediate environment including 
survival, progression through the cell cycle and differentiation. Furthermore, integrin 
ligation influences the expression of an increasing list of genes, including modulators of 
apoptosis, MMPs, cytokines and growth factors  
Focal adhesion formation and maintenance, depends upon the continuous 
application of local force applied by the cell's contractile machinery. Inhibition of 
myosin-II-driven contractility leads to the accumulation of focal complexes at the 
expense of focal adhesions (Totsukawa et al. 2004), whereas activation of myosin II 
induces assembly (Leopoldt et al. 2001). Similarly, the application of external force 
stimulates the growth of focal adhesions in the direction of the force even when myosin II 
activity is suppressed (Riveline et al. 2001). In HUVEC exposed to mechanical strain 1 
integrin reorganises in a linear pattern creating a fusion of focal adhesion plaques (Yano 
et al. 1997). Finally, mechanical manipulation of fibronectin-coated beads on the cell's 
dorsal surface reinforces the indirect interactions of these beads with the actin 
cytoskeleton (Galbraith et al. 2002). Thus, focal adhesions act as mechanosensing 
devices, responding to local force by increased assembly and to the relaxation of force by 
disassembly. Although other types of integrin-mediated adhesions besides focal adhesions 
demonstrate mechanosensitivity, the mode of response and the underlying molecular 
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mechanisms are not necessarily identical. For example, fibrillar adhesions associated with 
ECM fibrils evolve from focal adhesions in a force-dependent manner, although they do 
not disassemble when the force is relaxed (Zamir et al. 2000). Podosomes, another type 
of integrin-mediated contact, respond to substrate rigidity differently in that their lifespan 
rather than their shape is affected (Collin et al. 2006). 
Table 1.2 Mechanical activation of enzymes through integrins from Moore et al 2010 (Moore et al. 
2010) 
Abbreviations: FAK- focal adhesion kinase; MAPKs- mitogen activated protein kinases; GTP- glycerine 
tri-phosphate  
Experiments that involved twisting β1 integrin ligand-coated magnetic beads 
elegantly demonstrated that mechanotransduction requires integrins to be bound to ligand 
rather than being initiated by distortion of the receptors alone (Meyer et al. 2000). 
However, beyond this the interaction of the dynamic signalling moieties in focal 
adhesions and their down-stream targets involved in mechanotransduction are complex 
and vary according to the type of stimulus and cell. On the basis of data from several 
experimental systems, protein tyrosine kinases FAK, Src and Fyn, and the tyrosine 
phosphatases RPTP- and SHP-2 are involved in integrin-dependent mechanosensitivity 
(table 1.2; reviewed (Bershadsky et al. 2006)). The underlying mechanisms may involve 
the modulation of phosphorylation-dependent protein–protein interactions that are highly 
prominent in focal adhesions (Ballestrem et al. 2006). Adaptor proteins such as paxillin, 
p130Cas and zyxin are probably involved in the cellular response to mechanical stress. 
Zyxin translocates from focal adhesions to stress fibres following substrate stretching, 
when force is applied (Yoshigi et al. 2005). The adhesion-dependent pathways regulating 
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the activities of small Rho family GTPases (Tzima 2006) and Rap1 (Sawada et al. 2001) 
are also potential mediators of force-dependent regulation of focal adhesions. All these 
and other signalling events have yet to be integrated into a unified molecular scheme.  
In terms of understanding the cell’s response to mechanical forces, it seems clear 
that the machinery involved in sticking cells to their substrates is inevitably involved, not 
only because these assemblies are intensely active receivers and emitters of intracellular 
signals, but also because cells could not sense stretch without being anchored at multiple 
sites. Thus, it will not be possible to learn about mechosensitivity if in so doing adhesion 
is affected and it seems likely that mediators of mechanosensation will also control 
related cell behaviours such as adhesion and motility. Finally, it is not known how forces 
are sensed at focal adhesions, but three models have been proposed (figure 1.4) 
(Bershadsky et al. 2006). In the Stress-driven model A, the conformation of a protein is 
changed with a change in enzyme activity when ECM moves relative to the cytoskeleton. 
Secondly, in the Strain-driven model activation of the mechanosensitive proteins is 
triggered by compression of the top of the lower layer of the focal adhesion relatively to 
its bottom (B). Thirdly, the Thermodynamic model is specific to force-induced focal 
adhesion assembly and relies upon the effect of recruitment of components to the site to 
decrease strain (C). 
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A: Stress-driven model for adhesion site mechanosensitivity. The mechanosensitive protein unit 
(depicted by red symbol) is connected to an actin filament moving with retrograde actin flow. This results 
in dragging force acting on the protein unit from the filament. The mechanosensitive unit can be in one of 
two states that differ in the strength of link to the actin filament. (a) Passive state corresponds to a weak slip 
link. (b) Active state is characterized by a reinforced link. Transition from the passive to the active state 
occurs when the dragging force overcomes a critical value and involves a conformational change of the 
mechanosensitive protein. The model suggests a mechanism for maturation of focal complexes controlled 
by elasticity of the extracellular substrate, which undergoes deformation upon the force transmitted by the 
focal complex proteins 
 
B: Strain-driven mechanism for focal adhesion mechanosensitivity. The focal adhesion (FA) consists of 
two layers: the lower layer, containing the mechanosensitive proteins, and the upper layer, which is directly 
connected to the actin filaments and transmits the force to the lower layer. Activation of the 
mechanosensitive proteins driving the FA assembly is suggested to be triggered by compression of the top 
of the lower layer relatively to its bottom. This strain is generated at the ‘front’ edge of the FA. The model 
explains the FA growth in the direction of the pulling force 
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C: Thermodynamic model for focal adhesion mechanosensitivity. (a) The focal adhesion (FA) is 
modelled as an aggregate of elastic building blocks illustrated by hexagons containing short springs. The 
FA is connected to the substrate by links represented by small rods distributed along the aggregate surface. 
Free building blocks and free links enabling the FA assembly are distributed outside the focal adhesion. (b) 
Application of the pulling forces results in aggregate stretching and related accumulation of the elastic 
energy. The points of force application are distributed along the FA upper surface. (c) Insertion of new 
proteins into the aggregate results in energy relaxation, which drives FA assembly. 
Figure 1.4: The principles of stress- and strain-driven mechanosensing. Figures adapted from 
Bershasky (Bershadsky et al. 2006) 
 
1.6.4. Stretch-activated ion channels 
Mechanical forces can affect the permeability of the cell membrane to various ions, 
reflecting the activity of stretch-responsive ion channels. This is a paradigm for the 
sensing of molecular stress in that stretch-activated ion channels open when two-
dimensional or lateral membrane stress is applied. Both stretch-activated (SA) and -
inactivated ion channels have been characterized. Changes in the concentration of a 
specific ion in the cells lead to the conversion of the physical stimulus into an electrical or 
chemical signal. A membrane potassium channel, a non-selective cation channel that 
mediates calcium influx, and a voltage-gated Na+ channel are all mechanosensitive 
(Rosales et al. 1997). Recent advances have been made in determining the structure and 
function of stretch-sensitive channels (reviewed (Hamill and Martinac 2001)). 
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SA cation channels are involved in several cyclic strain induced vascular 
responses, including differentiation, proliferation, morphological changes and superoxide 
production (Kakisis et al. 2004). In endothelial cells, mechanical stress on integrin bound 
beads causes calcium entry into cells within 2-5 seconds (Matthews et al. 2006). 
Inhibition of SA channels with gadolinium, or application of cyclic strain in calcium-free 
medium, resulted in the loss of orientating and elongating effects of CMS in HUVEC and 
rat aortic SMC (Naruse et al. 1998; Hayakawa et al. 2001). 
Cyclic stretch activation of protein kinase C (PKC) in EC is calcium dependent. 
PKC is involved in shear stress and cyclic strain-induced expression of platelet-derived 
growth factor (PDGF), ET-1 and the chemokine, MCP-1. Similarly, in EC PKC isoforms 
are sequentially activated by cyclic strain inducing increased gene transcription via the 
Raf-1/extracellular signal-related kinase (ERK)1/2 pathway (Cheng et al. 2001)(Cheng, 
Wung et al. 2001).  
 
1.6.5. Intercellular junctions 
Adherens junctions are common to all endothelial cells, provide structural stability 
of cell–cell adhesions and are a primary regulator of paracellular permeability to fluid and 
solutes (Michel and Curry 1999; Yuan 2002). The extracellular domain of the 
transmembrane VE-cadherin forms hemophilic bonds with similar molecules on 
neighboring cells in a calcium-dependent manner. The intracellular portion of VE-
cadherin binds to p120ctn, -catenin and plakoglobin, and this membrane-bound complex 
links to the actin cytoskeleton. The disruption of adherens junctions can be mediated by 
the tyrosine phosphorylation of -catenin, which promotes the dissociation of -catenin 
from cadherins and their cytoskeletal anchors (Del Maschio et al. 1996). 
 
It is likely that adherens junctions act as mechanosensors in the pulmonary 
endothelium and that secondary messengers are transmitted across endothelial cell gap 
junctions and perhaps between different cell types (Adamson et al. 1991). For example, 
mechanical stimulation of n-cadherin in intercellular adherens junctions in fibroblasts 
caused gadolinium-sensitive calcium influx and induced actin polymerisation at the sites 
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where force was applied (Tegeder et al. 2001). Recent studies suggest that cadherin-
mediated cell–cell adherens junctions depend on myosin II-driven contractility, like 
integrin-mediated focal adhesions. Thus, inhibition of myosin II function reduced 
accumulation of adherens junction proteins at the cell–cell interface (Shewan et al. 2005). 
Furthermore mechanical forces acting on EC regulate adherens cell-cell junction size (Liu 
et al. 2010). 
Finally, another type of cell–cell junction receptor from the immunoglobulin 
family, platelet endothelial cell adhesion molecule (PECAM)-1 is implicated in 
mechanotransduction. PECAM-1 on EC is tyrosine phosphorylated and activates ERK1/2 
in response to both shear stress and mechanical strain. PECAM-1 itself, however, may lie 
downstream of another primary mechanosensor that itself activates a tyrosin kinase 
(Kaufman et al. 2004). Furthermore, PECAM-1 acts as a major mechanosensing molecule 
upstream of the v3 integrin, in the response of confluent EC to shear stress (Tzima et 
al. 2005). The last example suggests that cell response to mechanical stimuli can depend 
on a hierarchy of mechanosensing modules. Thus, mechanosensitivity (manifested by 
force-dependent reinforcement of adhesion strength) may not be unique to adhesion 
mediated by particular integrin complexes, but may instead be characteristic of various 
types of cell adhesions. 
 
1.6.6. Transcriptional and post-transcriptional regulation 
When cells were stimulated by manipulating integrin-bound microbeads, 
cytoskeletal filaments transmitted stresses to the cell nucleus and caused nucleoli to 
redistribute (Maniotis et al. 1997). Similarly, mechanical force affected gene expression 
directly by affecting the folding of restricted DNA molecules (Chen and Grinnell 1995) 
or by modulating nuclear pore size (Feldherr and Akin 1990), although it seems unlikely 
that these effects would be specific and reproducible. 
Increased release of a substance in the presence of an inhibitor of protein synthesis 
may be ascribed to a post-transcriptional mechanism, although mechanical disruption of 
intracellular storage sites should be considered in the case of pathological stretch. For 
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example, pre-labelled fibronectin is released by fetal lung epithelial cells despite the 
presence of cycloheximide (Mourgeon et al. 1999). Fibronectin is a characteristic 
component of the provisional matrix formed after injury to the alveolar epithelium. In a 
similar model, strain-induced release of pre-synthesised glycosaminoglycans was 
inhibited both by cytoskeletal disruptors and gadolinium (Xu et al. 1996). The release of 
matrix proteins from cells and matrix components induced by mechanical stimulation 
may affect the course of lung remodelling as many of these proteins have important 
signalling activity  
EC from different compartments of the pulmonary bed regulate barrier function 
differently in response to CMS. -catenin increased rat PAEC but decreased in rat 
microvascular EC after stretch (Adkison et al. 2006). EC are evidently well placed to 
sense both mechanical strain and shear stress. Figure 1.5 summarises cyclic stretch 
induced signalling pathways and cellular responses by EC. 
 
 
 
 
 
55 
 
Abbreviations (not already shown in figure): NAPDH- nicotinamide adenine dinucleotide phosphate; FAK- 
focal adhesion kinase; PKC – protein kinase C; Akt – protein kinase B; Src tyrosin kinase; GMP- guanine 
monophosphate; IP3- inositol-3-phosphate; DAG- diacylglycerol; ROS- reactive oxygen species; ERK- 
extracellular related kinase; JNK- janus kinase; GTP- guanidine tri-phosphate; NFkB- nuclear factor kappa 
B; ICAM- intercellular adhesion molecule; MCP- monocyte chemoattractant protein; TGF- transforming 
growth factor; tPA- tissue plasminogen activator; eNOS- inducible nitric oxide synthase; bFGF- basic 
fibroblast growth factor; IL-8 – interleukin-8; LDL- low density lipoprotein; MLCK- myosin light chain 
kinase. 
 
 
 
Figure 1.5: Summary of (A) pathways activated and (B) outcomes of endothelial cells subjected to 
mechanical strain. From Lehoux (Lehoux et al. 2006) 
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1.7. Monocyte chemoattractant protein-1  
1.7.1. An overview of chemokines 
Chemokines were first identified in the late 1980’s as a family of structurally 
related cytokines with chemotactic properties for leukocytes. Thus IL-8 (Yoshimura et al. 
1987), MCP (Yoshimura et al. 1989), and macrophage inflammatory protein (MIP)-1α 
and 1β (Wolpe et al. 1988) were characterised and found to have in common important 
structural features and the ability to attract leukocytes.  
Over 50 chemokines have subsequently been identified with between 20 and 70% 
homology in amino acid sequences (Luster 1998; D'Ambrosio et al. 2003), and they have 
been subdivided into families on the basis of the relative position of cysteine residues. 
The majority of chemokines contain four cysteines, and are divided into the CXC (α) and 
CC (β) families dependent upon whether the first two cysteines are separated by one 
amino acid (CXC) or lie adjacent to each other (CC). The -chemokines can be further 
subdivided into two families (figure 1.6): the MCP-eotaxin family and all others. Those in 
the first family are approximately 65% identical to each other. The -chemokines, in 
general, attract monocytes, eosinophils, basophils and lymphocytes with variable 
selectivity. The N-terminal amino acids preceding the CC residues are the critical 
components of the biological activity and leukocyte specificity: the addition of a single 
amino acid at the amino terminal of MCP-1 reduces the biological activity by 100 – 1000 
fold (Gong and Clark-Lewis 1995). Deleting a single amino acid in this region coverts the 
molecule from an activator of basophils to a chemoattractant of eosinophils (Weber et al. 
1996). 
As a result of the increasing number of chemokines described, a standardised 
nomenclature was adopted in 2002; chemokines were named according to their family 
(CXC, CC, CX3C or XC) then L to denote ligand prior to a number. Thus IL-8, and 
MCP-1 are named CXCL8, and CCL2 respectively; the traditional nomenclature is still 
used in this thesis.  
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Abbreviations: MCP- monocyte chemoattractant protein; MIP- macrophage inflammatory protein; 
RANTES- regulated upon activation normal T-cell expressed and secreted; MDC- macrophage derived 
chemokine; HCC-1- hemofiltrate CC chemokine; TECK- thymus-expressed chemokine; SDF-1- stromal-
cell derived factor-1; TARC- thymus and activation-regulated chemokine; ELC EBL-1- (Epstein Barr virus-
induced gene-1)-ligand chemokine; PARC- pulmonary and activation regulated chemokine; SLC- 
secondary lymphoid-tissue chemokine; 6Ckine- 6-cysteine chemokine; IP-10- interferon-inducible protein-
10; MIG- monokine induced by interferon ; I-TAC- interferon inducible T-cell alpha chemoattractant; DC-
CK1- dendritic-cell chemokine 1; LARC- liver and activation regulated chemokine; GCP- granulocyte 
chemotactic protein; GRO- growth regulated oncogene; ENA-78- epithelial cell derived neutrophil-
activating peptide 78; NAP-2- neutrophil-activating peptide 2, LIX- lipopolysaccharide –induced CXC 
chemokine 
 
Figure 1.6 Chemokines and their receptors; taken from Luster (Luster 1998). 
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The human chemokine system comprises about 50 distinct chemokines and 20 G-
protein coupled chemokine receptors (table 1.3) (Zlotnik and Yoshie 2000). The disparity 
between the large number of chemokines and the smaller number of receptors is balanced 
by the promiscuity of ligand-receptor interactions, with multiple chemokines binding to 
the same receptor and several chemokines binding to more than one receptor. 
Table 1.3 Summary of known chemokine receptors and ligand. From Rossi and Zlotinck (Rossi and 
Zlotnik 2000) 
Abbreviations: MCP- monocyte chemoattractant protein; MIP- macrophage inflammatory protein; 
RANTES- regulated upon activation normal T-cell expressed and secreted; MDC- macrophage derived 
chemokine; HCC- hemofiltrate CC chemokine; TECK- thymus-expressed chemokine; SDF-1- stromal-cell 
derived factor-1; BLC- B Cell attracting chemokine; TARC- thymus and activation-regulated chemokine; 
ELC- (Epstein Barr virus-induced gene-1)-ligand chemokine; PBP- platelet basic protein; 6Ckine- 6-
cysteine chemokine; IL-8- interleukin-8; IP-10- interferon-inducible protein-10; MIG- monokine induced 
by interferon ; I-TAC- interferon inducible T-cell alpha chemoattractant; DC-CK1- dendritic-cell 
chemokine 1; LARC- liver and activation regulated chemokine; GCP- granulocyte chemotactic protein; 
Gro- growth regulated oncogene; ENA-78- epithelial cell derived neutrophil-activating peptide 78. 
 
Chemokines provide directional cues for the movement of leukocytes in 
development, homeostasis and inflammation. They control the homeostatic circulation of 
leukocytes through tissues, for example ensuring that naive lymphocytes migrate to 
lymph nodes, where they encounter antigen and are transformed into memory 
lymphocytes. Inflammation is characterised by a dramatic increase in the local secretion 
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of chemokines, resulting in the recruitment of leukocytes into the inflamed tissue. 
Chemokines have been detected in most organs during inflammation, and have been 
identified in many types of cell, suggesting that most, if not all, cells can secrete 
chemokines given the appropriate stimulus.  
1.7.2. Monocyte chemoattractant protein (MCP)-1 
MCP-1 (or CCL2) is a member of the C-C class of the -chemokine family and a 
potent chemoattractant or activator of monocytes. Its structure and function is reviewed 
(Melgarejo et al. 2009).  It is secreted by many cells types, including fibroblasts, smooth 
muscle cells (SMC), EC and monocytes themselves, and principally interacts with the 
membrane CC chemokine receptor 2 (CCR2) on monocytes (O'Hayre et al. 2008). MCP-
1 is one of 4 MCPs (1-4) which is secreted in two predominant forms (9 or 13 kDa) (Van 
Coillie et al. 1999). It is able to recruit memory T lymphocytes and natural killer cells 
(NKC) in addition to monocytes and, along with IL-8, is able to trigger the firm adhesion 
of monocytes to the endothelium under flow conditions.  Consequently it is able to 
initiate and promote inflammation. 
Binding of MCP-1 to CCR2, a G-protein coupled receptor at the cell surface, 
triggers an intracellular signalling pathway resulting in the formation of inositol tri-
phosphate (IP3), intracellular calcium release and PKC activation (figure 1.7). Subsequent 
recruitment of nuclear factor-B (NFB) and altered gene transcription ultimately 
regulates directional movement of the monocyte. 
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Abbreviations: MCP- monocyte chemoattractant protein; G- G protein; PKC- protein kinase C; PLC- 
phospholipase-C; PIP2- phosphytidylinositol-bisphosphate; DAG- diacylglycerol; IP3- inositol tri-
phosphate; NFkB- nuclear factor kappa B. 
 
1.7.3. MCP-1 Regulation 
MCP-1 is encoded by the CCL2 gene on chromosome 17q11. It is itself regulated at 
the level of transcription and is released in response to a host of stimuli including TNF-, 
interferon gamma (IFN-), PDGF and mechanical strain (Boekhoudt et al. 2003; Gruden 
et al. 2005; Demicheva et al. 2008). Other factors, including glucocorticoids and 
oestrogen, are able to decrease MCP-1 expression (Mukaida et al. 1991). The pathways 
through which MCP-1 transcription is regulated vary and are summarised in figure 1.8. 
Commonly NFB or AP-1 transcription factors are involved, downstream of the classical 
NFB or canonical MAPK signalling pathways. Mechanical strain induced MCP-1 
release is dependent upon intact actin cytoskeleton and involves reactive oxygen species 
(ROS) (Okada et al. 1998; Guest et al. 2006). 
 
Figure 1.7: Overview of components of the signalling pathway activated upon MCP-1-CCR2 
binding- from. (Melgarejo et al. 2009) 
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ET-1: Endothelin-1, TNF-: Tumour necrosis factor; PDGF: Platelet derived growth factor; IL: interleukin; 
ROS: reactive oxygen species; PLC: phospholipase-C; PKC: phosphokinase C; Ikk: inhibitor kinase kinase; 
NFkB: nuclear factor kappa B; MAPK: mitogen activated protein kinases; ERK: ; AP-1 activator protein-1; 
MCP-1 monocyte chemoattractant protein-1. 
 
1.7.4. Clinical Importance of MCP-1 
MCP-1 has a key role in multiple pathologies (figure 1.9). It is expressed in a 
number of inflammatory conditions associated with monocyte recruitment, including 
arthritis, bacterial infection, atherosclerosis and renal disease (Van Coillie et al. 1999). 
MCP-1 levels are also increased during lung injury, shortly after myocardial ischaemia 
and in liver and renal ischaemia (Shin et al. 2002). Tumours including gliomas, ovarian, 
breast and oesophageal cancers over-express MCP-1 (O'Hayre et al. 2008). Levels 
correlate with tumour macrophage infiltration and vascularisation, which are potentially 
reflected by increased tumour progression or relapse (O'Hayre et al. 2008). Furthermore, 
MCP-1 is able to induce angiogenesis via MCP-1 induced protein (MCPIP) and MCPIP 
expression in HUVEC promotes cellular proliferation and migration (Niu and 
Kolattukudy 2009). 
Figure 1.8: Schematic representation of known signalling pathways involved in induction of 
monocyte chemoattractant protein-1. 
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Abbreviations: TNF- tumour necrosis factor; NFkB- nuclear factor kappa B; MCP- monocyte 
chemoattractant protein; PDGF- platelet derived growth factor. 
 
Specific roles for MCP-1 in pulmonary structural remodelling are discussed 
elsewhere (chapter 1.3.4.4). 
1.8. The biology of endothelins 
Endothelin-1 (ET-1) is a 21 amino acid (aa) peptide first isolated from porcine 
aortic endothelial cells and is a potent vasoconstrictor (Yanagisawa et al. 1988). The N-
terminal end of the peptide contains two disulphide bridges joining a cysteine amino acid, 
whilst the hydrophobic C-terminal end of the peptide provides the point of interaction 
with its receptors (figure 1.10) (Sawamura et al. 1989). There are three isoforms of the 
enzyme (figure 1.10), ET-1 being the only form secreted by the endothelium (Battistini et 
al. 1993).  
The action of ET-1 is mediated via ETAR or ETBR located on the surface of VSMC 
or EC, acting in a paracrine or autocrine manner (Battistini et al. 1993). Table 1.4 lists the 
numerous cell types that secrete endothelins.  
 
 
 
 
 
 
Figure 1.9: Factors stimulating Monocyte chemoattractant protein-1 transcription and pathologies 
associated with monocyte chemoattractant  protein-1 over-expression (From Melgarejo et al; 2009). 
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Endothelins (ET) are 21 amino acid peptides with two disulphide bridges joining the cysteine residues at 
positions 1-15 and 3-11. The C-terminal end is thought to be important in receptor binding and the N-
terminal end affects receptor affinity. Differences in ET-2 and ET-3 compared to ET-1 are represented by 
black amino acids. Taken from Kimji and Rockey(Khimji and Rockey 2010). 
 
Table 1.4 Cellular sources of endothelins 1-3- from Khimji (Khimji and Rockey 2010). 
The vascular endothelium is the most prominent source of ET-1. ET-2 is predominantly produced by the 
kidney and intestine and ET-3 is at highest concentration in neural tissue. 
 
The production of the mature ET-1 peptide occurs via a series of steps that cleave a 
203aa transcriptional product, preproendothelin (ppET-1) into the active 21aa final 
product (figure 1.11). Transcription of ppET-1 is regulated by c-fos, c-jun, NF-1 and 
GATA-2 transcription factor binding sites (Inoue et al. 1989; Yanagisawa et al. 1989). 
ppET-1 is cleaved by furin like endopeptidases to form big endothelin (big ET-1), an 
Figure 1.10: Schematic representation of the structure of endothelins 1-3 
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inactive 37-41aa intermediate (Kedzierski and Yanagisawa 2001). The final step in the 
pathway involves big-ET-1 cleavage to ET-1 by a family of metalloproteinase enzymes 
called endothelial converting enzymes (ECE) (Xu et al. 1994). Three isoforms of ECE 
exist- ECE 1-2 are most prominent, and 4 variants of ECE-1 are known to occur in 
humans (ECE 1a-d) (Xu et al. 1994; Valdenaire et al. 1995; D'Orleans-Juste et al. 2003). 
ECE-1 appears to act at the plasma membrane, processing big-ET-1 both 
intracellularly and at the cell surface (Schmidt et al. 1994). Its activity is not solely 
limited to ET-1, having the ability to hydrolyse other molecules including bradykinin, 
substance-P and insulin (Schmidt et al. 1994). The activity of ECE-2 is probably 
restricted to the intracellular (IC) compartment, being localised to the Golgi apparatus and 
acting optimally at pH 5 (Xu et al. 1994; Emoto et al. 1999). Both ECE-1 and -2 show 
highest affinity for big ET-1. 
 
Abbreviations: IL-1- interleukin-1; TGF- transforming growth factor; LDL- low density lipoprotein; ANP- 
atrial natruetic protein; BNP- brain natruetic protein; ET-1 endothelin-1; RNA- ribose nucleic acid 
 
Importantly ET-1 is constitutively expressed by a pathway running in parallel to the 
induced one (Russell and Davenport 1999). Whilst absent from some cell types, in the 
majority this is the primary release pathway. It is hypothesised that the constitutive 
Figure 1.11: Factors regulating and schematic representation of the synthesis of endothelin-1. From 
Attina (Attina et al. 2005). 
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pathway is of primary importance in regulation of vascular tone (Russell and Davenport 
1999).  
 
1.8.1. ET-1 Release 
EC release ET-1 predominantly in a basolateral direction, facilitating a selective 
action on the adjacent VSMC. Consequently, plasma levels might not accurately reflect 
tissue levels and hence, inaccurately correlate to physiological effects. Stimulated release 
above basal levels occurs over 2-5 hours, in keeping with an increase in transcription, 
synthesis and release (Haynes and Webb 1998). The half-life of the peptide is short, with 
clearance predominantly via the pulmonary vasculature, predominantly involving the 
ETBR (Sakurai et al. 1990). Hence, alteration in receptor expression or availability may 
be as important in regulating ET-1 levels as de novo synthesis. 
Shear stress (i.e. flow) sensed by receptors on EC, is a potent stimulus in ET-1 
homeostasis. Increased flow across EC increases nitric oxide (NO) and decreases ET-1 
levels. Other stimuli leading to production of ET-1 are shown above (figure 1.11). 
 
1.8.2. Endothelin Receptors: Endothelin A receptor (ETAR) and Endothelin B 
receptor (ETBR) 
ETAR and ETBR are thought to be the principle receptors through which ET-1 
exerts it effect. These G-protein coupled receptors span the cellular membrane. ETAR are 
located principally on SMC and cardiac muscle, while ETBR are abundant on EC 
(Huggins et al. 1993). This distribution is not exclusive however, ETBR are also present 
on macrophages and platelets, and both receptors are expressed throughout the kidney 
(Davenport et al. 1991; Dockrell et al. 1996). This latter finding is unsurprising in an 
organ in which the control of vascular tone is vital. 
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Receptor ETA ETB 
ET Affinity ET-1>ET-2>>ET-3 ET-1=ET-2=ET-3 
Predominant Tissue Vascular Smooth Muscle Endothelium Vascular Smooth Muscle 
Action Constriction 
Dilation (Endothelium) 
Constriction (Vascular 
Smooth Muscle) 
Antagonist Sixasentan; BQ-123 BQ 788 
 Bosentan (Mixed ETA and ETB)  
Table 1.5 Properties of endothelin receptor subtypes 
 
The affinity of the receptors for the different ETs is shown in table 1.5. ETAR 
principally mediates vasoconstriction and cellular proliferation, with ETBR having a 
broader spectrum of effects, including ET-1 clearance, eNOS regulation and prostacyclin 
and ECE-1 regulation. 
 
1.9. Bone morphogenetic proteins (BMP) and their receptors (BMPR) 
1.9.1. Bone morphogenetic proteins 
BMPs form a specific subclass of the transforming growth factor TGF- 
superfamily. Initially identified as molecules with the capacity to induce bone and 
cartilage formation in rats, they also regulate proliferation, differentiation, migration and 
apoptosis of multiple cell types including EC and VSMC (Urist 1965; Wozney et al. 
1988). This summary will concentrate upon the properties of BMPs and their receptors 
and the important components of their signalling pathways. 
BMPs are transcribed to large precursor proteins carrying an N-terminal signal 
peptide, responsible for directing the protein to the secretory pathway, a prodomain that 
ensures proper folding, and a C-terminal mature peptide. The monomer is stabilised by 
intramolecular disulphide bonds forming a cysteine knot motif (Sieber et al. 2009). The 
final active molecule is usually formed by homodomerization. Cleavage of the pro-
protein occurs in the golgi apparatus with subsequent secretion of the active substance. 
BMP-9 is an exception to this and is secreted with the pro-region still attached. 
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Heterodimers also occur in vivo (e.g. BMP 2/6 or BMP 2/7) which confer increased 
potency (Little and Mullins 2009).  
 
1.9.2. Classification 
BMPs are classically grouped by their ability to exert their action upon binding with 
BMP type I receptors (BMPR1) and subsequent phosphorylation of intracellular Smads 1, 
5 and 8. They can however, be further sub-grouped (figure 1.12) into BMP-2/4 group, 
BMP 5/6/7/8/ group (osteogenic protein (OP)-1 group), growth and differentiation factor 
(GDF)-5/6/7 group, and the BMP-9/10 group. The BMP 2/4, the OP-1 and the BMP 9/10 
group tend to induce the formation of bone and cartilage in vivo, but the GDF -5/6/7 
group only induce cartilage and tendon, but not bone-like tissues (Miyazono et al. 2010). 
BMP-3 and myostatin (GDF-8) are members of this TGF- sub-group that have been 
misclassified, neither activating Smad 1/5/8 nor inducing bone or cartilage in vivo.  
Abbreviations: GDF- growth differentiation factor; OP- osteogenic protein, BMP- bone morphogenetic 
protein; BMPR- bone morphogenetic protein receptor; ActR-II- Activin type II receptor; Alk- activin 
receptor-like kinase receptor; Smad –mothers against Decapentaplegic Homolog protein. 
 
Figure 1.12: Classification of bone morphogenetic proteins (BMP) and their effect on bone, 
cartilage and tendon formation (adapted from Miyazono et al) 
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1.9.3. Bone morphogenetic protein receptors 
The BMP receptors (BMPR) and their signalling pathways have been well reviewed 
(Kawabata et al. 1998; Miyazono et al. 2005; Sieber et al. 2009; Miyazono et al. 2010). 
BMPs bind to heteromeric receptor complexes composed of type I and type II 
transmembrane serine/threonine kinase receptors. Seven different receptors have been 
identified that bind BMPs (table 1.6) (Miyazono et al. 2005).The BMPR1a and  Activin 
like kinase (Alk) 2 receptors are expressed in multiple cell types. Expression of BMPR1b, 
however, is more restricted and Alk-1 expression is primarily restricted to EC (Miyazono 
et al. 2010). 
 
Type I receptor Type 2 receptor 
BMP receptor type 1a (BMPR1a / Alk 3) 
BMP receptor type II (BMPR2) 
BMP receptor type 1b (BMPR1b or Alk 6) 
Activin receptor type 2a (ActR2a) 
Alk 1 
Activin receptor type 2b (ActR2b) 
Activin receptor type 1a (ActR1a or Alk 2) 
 
Table 1.6 Type 1 and type 2 BMP receptors 
Abbreviations: BMP- bone morphogenetic protein; Alk- activin receptor-like knase. 
 
Both receptors are required for signalling. The type 2 receptor kinase is 
constitutively active, but the type 1 receptor requires ligand binding, receptor-ligand 
oligomerisation and transphosphorylation of a glycine/serine rich region via the type 2 
receptor (Shimasaki et al. 2004).  
 
1.9.4. Ligand-receptor oligomerisation and signalling 
Different BMPs bind the different receptors with differing affinities. BMP 2 and 4 
bind more readily to BMPR1a and BMPR1b, whereas BMP-6 and BMP-7 bind strongly 
to Alk-2 and only weakly to BMPR1b (ten Dijke et al. 1994; Nishitoh et al. 1996). BMP-
9 and BMP-10 bind to Alk 1 and Alk 2 (Scharpfenecker et al. 2007; Upton et al. 2009). 
These differing affinities allow receptors to be oligomerised in a very specific manner, 
activating distinct signalling cascades (Gilboa et al. 2000; Nohe et al. 2002). In addition 
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to ligand-receptor affinities, the expression level of receptors, co-factors and the presence 
of preformed type I/ type II receptor complexes on the cell surface can determine the 
signalling pathway that is activated. For example, BMP-2 is able to bind either BMPR1a 
alone and recruit BMPR2, or bind to the preformed complex of BMPR1a and BMPR2. 
Depending which it binds determines the signalling pathway activated: either the classical 
Smad pathway or a Smad independent pathway (p38/ERK) (Nohe et al. 2002). Hence, the 
different ligand affinities and different binding patterns confer marked versatility on the 
BMP system. 
 
1.9.5. Downstream signalling  
The Smad proteins are the major signal transducers for the TGF- family receptors. 
Three subclasses of Smad proteins are described: receptor regulated Smads (R-Smads), 
common mediator Smads (co-Smads) and inhibitory Smads (I-Smads).  Smads 1/5 and 8 
are R-Smads commonly involved in BMP signalling and Smad-2 and 3 are principally 
involved in the TGF-/activin signalling pathways (figure 1.13). Smad-4 is the co-Smad 
for both pathways and is the only known co-Smad in mammals. Smads 6 and 7 act as 
inhibitory Smads.  
Abbreviations: GSK- glycogen synthase kinase; MAPK- mitogen activated protein kinase; BMP- bone 
morphogenetic protein; BMPR- BMP receptor; Smad- Mothers Against Decapentaplegic Homolog protein; 
MH- Mad homology 
 
Smads have highly conserved N-and C- terminal regions known as Mad homology 
(MH)-1 and MH-2 domains respectively (figure 1.13). These are linked by a variable 
proline-rich linker region. The MH-2 domains are present in all three Smad sub-types, but 
the MH-1 domains are only present in R-Smads and I-Smads. In R-Smads, the MH-2 
domain is involved in interaction with receptors, oligomerisation with other Smads and 
Figure 1.13: Schematic represenatation of Smad structure 
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transcriptional activation. In the quiescent form the MH-1 and MH-2 domains physically 
bind to each other and suppress function. This binding is broken upon phosphorylation by 
the type 1 receptor, R-Smad is activated and is able to bind the co-Smad prior to 
translocation to the nucleus. Motifs that can be phosphorylated by MAPKs and glycogen 
synthase kinase (GSK)-3 are located in the linker region and when phosphorylated 
increase the degradation of the R-Smad (Miyazono et al. 2010). 
Some cross talk does occur between the two signalling pathways: TGF- activated 
Smads 1,5 and 8, via Alk 1 and Alk 2 and BMP-9 phosphorylated Smad-2 in EC 
(Goumans et al. 2003; Upton et al. 2009).  
Abbreviations: BMP- bone morphogenetic protein; Smad- Mothers Against Decapentaplegic Homolog 
protein; MH- Mad homology; Smurf- Smad ubiquitination regulatory factor 
 
I-Smads (Smads 6/7) do not contain an MH-1 domain and act to inibit R-Smads at 
several levels (figure 1.14). Initially they compete with R-Smads for the activated type 1 
receptor, but can also bind with Smad-4 to form non functioning oligomers. Furthermore, 
they can inhibit BMP signalling by binding to the Smad responsive DNA binding element 
(SBE) in the nucleus, preventing formation of the functional Smad-DNA complex 
induced upon BMP-receptor binding (Zhang et al. 2007). 
1.9.6. Nuclear effects and target genes 
Smads are able to effect transcription of target genes by directly binding to DNA, 
interacting with other DNA-binding proteins and by recruiting transcriptional co-
activators and co-repressors. BMP specific R-Smads bind to GC- rich sequences and to a 
Figure 1.14:Modes of action of I-Smads (from Miyazono (Miyazono et al. 2010)) 
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GTCT/AGAC sequence that is specific to Smad 3 and Smad-4 (Karaulanov et al. 2004; 
Truksa et al. 2009). In the Id-1 promoter (the classical effector gene of BMPs), both SBE 
and GC-rich boxes are important (Korchynskyi and ten Dijke 2002). Co- factors include 
p300 and CREB binding protein (CBP) which facilitate R-Smad DNA binding and gene 
transcription (Rodriguez-Pascual et al. 2003). TNF-, through activation of NFB is able 
to interfere with Smad DNA binding reducing BMP signalling effects (Yamazaki et al. 
2009). 
Id genes are an important targets of BMP signalling (Ogata et al. 1993). The Id genes 
transcribe four isoforms of the Id protein which all contain a helix-loop-helix (HLH) 
domain, but lack a region responsible for DNA binding. Due to this structure they are 
able to sequester the ubiquitously expressed basic HLH transcription factors, hence 
inhibiting their function. R-Smad signalling also stimulates the transcription of I-Smads 
(Smads 6/7) presumably as a negative feedback mechanism (Miyazono et al. 2005). 
Figure 1.15 summarises the BMP/Smad signalling pathway and its interplay with TGF- 
signalling. 
Abbreviations: BMP- bone morphogenetic protein; BMPR- BMP receptor; TGF-transforming growth 
factor; TR- TGF receptor; Smad- Mothers Against Decapentaplegic Homolog protein. 
 
 
 
 
 
Figure 1.15: Schematic representation of bone morphogenetic protein (BMP) signalling via Smads 
and the interaction with the transforming growth factor (TGF)- pathway 
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1.9.7. BMPs and mechanotransduction 
This work hypothesises that mechanical strain at the pulmonary microvasculature as 
a result of raised LAP is important in the pathophysiology of ACM remodelling and the 
stimulation of inflammatory mediators in CHF. BMPs alter inflammatory gene expression 
as discussed below. BMPs themselves are also regulated by mechanical strain albeit in 
non-vascular cells (Aspenberg et al. 2000; Rath et al. 2008). BMP-2 and -4 were 
increased in porcine aortic valve cusps exposed to prolonged mechanical strain, and 
BMP-2 is upregulated in the hypertensive vessels of rats subjected to aortic banding 
(Ungvari et al. 2003; Balachandran et al. 2010). Furthermore CMS is known to alter 
mitogen activate kinase (MAPK) activity, which in turn are able to impact upon the R-
Smad linker region and alter Smad signalling. It is therefore possible that BMPs 
themselves may not only be mechanosensitive, but also integral in the CHF syndrome. 
1.9.8. Bone morphogenetic proteins and non-Smad signalling 
Increasing evidence exists that BMPs are able to signal via Smad independent 
pathways. BMP-2 and GDF-5, via BMPR1, phosphorylate p38 or JNK via TAK1 
(Iwasaki et al. 1999; Nakamura et al. 1999; Shim et al. 2009). Furthermore ERK 
stimulation enhance the transcriptional activity of Smad-1 in osteoclastic cells (Suzawa et 
al. 2002). These effects are contradictory to the antagonistic effects of MAPKs via 
phosphorylation of the linker region of R-Smads, preventing their nuclear translocation 
(Kretzschmar et al. 1997). These paradoxical effects may take on more importance in the 
absence or decreased function of the BMPR2, as in primary or secondary PAH. If the 
BMPR2 function is decreased then the result is a decrease in signalling through the Smad 
1 pathway. The effect of this is two-fold. Firstly, there is a loss of opposition to the Smad-
2/3 pathway, but also the potential for preferential BMP signalling via Smad independent 
pathways such as the MAPK, which may result in a proliferative or inflammatory 
phenotype. 
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1.9.9. Bone Morphogenetic Protein-9 
BMP-9, also known as GDF-2 was originally cloned from a fetal mouse liver 
cDNA library and had the ability to bind to cells from a human hepatoma cell line 
(HepG2 cells) (Song et al. 1995). In the adult rat BMP-9 is expressed predominantly in 
the liver and induced proliferation of cultured hepatocytes (Miller et al. 2000). It has also 
been located to the septum and spinal cord of mice (Lopez-Coviella et al. 2000). BMP-9 
is present in the serum of healthy humans at concentrations between 2 and 12g/ml, a 
value in excess of the EC50 (50pg/ml) (David et al. 2008). Unlike other BMPs in which 
the pro-regions generally dissociate, the pro-region of BMP-9 remains tightly associated 
after secretion, but without any apparent adverse effect on activity (Brown et al. 2005). 
BMP-9 binds Alk-1 and BMPR2 or ActR2 on EC (David et al. 2007; Upton et al. 2009; 
Suzuki et al. 2010).  
Much of the initial investigation in to the function of BMP-9 concentrated on its 
role in development and bone biology. More recently work in EC identified a varied 
action of BMP-9, including inflammatory mediator induction and inhibition of 
angiogensis and cell proliferation (David et al. 2008; Upton et al. 2009). Tables 1.7A and 
1.7B summarise genes induced by BMP-9 in EC and pertinent effects of BMP-9 on EC 
physiology.  
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Table 1.7A Summary of gene induction by BMP-9 in 
endothelial cells (EC) 
* from (David et al. 2007); **from (Upton et al. 2009) 
Abbreviations: Id-inhibitor of DNA synthesis; BMPR- Bone 
morphogenetic protein receptor; IL- interleukin; Smad- 
Mothers Against Decapentaplegic Homolog protein; 
   
   
  







   
  


   
   



Table 1.7B Summary of published data of the effect of bone morphogenetic protein-9 on relevant 
endothelial cell (EC) types 
Abbreviations: HLMVEC- human lung microvascular EC; MESEC- murine stem cell derived EC; TEC- 
tumour (renal cell carcinoma) derived EC; NEC- normal dermal EC; HAEC- human aortic EC; BAEC-
bovine aortic EC; HMVEC-d- dermal human microvascular EC; HUVEC- human umbilical vein EC. ET-1- 
endothelin-1; VEGF- vascular endothelial growth factor; VEGFR- vascular endothelial growth factor 
receptor; bFGF- basic fibroblast growth factor; Tie- Tie 2 receptor tyrosine kinase 
 
The in vitro data regarding the role of BMP-9, at physiological concentrations, in 
EC proliferation, angiogenesis and upregulation of inflammatory mediators makes it an 
attractive potential contributor to the pathophysiology of vascular and structural 
remodelling in CHF. 
 
1.10. Mitogen-activated protein kinases 
MAPK pathways regulate fundamental and diverse cellular processes, such as 
proliferation, differentiation and apoptosis. After activation by an enormous array of 
 
 
 
 
 
 
 
 
 
 
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stimuli, MAPK phosphorylate numerous proteins, including transcription factors, 
cytoskeletal proteins and other enzymes. Five families of MAPKs have been defined in 
mammalian cells: extracellular signal-regulated kinases (ERK1 and ERK2), Jun N-
terminal kinases (JNK1, JNK2 and JNK3); p38 kinase isozymes (p38, p38, p38 and 
p38); ERK3/ERK4; and ERK5. The first three, and their activators, are implicated in 
human diseases and are targets for drug development. Mammalian MAPK modules 
associate with numerous scaffold proteins that regulate their activity and localization in 
various cells. The scaffold proteins can bind to other proteins, including phosphatases and 
cytoskeletal proteins. While the significance of scaffolding is not yet fully defined in most 
instances, it appears to be a method generally used to segregate individual MAPK 
modules and may help to define specific MAPK pathways (Morrison and Davis 2003). 
Each MAPK pathway contains a three-tiered kinase cascade comprising a MAP 
kinase kinase kinase (MAPKKK, MAP3K, MEKK or MKKK), a MAP kinase kinase 
(MAPKK, MAP2K, MEK or MKK) and the MAPK (figure 1.16). This three-tier module 
facilitates amplification and tight regulation of the pathways leading to sensitive and 
specific responses to stimuli (Huang and Ferrell 1996). Frequently, a MAP3K kinase 
(MAPKKKK, MAP4K or MKKKK) activates the MAP3K. The MAP4K or MAP3K can 
be linked to the plasma membrane, for example by associating with a small GTPase. 
Numerous different MAP3Ks exist, including Raf isoforms. The MAP3Ks can have large 
regulatory domains that interact with upstream regulators (e.g. Rho, Ras), have functions 
such as ubiquitination, and are activated by relief of auto-inhibition and oligomerisation. 
MAPKKs typically have smaller regulatory domains and are activated by dual 
phosphorylation of serine and threonine residues within the activation loop of the 
catalytic domain. They exhibit great specificity for their cognate MAPK but are regulated 
by many MAP3Ks. 
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MAPKK, MAPK kinase; MAPKKK, MAPK kinase kinase; Raf, v-raf-1 murine leukemia viral oncogene 
homolog; Ras, v-Ha-ras Harvey rat sarcoma viral oncogene homolog; MEK, mitogen-activated protein 
kinase kinase; p90RSK, ribosomal protein S6 kinase, 90kD, polypeptide 1; ELK1,  member of ETS 
oncogene family; ATF-2, activating transcription factor 2; CHOP, DNA-damage-inducible transcript 3; 
ELK4, ETS-domain protein (SRF accessory protein 1, SAP1); SP1, specificity protein 1; MAX/MYC, 
MAX protein or helix-loop-helix zipper protein or myc-associated factor X; MAKAP-2,3, mitogen-
activated protein kinase-activated protein kinase 2, 3 
MAPKs are activated by dual phosphorylation of conserved threonine and tyrosine 
residues within the activation loop (denoted T-X-Y) and phosphorylate targets on serine 
and threonine residues within a consensus PXT/SP motif, where X depends on the MAPK 
(Chen et al. 2001). Pathway specificity is regulated at several levels, including kinase-
kinase and kinase-substrate interactions, co-localization of kinases by scaffold proteins, 
and inhibition of cross-talk/output by the MAPKs themselves (Burack and Shaw 2000). 
MAPKs bind stably to substrates, MAPKKs and scaffold proteins through multiple 
docking domains distinct from their active sites, that recognize homologous sites on 
different targets. MAPKs may inhibit signalling by binding substrates when catalytically 
inactive (Madhani and Fink 1998). Finally, MAPKs activity is regulated by multiple 
phosphatises (Keyse 2000).  
Signalling complexes of MAPK module components can vary with time and 
location. Active MAPKs translocate from the cytoplasm to the nucleus to phosphorylate 
Figure 1.16 Diagrammatic representation of a typical MAPK pathway and the three classical MAPK 
pathways 
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nuclear targets, and MAPKKs and MAPK scaffold proteins can shuttle in and out of the 
nucleus carrying the MAPK or anchor them in the cytoplasm. MAPKs associate with 
numerous sub-cellular structures, including microtubules, the endoplasmic reticulum and 
the actin cytoskeleton. MAPK phosphatases may attenuate MAPKs in a site-specific 
manner. 
1.10.1. The ERK1/2 signalling pathway 
The ERK1/2 signalling pathway was the first discovered and one of the best 
characterised. It has been a major focus for this work and so it is discussed here in greater 
detail. Signalling through the Ras/Raf/MEK/ERK1/2 pathway has been implicated in 
many cellular processes, including proliferation, differentiation, survival, metabolism and 
morphology. Deregulation of the pathway has been associated with various pathologies, 
most notably with proliferative disorders such as cancer but also, more recently, with 
specific developmental abnormalities (Bentires-Alj et al. 2006). Temporal regulation of 
the pathway is critical, for example transient activation of the pathway in 
phaeochromocytoma-derived PC12 cells is associated with proliferation, whereas 
sustained activation drives differentiation into neuronal-like cells (Marshall 1995).  
The two ERKs, ERK1 (also called p44ERK1) and ERK2 (also called p42ERK2), 
have numerous substrates, many of which are nuclear and participate in the 
transcriptional regulation. The two kinases are very similar in sequence and have tended 
to be thought of interchangeably (Yoon and Seger 2006). The activity of the pathway is 
often represented by the levels of MEK-directed phosphorylation of ERK1 and ERK2, as 
detected by phospho-specific antibodies; the double bands on electrophoresis gels that 
appear in response to numerous stimuli are usually taken together as representing total 
ERK activity. Likewise, the importance of this signalling pathway in various cellular 
processes tends to be deduced from the effects of well-characterized inhibitors of the 
upstream kinase MEK such as U0126 and PD98059. 
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1.10.2. Components of the ERK1/2 signalling cascade 
The components of the ERK cascade were initially elucidated as the building blocks 
that participate in the transmission of mitogenic signals by growth factors and hormones. 
Under these conditions, the cascade is usually activated by the small GTP binding protein 
Ras that utilizes either Raf1 or B-Raf in the MAP3K tier, MEK1/2 in the MAPKK tier, 
ERK1/2 in the MAPK tier and RSK1/2 in the MAPKAPK tier of the cascade. However, 
other components may change the flow of the signals under specific conditions. Thus, 
upstream of the cascade, another small GTP binding protein, Rap1, may accompany Ras 
and induce a prolonged activation of the ERK cascade (York et al. 1998). Furthermore, 
several MAP4K have been implicated in the activation of the cascade, including PKC 
(Kolch et al. 1993) and various protein Tyr kinases (figure 1.17) (Dhillon and Kolch 
2002). In addition, the activation of Raf1 involves a big complex of interacting proteins, 
including kinase suppressor of Ras (KSR), which can serve as a scaffold protein 
(Morrison and Davis 2003), or a protein kinase (Xing et al. 2000). 
The complexity of the ERK cascade is very apparent at the MAP3K tier. Although 
Raf1 was initially identified as the main MAP3K component of the cascade, there is 
increasing evidence that B-Raf is the main signalling isoform. B-Raf is activated by both 
Ras and Rap1; prolonged activation by Rap1, and transient activation of Ras, may 
produce sustained ERK signalling, such as in NGF-stimulated PC12 cells (York et al. 
1998). In addition, Raf1 activation involves its association with several proteins, while 
the simpler mode of B-Raf activation involves phosphorylation at Thr598 and Ser601 
(Wellbrock et al. 2004). Therefore, B-Raf and Raf1 can transmit signals from distinct 
extracellular stimuli with different effects. Other kinases may also act in the MAP3K tier 
of the cascade under various conditions although the effects of these are still 
controversial.  
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Activation and inactivation processes are indicated. Dashed lines indicate indirect activations, and dark 
arrow stand for the main pathway upon growth factor activation. The phosphorylation by PAK (on Ser298) 
increases MEK-ERK interaction, which facilitates the kinetics of ERK activation. It can be inhibited by a 
feedback phosphorylation by ERK (on Thr292). ERK also negatively regulates B-Raf and Raf1 by a 
feedback phosphorylation. MAPKPKs, MAPK-activated protein kinases; MAPKK, MAPK kinase; 
MAP3K, MAPK kinase kinase; MAP4K, MAPK kinase kinase kinase; PAK1, p21/Cdc42/Rac1-activated 
kinase 1; MLK3, mitogen-activated protein kinase kinase kinase; PKC, Protein kinase C;  TPL2, tumour 
progression locus 2; A-Raf, v-raf murine sarcoma 3611 viral oncogene homolog 1; B-Raf, v-raf murine 
sarcoma viral oncogene homolog B1;  Raf-1, v-raf-1 murine leukemia viral oncogene homolog 1; MEK, 
mitogen-activated protein kinase kinase; MNK, MAP kinase-interacting serine/threonine kinase; MSK, 
ribosomal protein S6 kinase, 90Kd; PAK, p21-activated kinase; p90RSK, ribosomal protein S6 kinase, 
90kD, polypeptide 1; CREB, cAMP responsive element binding protein 1; ER, estrogen receptor; ELK1, 
member of ETS oncogene family; STAT1, signal transducer and activator of transcription 1;  AFT-2, 
activating transcription factor 2 
All MAP3K phosphorylate the kinases in the MAPKK level. MAP3K 
phosphorylate MEK on two serine residues in their activation loop (Ser218 and Ser222 in 
MEK1/2), which induces full activation (Seger et al. 1992). The activated MEK are dual 
specificity protein kinases that appear to be the only kinases capable of specifically 
activating ERK1 and ERK2  as well as several alternatively spliced forms of these genes 
(Boulton et al. 1990; Boulton et al. 1991). ERK activation requires phosphorylation of 
their two regulatory residues, located within the MAPK activation motif Thr-Xaa-Tyr 
Figure 1.17: Schematic representation of the ERK1/2 signalling cascade 
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(Thr202, Glu203 and Tyr204 for ERK1 and Thr183, Glu184 and Tyr185 for ERK2 
(Payne et al. 1991). Finally, apart from the RSK1/2 in the MAPKAPK tier, ERK can also 
activate also RSK3/4, mitogen- and stress-activated kinase (MSK), MAPK-interacting 
kinases (MNK), and MAPKAPK3 and 5 (Yoon and Seger 2006). 
 
1.10.2.1. Regulation of ERK activity 
Recently, it has become evident that the identity of the ERK cascade's participants 
can be dictated by their differential expression in different cell types. However, another 
major mechanism for the determination of the components is their protein–protein 
interactions, which can be determined in part by specific domains in the different kinases 
(Takekawa et al. 2005), but more importantly by specific scaffolds (Morrison 2001). 
Scaffold proteins induce association of the relevant components of the cascade, and 
subsequently attract them to their proper activators and targets. This association 
encourages signalling specificity, and faster reactions within the cascade. One of the best-
studied scaffolds of the ERK cascade is the KSR (Morrison 2001)), which is 
constitutively associated with MEK1/2, 14-3-3 proteins, C-TAK1 and IMP and is located 
primarily in the cytosol (Morrison and Davis 2003; Matheny et al. 2004). Upon 
stimulation, 14-3-3 and IMP are released from the complex, and this allows the rest of the 
KSR complex to translocate to the plasma membrane and recruit activated Raf1 and ERK, 
and thereby facilitates signal transmission through the cascade. Other scaffolds of the 
ERK cascade include: -arrestin (Tohgo et al. 2002) that participates in the transmission 
of signals from G-protein coupled receptors, and paxillin that recruits ERK to the 
cytoskeleton (Ishibe et al. 2003). 
Several distinct sites in ERK interact with MEK suggesting a close interplay 
between the two molecules, which may be reflected not only in the activation process, but 
also in functions such as cytosolic anchoring and nuclear export of inactive ERK 
(Rubinfeld et al. 1999; Adachi et al. 2000). Phosphorylation of the regulatory residues in 
the ERK activation loop by MEK induces a major conformational change, dramatically 
increasing the catalytic activity of ERK and forcing the detachment of the two proteins 
(Canagarajah et al. 1997; Wolf et al. 2001). This dissociation allows the translocation of 
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the two proteins separately to the nucleus, where ERK remains for between a few minutes 
to several hours, while MEKs are rapidly exported to the cytosol (Pouyssegur et al. 
2002). 
ERK activity is also regulated by protein phosphatases. Inactivation is mediated 
by the removal of phosphates from either or both of the regulatory residues. Indeed, 
protein Ser/Thr phosphatase, protein Tyr phosphatase and dual specificity phosphatase 
(DuSP, classified as MAPK phosphatases MKPs) all down-regulate ERK activity. The 
best studied ERK phosphatase is MKP3, a product of an inducible gene that is highly 
specific to ERK (Camps et al. 1998). Unlike the interaction with MEK, the ERK-MKP3 
interaction is independent of phosphorylation of the key residues for ERK activation, as 
this does not induce a dissociation of the ERK-MKP3 complex. However, similar to 
MEK, the interaction has other functions apart from dephosphorylation, such as 
determination of the sub-cellular localisation of ERK. Interestingly, phosphorylation of 
MKP3 enhances its degradation, which further facilitates ERK activity (Marchetti et al. 
2005). Several other MKP, such as MKP1/2, have ERK inactivating activity, and the 
phosphorylation of some leads to stabilisation, rather than degradation of the phosphatase 
(Brondello et al. 1999). 
 
1.10.2.2. Nuclear substrates of ERK 
The first proteins expressed when cells are stimulated appear within a few minutes; 
the genes encoding them are known as immediate early genes (IEG). The transcription of 
IEGs is often regulated by special elements in their promoters (e.g. serum responsive 
elements (SRE)), that are activated by constitutively expressed transcription factors. 
Multiple different IEGs are induced by ERK signalling (figure 1.17). Two such factors 
will briefly be discussed here to represent the role of ERK. 
The earliest transcriptional event known to occur in response to mitogens is the 
induction of c-Fos expression. c-Fos is a bZIP transcription factor that, together with c-
Jun, comprises one form of AP-1. Quiescent cells do not express c-Fos, but their 
stimulation promotes rapid induction of the c-Fos gene by a mechanism that involves 
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Elk1. Under distinct conditions, the duration of c-Fos expression can vary from a few 
minutes to several hours after stimulation, and this can dictate the number and type of 
genes that the c-Fos-containing AP-1 transcribes (Eferl and Wagner 2003). These changes 
in the duration of expression are regulated by a combined action of protein kinases and 
proteinases. Thus, without phosphorylation, both the mRNA and protein of c-Fos undergo 
rapid degradation, which restricts the expression of the protein to several minutes. 
However, phosphorylation by both ERK and RSK can stabilize the c-Fos protein for 
several hours (Murphy et al. 2002). 
The phosphorylation of c-Fos requires the existence of active ERK and RSK in the 
nucleus of the stimulated cells, which occurs only upon a strong and sustained stimulation 
of the ERK cascade. Since the phosphorylation of the newly transcribed c-Fos can be 
mediated only by ERK that has been active for a long time, c-Fos can mediate responses 
to differences in ERK’s kinetics resulting in differential gene expression. C-Fos can 
thereby serve as an important tool in the specificity determination of signals transmitted 
via the ERK signalling cascade, such as oncogenic transformation mediated by prolonged 
ERK activation (Murphy et al. 2002). Similar phosphorylation by ERKs seems to be 
important for the stability and activity of additional IEGs such as c-Myc and Fra (Murphy 
et al. 2004). It should be noted that c-Jun activity is also enhanced by ERK 
phosphorylation, which may occur independently from the activation by JNKs (Morton et 
al. 2003). Thus, ERKs serve as key regulators of IEGs in general, and AP-1 in particular, 
under many conditions and in most cells. 
Elk1 is a member of the ternary complex factors (TCFs) subfamily of ETS-domain 
transcription factors, which contains a C-terminal transcriptional activation domain with 
multiple MAPK core consensus phosphorylation sites (Buchwalter et al. 2004). 
Stimulation of cells with, for example growth factors, induces phosphorylation of 6–9 
distinct sites on Elk1, which enhances DNA binding and recruits coactivators such as 
CBP, p300 or Srb, which dramatically increases the transcriptional activity of Elk1. 
Extra-cellular signal-dependent phosphorylation and activation of Elk1 can be mediated 
to a lesser extent by other MAPK, including JNK and p38 (Whitmarsh et al. 1997). 
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1.10.2.3. Cytoplasmic substrates of ERK 
Although many ERK substrates are located in the nucleus and are phosphorylated 
after nuclear translocation, the number of cytosolic ERK substrates is not much smaller. 
One of the first identified targets of ERK is cytoplasmic phospholipase A2 (PLA2) that 
regulates the production and release of arachidonic acid in stimulated cells (Lin et al. 
1993). Since then, many cytosolic substrates of ERK have been described that propagate 
the cascades' signals to additional cytosolic and nuclear targets. In addition, ERK 
phosphorylates many cytoskeletal elements that influence cellular morphology, and act as 
anchor proteins that direct ERK movement. Representative members of the latter two 
groups of substrates are described below. 
 
1.10.2.3.1. RSK and other MAPKAPK 
The RSK family contains four human isoforms (RSK1-4), with similar structural 
properties. RSK participate in both nuclear and cytoplasmic ERK signalling, for example, 
mediating the prevention of apoptosis and induction of the cell cycle. Unlike most protein 
kinases, RSK contain two distinct catalytically active kinase domains that are both 
significant for their cellular functions. The C-terminal domain induces auto-
phosphorylation that is important for the activation by ERKs, whereas the N-terminal 
domain is responsible for the phosphorylation of the exogenous substrates of RSK. 
 
1.10.2.4. Paxillin and other cytoskeletal elements 
Paxillin is a focal adhesion protein that plays an important role in integrin and other 
receptor signalling, and regulates a variety of cellular processes including proliferation, 
morphology determination and motility. The ability of paxillin to transmit extra-cellular 
signals is mediated by protein–protein interactions that provide multiple docking sites for 
signalling and structural proteins. Thus, upon stimulation, paxillin recruits protein 
tyrosine kinases such as FAK and Src, which interact with and phosphorylate paxillin. 
This tyrosine phosphorylation also induces the further recruitment of adaptors and other 
signalling molecules that allow propagation of the signals at the plasma membrane level. 
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Among the intracellular signalling molecules that are induced through paxillin are the 
MAPK cascades, PI3K-dependent pathways and Rho-dependent kinases. Paxillin in turn 
is phosphorylated by p38 in order to stimulate neurite outgrowth in PC12 cells and by 
JNK to regulate cell motility (Brown and Turner 2004). Phosphorylation of paxillin by 
ERK was first noticed in EL4 thymoma cells, where it was suggested that this 
phosphorylation participates in the regulation of adhesion (Ku and Meier 2000). The 
phosphorylation by ERK is also induced by hepatocyte growth factor (HGF) resulting in 
recruitment and activation of FAK, as well as a subsequent enhancement of cell spreading 
and adhesion (Liu et al. 2002). Paxillin constitutively associates with MEK, while HGF 
induces recruitment of active Raf1 and inactive ERK to the complex (Ishibe et al. 2003). 
In this way, paxillin facilitates the activation of ERK, which in turn phosphorylates 
paxillin on its Ser81 in order to regulate FAK signalling (Ishibe et al. 2004). Thus, 
paxillin serves as a focal adhesion specific scaffold of the ERK cascade and may regulate 
ERK-mediated regulation of adhesion and morphogenesis. 
Besides the phosphorylation of paxillin, ERK appears to interact with, and 
phosphorylate, several other cytoskeletal elements. For example, ERK phosphorylation of 
vinexin participates in the regulation of cell spreading, and the induction of the 
anchorage-dependent activation of ERK2 (Mitsushima et al. 2004). Thus, ERK 
interaction can result either in phosphorylation of the skeletal protein and regulation of 
their functions, or in the recruitment of ERK to their appropriate targets. The latter 
process can facilitate ERK activity, and can occur without direct phosphorylation of the 
cytoskeletal element, as for tubulin  or vimentin (Reszka et al. 1995; Perlson et al. 2005). 
 
1.10.3. The p38 MAPKs 
These play an important role in asthma and autoimmunity in humans and are 
activated by numerous physical and chemical stresses, including hormones, UV 
irradiation, ischaemia, cytokines, osmotic shock and heat shock. Numerous MAP3Ks 
participate in p38 modules, including ASK1, MEKK1-MEKK 4, MLK2 and 3, DLK, 
ASK1, Tpl2, Tak1 and Tao1/Tao2. This diverse array of proximal kinases allows for 
activation by a wide range of stimuli. By contrast, only two MAPKKs have been 
 identified, MEK3 and MEK6. All four isoforms of p38 can be activated by
and p38ß are also activated by MEK3
p38 MAPKs are members of the MAPK family that are activated by a variety of environmental stresses and 
inflammatory cytokines. Stress signals are delivered to this cascade by members of small
Rho family (Rac, Rho, Cdc42). As with other MAPK cascades, the membrane
MAPKKK, typically a MEKK or a mixed lineage kinase (MLK). The MAPKKK phosphorylates and 
activated MKK3/5, the p38 MAPK kinase. MKK3/6 can also b
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immunosuppressive phenotype typical of late sepsis through the liberation of IL-10 and 
expansion of the immunosuppressive Th-2 cytokine phenotype within the T cell 
population (Lyons et al. 1997).  
1.10.4. The JNK family 
JNK was originally identified as 54-kDa stress-activated protein kinase (SAPK) 
(Chen et al. 2001). Members of the JNK family regulate apoptosis and responses to 
various stresses, including inflammation and radiation. JNK1 and JNK2 are the products 
of alternative splicing of a single gene and are expressed in many tissues, but JNK3 is 
specifically expressed in brain. JNK activation is much more complex than that of 
ERK1/2 owing to inputs by a greater number of MAP3Ks (at least 13, including MEKK1-
MEKK4, ASK and MLK, which are activated by upstream Rho-family GTPases). These 
activate JNK MAPKKs MEK4 and MEK7. The JNK MAPK modules are regulated by a 
number of different scaffold proteins, including JIP1, JIP2, JIP3/JSAP1, JIP4, ß-arrestin 
2, filamin and CrkII. The scaffold proteins are thought to target MAPK to different sites 
in the cell and play roles in kinase activation and substrate selection. Activated JNK 
phosphorylates ATF-2, Elk-1, and the transcription factor AP-1, which is made up of 
either a c-Jun homodimer or a c-Jun-c-Fos complex (figure 1.18). Although the effects of 
JNK are not as well understood as those of ERK and p38, JNK plays an important role in 
TNF- and inducible NOS expression in macrophages (Lahti et al. 2003). Gene targeting 
experiments indicate that JNK1 regulates differentiation of the Th2 subset of T cells, T-
cell activation, apoptosis of thymocytes and the insulin response, whereas JNK1 and 
JNK2 are required for neural tube development, control of IL-2 production in T cells and 
responses to UV. 
1.10.5. MAPK in chronic heart failure 
The role of MAPKs in pathological cardiac remodelling has been well studied, but 
the role in the lung in heart failure has not (Muslin 2008). ERK 1/2, JNK 1/2 and p38 are 
all activated in both the infarcted and adjacent normal heart immediately following the 
insult in rat and murine models (Yoshida et al. 2001; Ren et al. 2005). The ERK 1/2 and 
p38 signalling pathways are stimulated acutely by myoctye stretch, but not by the already 
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hypertrophied myocardium, suggesting that cardiac stretch secondary to volume overload 
is the early stimulus for MAPK activation (Takeishi et al. 2001).  
1.10.5.1. JNK and p38 
p38 was consistently activated for several weeks post MI and genetic inactivation 
of this MAPK reduced infarct zone scarring, cardiac myocyte apoptosis and left 
ventricular end-systolic volume (Ren et al. 2005). Transgenic mice over-expressing p38 
had increased ischaemia/reperfusion injury post MI (Kaiser et al. 2004). Pharmacological 
inhibition of p38 was associated with improved systolic function, decreased myocardial 
fibrosis and lower collagen-I levels, although the timing of intervention may be pertinent 
(See et al. 2004; Frantz et al. 2007; Yin et al. 2008). Mice with ASK1 (a MKKK able to 
activate both p38 and JNK) deletion exhibited reduced cardiac remodelling (Yamaguchi 
et al. 2003). Over-expression of MEKK4, an upstream regulator of JNK1/2 and p38 
induced, cardiomyocyte aopotosis in vitro and resulted in early mortality with evidence of 
heart failure in vivo (Mizote et al. 2010). JNK 1/2, but not p38, activation was reduced 
in the infarct border zone in animals post LCA ligation, suggesting that JNK 1/2 
signalling promotes pathological cardiac remodelling after MI (Yamaguchi et al. 2003). 
Figure 1.19 summarises the signalling mechanism through which p38 and JNK are 
thought to be involved post MI. 
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MAPKPKs, MAPK-activated protein kinases; MAPKK, MAPK kinase; MAPKKK/MAP3K, MAPK kinase 
kinase; MEK, mitogen-activated protein kinase kinase; MNK, MAP kinase-interacting serine/threonine 
kinase; MSK, ribosomal protein S6 kinase, 90Kd; PAK, p21-activated kinase; JNK- c-Jun NH2- terminal 
protein kinase; TAK- transforming growth factor -activated kinase 1; ASK- apoptosis signal-regulating 
kinase 1; TAO- thousand-and-one amino acid kinase. 
 
1.10.5.2. ERK 1/2 
Differences in MAPK signalling occur in the heart, with ERK activation remaining 
more prominent in the infarcted compared to remote myocardium, whereas p38 activation 
showed the opposite pattern (Yeh et al. 2010). Over-expression of MEK1, an upstream 
kinase of ERK 1/2, lead to marked cardiac hypertrophy without fibrosis.  
It is clear that the MAPK signalling pathways have differing roles in the heart in 
CHF, contributing to cardiac hypertrophy, apoptosis and fibrosis. It is unknown how 
these pathways are affected in the lungs of CHF animals. 
 
 
 
 
 
 
Figure 1.19: Signalling cascades leading to the activation of the MAPK p38 and JNK (from Avikran 
and Marber (Avkiran and Marber 2010)) 
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1.11. In vivo models of chronic heart failure 
The availability of an in vivo model in which to test in vitro hypotheses is 
paramount. Ideally in vivo work would be carried out in the most relevant model- the 
human in vivo or in vitro heart and lungs. Here, however, are problems of availability, 
ethical implications and cost. Consequently appropriate animal models have been sought 
as an alternative (Hearse and Sutherland 2000). Animal models of heart failure range 
from cellular component models, through mice and rats, up to large animal models such 
as the pig and the dog (Hasenfuss 1998; Hearse and Sutherland 2000). Generally as the 
size of the animal model increases so does the relevance, but also the cost (figure 1.20)  
Figure 1.20: The trade off between clinical relevance, cost and quantity, quality and reproducibility 
of data in differing animal models of heart failure (from Hearse and Sutherland; (Hearse and 
Sutherland 2000)) 
 
1.11.1. Myocardial infarction secondary to left coronary artery ligation in the rat 
Coronary ligation to induce myocardial infarction in vivo in rats has been used to 
study the acute and chronic effects of myocardial infarction since the first description by 
Heimburger in 1946 (Heimburger 1946). The rat is an appropriate species to create this 
model as the rat heart has relatively few collateral vessels. After myocardial infarction, 
progressive remodelling of both the infarct and the ventricle occurs. Progressive LV 
dilatation develops for 4 months post infarction, with increases in chamber volume up to 
81% compared with normal age matched controls (Roberts et al. 1983; Olivetti et al. 
1991).  
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A review of all animal models is outside the scope of this thesis and has been 
comprehensively performed by others (Hasenfuss 1998; Hearse and Sutherland 2000). 
This work intends to investigate the effects of myocardial infarction on pulmonary 
parameters, specifically the production of inflammatory and fibrogenic mediators. As 
such the rat left coronary artery ligation (LCA) model is a suitable model because the 
progression of left ventricular failure is associated with neurohormonal activation similar 
to that seen in patients with CHF(Yamagishi et al. 1993; Teerlink et al. 1994; van 
Veldhuisen et al. 1994). 
 
1.11.2. Sarco/endoplasmic reticulum Ca2+ ATPase (SERCA)2a gene therapy and 
heart failure 
 
1.11.2.1. The role of sarco/endoplasmic reticulum Ca2+ in the cardiac cycle 
Cardiac calcium is crucial in excitation-contraction coupling, the process within 
myocytes that allows heart contraction (systole) and relaxation (diastole). During systole 
the cardiac myocyte membrane is depolarised resulting in a small calcium influx through 
the sarcolemma L-type calcium channel (LTCC). In response to this small influx a 
ryanodine receptor (RyR2) releases further calcium from the sarcoplasmic reticulum 
(SR). The consequential further increase in IC calcium allows calcium binding to the 
myofilament protein troponin C, leading to sarcomere shortening and hence contraction. 
In turn the RYR2 closes, calcium dissociates from troponin C and 75% of the IC calcium 
is returned to the SR by a SR calcium channel pump- SERCA2a.  This results in muscle 
relaxation. Hence, SERCA2a facilitates diastole by lowering cytosolic calcium and 
prepares the cell for further systole by replenishing the SR with calcium. 
 In CHF, excitation-contraction coupling is aberrant with abnormal calcium 
trafficking. Cardiac myocytes in CHF have increased IC calcium with dampening and 
prolongation of the calcium transient (Lipskaia et al. 2007; Kawase and Hajjar 2008). In 
keeping with this, SERCA2a expression and activity is reduced in the failing myocardium 
with decreased SR calcium uptake (Lipskaia et al. 2007; Kawase and Hajjar 2008). In 
addition to the effects upon cardiac cell mechanics the dependence of multiple signalling 
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pathways on calcium mean that disturbances in calcium homeostasis has other wide-
reaching effects including: mitochondrial dysfunction, cardiac arrhythmias and alterations 
in gene transcription, vascular smooth muscle cell proliferation and nitric oxide 
expression Except for the latter, these consequences of altered IC calcium levels in the 
cardiac myocyte are detrimental. Restoration of SERCA2a in the myocardium is therefore 
an attractive therapeutic strategy. 
 
1.11.2.2. SERCA2a gene therapy in chronic heart failure 
Persistent over-expression of SERCA2a, but not SERCA2b, in transgenic animals 
improved cardiac contractility. Over expression of SERCA2b resulted in cardiac 
hypertrophy and dysfunction (He et al. 1997; Ver Heyen et al. 2001). SERCA2a gene 
transfer improved energy utilisation by cardiac myocytes and increased survival in a rat 
model of CHF (del Monte et al. 2001; Sakata et al. 2007). Adenoviral directed SERCA2a 
gene transfer suppressed arrhythmias in animal models of cardiac reperfusion models, and 
increased ejection fraction and decreased bone naturetic protein (BNP) levels in large 
animal models of CHF (del Monte et al. 2001; Byrne et al. 2008; Kawase et al. 2008). 
Transgenic over-expression of SERCA2a alone however, increased the occurrence of 
fatal ventricular tachyarrhythmias.  
 
1.11.2.3. SERCA2a and the lung 
The lungs are the immediate upstream target of the failing heart and as such are 
exposed to PVH. The effects of SERCA2a gene therapy in the lung have not been 
studied. SERCA2b was the predominant isoform present in airways smooth muscle cells 
with a decreased expression in cells from asthmatic patients(Mahn et al. 2009). The lung 
is receptive to SERCA2a gene delivery- at five days after adenoviral delivery SERCA2a 
DNA was isolated from liver and lung in porcine experiments. At 90 days post delivery, 
increased SERCA2a expression occurred in the right ventricle, left ventricle, coronary 
arteries, pulmonary arteries, diaphragm and lung tissues. It is not known whether there is 
any functional consequence of this extra-cardiac uptake. 
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 The importance of understanding the functional effect of SERCA2a uptake by the 
lung is two-fold. Firstly, if cardiac parameters are improved by gene therapy, but 
pulmonary remodelling is fixed, then improvements in cardiac function could potentially 
be offset by persistent impairment in gas transfer and hence continued dyspnoea. 
Secondly, if pulmonary reverse remodelling does occur, but the rate is ahead of that of 
improvements in cardiac output, it is possible that the protection that ACM remodelling 
provides from acute pulmonary oedema (APO) in the face of raised left atrial pressure 
could be lost. Hence, patients would be more susceptible to APO and may be clinically 
worse rather than better until the cardiac output is restored to sufficient levels. Clinically 
this problem could be circumvented by supporting the LV with a ventricular assist device 
(VAD) ensuring the forward flow is sufficient whilst allowing the lungs and heart to 
recover. 
1.12. Hypothesis 
Abbreviations: PMVEC- pulmonary microvascular endothelial cells; ET-1 – endothelin-1; MCP-1- 
monocyte chemoattractant protein-1; ACM- alveolar capillary membrane; BMPR- bone morphogenetic 
receptor protein; TGF- transforming growth factor; BMP- bone morphogenetic protein. 
 
Figure 1.21 Schematic representation of the hypothesis to be tested by this thesis 
93 
 
The hypothesis to be tested by this thesis (figure 1.21) is that LV failure leads to 
raised LAP and PVH that imparts a mechanical strain at the pulmonary microvasculature. 
Mechanotransduction of this stimulus results in the release of inflammatory and 
fibrogenic mediators that contribute to ACM remodelling and the debilitating dyspnoea 
suffered by patients with CHF. Expression of BMPR was altered in lungs of CHF patents 
(Du et al. 2003). It is also hypothesised that such changes in receptor expression alter the 
TGF-BMP signalling balance and provide another stimulus for lung remodelling 
 
1.13. Experimental Strategy 
The pathophysiology of ACM and vascular remodelling in CHF is unclear, but is 
likely to involve a variety of resident cells, recruited cells and multiple mediators. The 
source of these “inflammatory” and fibrogenic mediators is unclear. MCP-1, ET-1 and 
IL-6 have been implicated in the pathophysiology of CHF and correlate with clinical 
outcome. All were elevated in animal models of CHF and were released by EC, although 
not pulmonary EC, in response to mechanical strain.  
Using the Flexercell apparatus, we sought to identify a robustly upregulated 
mediator by EC subjected to mechanical strain. Furthermore we aimed to determine the 
potential role of a “strain-induced” mediator in ACM and vascular remodelling by 
assessing the ability of supernatants from strained cells to increase fibroblast proliferation 
and differentiation, and cellular inflammation. Having established a robustly induced 
mediator, the next aim of this work was to identify components of the 
mechanotransduction pathway with particular attention to the MAPK pathways because 
they are known to signal in mechanotransduction pathways in other EC. 
 Experiments were performed using primary HLMVEC where possible, or, due to 
cell availability and cost, an endothelial cell line (Ea.hy 926), with confirmatory 
experiments performed using the primary cells. 
 BMPs and their receptors, the BMPRs, are considered important in the pathobiology 
of PAH, and expression or activity of the receptors are altered in CHF. We therefore also 
investigated the ability of BMPs to stimulate the release of ET-1 and MCP-1 by PAEC as 
a potential further contributory pathway to the pathophysiology of CHF. 
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 Finally through a local collaboration, a rodent model of CHF was used to test the 
relevance of the in vitro finding and to determine whether gene therapy used to restore 
haemodynamic function had an effect upon pulmonary parameters. 
The hypothesis to be tested is represented by curved boxes with a black border, filled with blue, green or 
red. Un-bordered boxes with red text represent a summary of the experimental strategy used to test the 
hypothesis. Abbreviations: PMVEC- pulmonary microvascular endothelial cells; ET-1 – endothelin-1; 
MCP-1- Monocyte chemoattractant protein-1; ACM- alveolar capillary membrane; BMPR- bone 
morphogenetic receptor protein; TGF- transforming growth factor; BMP- bone morphogenetic protein; EC- 
endothelial cell; SMC- smooth muscle cell; LCA- left coronary artery 
Figure 1.22 Diagrammatic representation of the proposed experimental tools used to test the differing 
components of the hypothesis 
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2. Chapter 2: Materials and Methods 
2.1. Materials 
2.1.1. Cell culture reagents 
Ea.hy 926 cells, 
Human fetal lung (HFL)-1 fibroblast cells 
Human pulmonary artery smooth muscle  cells (PASMC) 
  
 
Ea.hy 926 endothelial cells ECCC 
HFL-1 cells Gift of Dr. R. Chambers 
PASMC Lonza (CC 2581) 
Dulbecco's modified eagles medium  Sigma-Aldrich (D6546) 
Fetal calf serum Invitrogen (10108-165) 
Glutamine Invitrogen (25030-024) 
Phosphate buffered saline Sigma-Aldrich (D8662) 
Penicillin/Streptomycin Invitrogen (15140-122) 
Trypan Blue Sigma-Aldrich (T8154) 
Trypsin  (0.25%) + EDTA (1mM) Invitrogen (15400-054) 
HAT (hypoxanthine, aminopterin, thymidine) 
media supplement 
Sigma-Aldrich (H0262) 
Non-essential amino acid (NEAA) 100x Sigma-Aldrich (M7145) 
Human lung microvascular endothelial cells (HLMVEC) 
Human pulmonary arterial endothelial cells  (PAEC) 
 
HLMVEC Lonza (CC 2527) 
HLMVEC Promocell (C 12281) 
PAEC Lonza (CC2530) 
EGM -2 growth medium with supplements Lonza (CC3162) 
EGM-MV2 growth medium with supplements Lonza (CC3202) 
Reagent Pack (Trypsin, HEPES, TNS)) Lonza (CC5034) 
Endothelial Growth Medium MV2 Promocell (CC-2022) 
Detach Kit Promocell (CC-41210) 
 
2.1.2. Cytokines, inibitors and other drugs 
Recombinant human (Rh) bone morphogenetic 
protein (BMP)-2 R&D Systems (355-BM-010) 
Rh BMP-4 R&D Systems (314-BP-010) 
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Rh BMP-6 R&D Systems (507-BP-020) 
Rh BMP-9 
R&D Systems (3209-BP-
010) 
Human monocyte chemoattractant protein  
(MCP)-1  R&D Systems (279-MC-010) 
Anti-MCP-1 blocking antibody R&D Systems (AB-279-NA) 
U0126 Calbiochem (662005) 
PD98059 Calbiochem (513000) 
U0124 Calbiochem (662006) 
SB203580 Calbiochem (559395) 
SP600125 Tocris (1496) 
Phosphoramidon Sigma-Aldrich (P191) 
SC-514 Tocris (3318) 
BQ788 Sigma-Aldrich (B6791) 
BQ123 Sigma-Aldrich (B150) 
Cocktail inhibitor Roche (1836153) 
 
2.1.3. Molecular Biology Reagents 
2.1.3.1. RNA extraction, reverse transcription and RT-PCR 
RNeasy Mini Kit Qiagen (74104) 
RNase free DNase set Qiagen (79254) 
dNTP (set) Sigma-Aldrich (DNTP100A) 
Moloney murine leukaemia virus reverse 
transcriptase (MMLV) 
Invitrogen (28025-013) 
Moloney murine leukaemia virus RT buffer Invitrogen (Free with MMLV) 
Oligo (dT)12-18 primer Invitrogen (18418-012) 
PCR oligonucleotide primers Invitrogen Life Sciences 
Quanti Tect SYBR Green PCR kit Qiagen (204143) 
RNase Sigma-Aldrich (R4875) 
RNasin Promega (N2111) 
Trizol Sigma Aldrich (1559-026) 
PCR Tubes and Caps Qiagen 
Quantitect Primer Pairs Qiagen 
 
2.1.3.2. siRNA  
Control siRNA  Dharmacon (D-001810-01-05) 
OPTI-MEM I reduced serum medium  Invitrogen (31985062) 
97 
 
Dharmafect™ siRNA transfection reagent  Dharmacon (T2001-01) 
siRNA dilution buffer  Dharmacon (B-00200-UB-100) 
RNase free water Dharmacon (B-03000-WB-100) 
siRNA Smad-4 Dharmacon (L003902-00-005)  
siRNA Smad-2 Dharmacon (L003561-00-0005) 
Trizol Sigma Aldrich (1559-026) 
 
2.1.3.3. Western Blotting 
100bp ladder Promega (G6951) 
10% Tris-HCl ready gel Bio-Rad (161-1155) 
10X Cell Lysis Buffer New England Biolabs (9803) 
10x Tris/Glycine/SDS (TGS) buffer Bio-Rad  (161-0732) 
Chloroform Sigma-Aldrich (C 2432) 
CM-H2DCFDA  Invitrogen (C-6827) 
Laemmli Sample Buffer  Bio-Rad  (161-0737) 
5x Loading Buffer  
LumiGLO™ Reagent and Peroxide New England Biolabs (7003) 
Nitrocellulose Hybond ECL Amersham Biosciences 
(RPN203D) 
Phototope®-HRP Western Blot Detection New England Biolabs 
Protein A/G + agarose Santa Cruz 
Hyperfilm ECL (X ray film) Amersham 
Biosciences(RPN3114K) 
Milk powder Waitrose 
2.1.3.4. Antibodies 
See Table B.1, Appendix B 
 
2.1.4. General Reagents 
2-mercaptoethanol Sigma-Aldrich (M-7522) 
2-propanolol Sigma-Aldrich (S918121) 
Acetone Sigma-Aldrich (650501) 
Actinomycin D Sigma-Aldrich (A9415) 
Antimycin A Sigma-Aldrich (A8674) 
Aprotonin Sigma-Aldrich (A2268) 
Azino-di-(3 ethylbenzthiazoline sulphonic acid) 
diammonium salt (ABTS) 
Sigma-Aldrich (A9941) 
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Benzamidine Sigma-Aldrich 
Bovine serum albumin (BSA) Sigma-Aldrich (A7030) 
Bradford protein assay dye reagent concentrate Bio-rad (500-0203) 
Citric Acid BDH (100813M) 
Dimethyl sulphoxide (5×5ml DMSO) Sigma-Aldrich (D2650) 
Dimethyl sulphoxide (DMSO) Sigma-Aldrich (D5879) 
Dithiobis(2-nitrobenzoic acid) (DTNB) Sigma-Aldrich (D8130) 
Dithiothreitol (DTT) Sigma-Aldrich (D5545) 
Dulbecco's phosphate buffered saline solution 
(PBS without Ca2+) 
Sigma-Aldrich (D8537) 
Dulbecco's phosphate buffered saline solution 
(with Ca2+) 
Sigma-Aldrich (D8662) 
ELISA substrate reagents A+B BD Biosciences (555214) 
Ethanol BDH (L227007) 
Ethidium bromide solution Sigma-Aldrich (E1385) 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich (E6511) 
Glycine  Sigma-Aldrich (G8898) 
HEPES Sigma-Aldrich (H7006) 
Human albumin solution (20%) Bioproducts Laboratory 
Hydrogen Peroxide (H2O2) Sigma-Aldrich (H6520) 
Mayer’s hematoxylin solution Sigma-Aldrich (MHS-1) 
Meta phosphoric acid solution  Sigma-Aldrich (M-5043) 
Methanol BDH (10158BD) 
Methylthiazolitetrazolium (MTT) Sigma-Aldrich (M2128) 
Phenylmethanesulphonyl fluoride (PMSF) Sigma-Aldrich (D7626) 
Phosphate buffered saline tablets Sigma-Aldrich (P4417) 
Protein standard  Sigma-Aldrich (P5619) 
Sodium Azide (NaN3) Sigma-Aldrich (S2002) 
Sodium chloride (NaCl) Sigma-Aldrich (S7653) 
Sodium citrate solution Sigma-Aldrich (77437) 
Sodium dodecyl sulphate (SDS) BDH (436696) 
Sodium fluoride (NaF) Sigma-Aldrich (S7920) 
Sodium phosphate (dibasic - Na2HPO4) Sigma-Aldrich (S5136) 
Sodium pyruvate  Sigma-Aldrich (P5280) 
Streptavidin Peroxidase (for ELISA) Sigma-Aldrich (S5512) 
Sucrose  BDH (102745C) 
Triton X-100 BDH (30632) 
TRIZMA base Sigma-Aldrich (T6791) 
TRIZMA hydrochloride Sigma-Aldrich (T3253) 
Uridine  Sigma-Aldrich (U3003) 
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2.1.5. Kits 
Nuclear Extract Kit Active Motif (40010) 
Human CCL1/MCP-1 DuoSet ELISA Kit R & D (DY279) 
Human CXCL8/IL-8 DuoSet ELISA Kit R & D (DY208) 
Human IL-6 DuoSet ELISA Kit R & D (DY206) 
Human Angiopoeitin 1 DuoSet ELISA Kit R & D (DY923) 
Human Endothelin-1 ELISA Kit R & D (BBE5) 
Rat IL-6 Duoset ELISA Kit R & D (DY506) 
Mouse MCP-1 Duoset ELISA Kit R & D (DY479) 
PGE2 ELISA Kit R & D (KGE004) 
Cytotoxicity Detection Kit (LDH) Roche (11 644 793 001) 
 
2.1.6. Company Locations 
Active Motif Rixensart, Belgium 
Amersham Biosciences Little Chalfont, UK 
Axis Shield Dundee, UK 
Baxter Deerfield, IL, USA 
BD Bioscience Palo Alto, CA, USA 
BDH Poole, UK 
Bio-Rad Laboratories Hercules, CA, USA 
Biosource International Camarillo, CA, USA 
Calbiochem San Diego, CA, USA 
Cambridge Bioscience Cambridge, UK 
Cell Signalling Technologies Beverley, MA, USA 
European Collection of Cell Cultures Porton Down, UK 
Genlantis San Diego, CA 
Invitrogen Carlsbad, CA, USA 
Lonza Wokingham, UK 
Merck Poole, UK 
Molecular Probes Eugene, OR, USA 
Neuroprobe Gaithersburg, MD, USA 
New England Biolabs Hitchin, UK 
Pharmingen San Diego, CA, USA 
Promega Madison, WI, USA 
Promocell Heidelberg, Germany 
R&D Systems Abingdon, UK 
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Roche Mannheim, Germany 
Sigma-Aldrich Poole, UK 
Thermo Fisher Scientific (Dharmacon) Lafayette, CO, USA 
Tocris Bristol, UK 
 
 
2.2. General Methods 
2.2.1. Centrifugation 
Centrifugations were carried out for volumes less than 2 mls in one of two fixed 
angle machines Hawk 15/05 (Sanyo GallenKemp, Etten Leur, Netherlands) or Boeco M-
240 R (Hettich, Germany). For larger volumes a Hettich Rotina 46R swing bucket 
centrifuge was used (Hettich AG). Centrfugation speeds are quoted as the relative 
centrifugal force (e.g. RCF) or centrifuge rotor speed (RPM) followed by time, 
temperature and brake in parentheses 
2.2.2. Flexercell FX-4000TM system 
2.2.2.1. System components and working principle 
A computer controlled system, Flexercell® FX-4000TM was used to stretch cells 
according to computer-controlled protocols. The system consists of FlexCentral 
computer controller and software, BioFlex® base plate and gaskets, BioFlex® loading 
stations and BioFlex® plates (figure 2.1) (Gilbert et al. 1994; Schaffer et al. 1994). 
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The system achieves the biological strain conditions using vacuum pressure to 
deform a flexible membrane upon which cells are cultured. The BioFlex culture plate is a 
6-well culture plate with an optically clear thin membrane which can be deformed up to 
30% substrate elongation in the absence of loading stations or up to 20% substrate 
elongation in their presence. The membranes may be coated with different matrix proteins 
including collagen (type I or IV), elastin, laminin and fibronectin. The purpose of loading 
stations is to ensure uniform radial and circumferential strain is applied to the membrane 
surface for stretch up to 20% elongation. On application of a vacuum the membrane is 
pulled over the loading post and as a result each radius is stretched by the same amount at 
any point in the surface, hence applying uniform “equibiaxial” strain for all cells on the 
membrane (figure 2.2A). At elongations in excess of 20% loading posts are removed 
(figure 2.2B). 
 
 
 
Figure 2.1 Flexercell FX 4000TM System 
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Side view of the membrane being pulled over with and without a loading post 
 
2.2.2.2. Application of mechanical strain to the cells 
Amplitudes of 0, 30% strain were used in initial experiments in sinusoidal fashion 
at frequency of 20 cycles per minute to establish optimal cell seeding densities. 
Subsequently 0%, 20% continuous strain (with loading posts) or 30% cyclical strain 
(without loading posts) were applied. The vacuum produced up to 30% elongation on the 
flexible bottom membranes at a frequency of 20 cycles per minute, with a 
stretch/relaxation ratio of 1:1. In our experiments the latter two parameters were not 
varied, firstly for simplicity and secondly because these parameters allowed the 
membrane time to reach peak elongation and relax back to resting state. 
The inability to achieve 30% strain whilst using the loading posts is a limitation of 
the Flexercell™ system. Without loading posts a radially non-uniform strain field is 
produced, such that only a fraction of cells in the well's periphery are exposed to the 
desired amplitude of strain (i.e. 30%) (Gilbert et al. 1994; Schaffer et al. 1994). 
Furthermore, mechanical strain is not confined to the basolateral cell surface. The radial 
acceleration of cells relative to the stationary medium produces shear forces over the 
apical cell surface that are of uncertain significance. 
}BioFlexwell
Loading post
Gasket Gasket
Loading post
VacuumGasket
Gasket
}BioFlexwell
}BioFlexwell
Gasket Gasket
Vacuum
Gasket Gasket
}BioFlexwell
A B
Figure 2.2 Principle of Flexercell® FX-2000TM with (A) and without (B) loading posts 
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There are no definitive studies currently to quantify the levels of strain that the 
pulmonary microvascular EC are exposed to during the normal cardiac cycle or in the 
presence of raised LAP.  
2.2.3. Cell counting 
Cells were counted by using a haemocytometer (improved Neubauer model) under 
a phase contrast microscope (CK40, Olympus UK, Southend, UK). The total cell number 
in the four corner squares was counted including cells that overlapped the bottom and 
right border of squares but not those overlapped top and left border. Appropriate dilutions 
were made such that the total number of cells counted was between 100 and 400. The 
volume of each squares area was 10-4ml, and the number of cells per ml was calculated 
using the following formula: 
 
2.2.4. Kimura Stain 
Leukocytes from bronchoalveolar lavage (BAL) samples were counted in Kimura 
stain. The stain was prepared according to the protocol in Figure 2.3. Kimura contains 
saponin which enables it to breach the membranes of viable cells.  Nuclei stain dark 
purple. Cell suspensions are mixed with Kimura and examined under the microscope on a 
haematocytometer. Kimura was used to differentiate leukocytes on the basis of nuclear 
morphology. 
 
 
 
 
 
Cells/ml = Total cell number of four corner squares
4
X 10,000
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2.2.5. Determination of cell viability and proliferation 
2.2.5.1. MTT cell viability assay 
Yellow tetrazolium MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium 
bromide) is cleaved into purple formazan by metabolically active cells, in part by the 
action of dehydrogenase enzymes, to generate reducing equivalents such as NADH and 
NADPH (Mosmann 1983). The resulting intracellular purple formazan can be solubilised 
and quantified spectrophotometrically. In a homogeneous cell population, the amount of 
formazan generated is directly proportional to the number of viable cells over a wide 
range. After stretch experiments, cell supernatants were removed, the cells washed with 
buffer and incubated at 37°C with 1mg/ml MTT in medium for a period of time 
Preparation of Kimura stain 
 
Stock solutions 
Toluidine Blue   50mg toluidine blue,  
900mg sodium choloride,  
22mL 99.97% ethanol, 78mL distilled water. 
Light Green   150mg light green, 500mL distilled water 
Saponin  50mL 99.97% ethanol,  
    50mL distilled water.   
Add saponin until it is in excess and a 
significant amount precipitates out. 
0.2M phosphate buffer 1.42g disodium hydrogenphosphate dehydrate 
(MW 142), 1.36g potassium 
dihydrogennphosphate anhydrous (MW136) 
100mL distilled water 
 
Working solution 
Mix: 
 11mL  toluidine blue stock 
 0.8mL  light green stock 
 0.5mL  saponin stock (mix well first so precipitate resuspends) 
 5 mL  0.2M phosphate buffer. 
 
Figure 2.3 Protocol for preparation of kimura stain 
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dependent on the cell type (table 2.4). Following incubation, MTT solution was removed 
completely and the plates dried. Formazan dye was dissolved in DMSO for 15 minutes 
and the extinction measured at 550nm.  
 
2.2.5.2. CyQUANTTM cell proliferation assay 
The CyQUANT Cell Proliferation Assay Kit was used for the assessment of cell 
proliferation. This measures the total nucleic acid content of lysed cells. The green 
fluorescent dye, CyQUANT GRdye, exhibits strong fluorescence when bound to nucleic 
acid. After cell lysis and incubation with this dye the intensity of fluorescence from the 
nucleic acid-dye complex is measured by standard fluorimetry, with an increase in 
fluorescence that is proportional to increasing cell number.  
The assay does not depend on metabolic activity and cells may therefore be frozen 
prior to assaying. The assay reagents are shown in table 2.1 and the protocol is shown in 
figure 2.5. Data were expressed as proliferation relative to cell numbers in negative or 
unstimulated controls, with the unstimulated controls given a value of 1. 
Figure 2.4 MTT assay for cell viability and proliferation 
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Table 2.1 Reagents and their preparation for CyQUANT cellular proliferation assay 
2.2.6. Statistical Analysis 
Data are presented as mean plus or minus standard error of the mean (± SEM) for 
parametric data or as median with inter-quartile ranges for non-parametric data.  
Statistical analysis of normally distributed data was performed using an unpaired 
student’s t-test for comparison of 2 groups and a one-way anaysis of variance (ANOVA) 
followed by Bonferroni post test correction for comparison of 3 or more groups. Data 
Figure 2.5 CyQUANT proliferation assay protocol 
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were log transformed prior to analysis if variances were significantly different by 
Bartlett’s test. 
Analysis of non-parametric data was performed using a Mann-Whitney U test for 
comparison of 2 groups and a Kruskal Wallis test followed by Dunn’s post test correction 
for comparison of 3 or more groups.  
Data were analysed using GraphPad Prism version 3.00 (GraphPad Software Inc, 
San Diego, CA). Statistical significance was defined at the 95% level throughout, p<0.05. 
2.3. Cell Culture Protocols 
2.3.1. Primary human lung microvascular cells (HLMVEC) 
Primary HLMVEC were purchased from Lonza (UK). These cells are established at 
BioWhittaker’s cell culture facility from post mortem normal human tissue and are 
shipped at passage 4. The cells were maintained in microvascular endothelial cell growth 
medium-2 (EGM2®-MV) supplemented with 5% FBS and growth factors, antibiotics and 
other additions listed in table 2.2. They were incubated at 37oC in a humidified 
atmosphere of 5% CO2 in air. Cells were passaged when 60-70% confluent using 
Trypsin/EDTA for between 2 and 5 minutes, until 90% of cells were detached from the 
growth flask. Trypsin activity was stopped using trypsin neutralising solution (TNS). The 
cells were centrifuged at 190g for 5 min at room temperature and re-suspended in culture 
medium. The morphology of confluent HLMVEC under phase contrast microscopy is 
shown in figure 2.6. After a variable number of passages cell growth pattern or 
morphology altered, at which point cells were abandoned and a new vial purchased. For 
all experiments cells were used at passage 3-8. 
Figure 2.6 Morphology of confluent HLMVEC 
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Supplement Volume (ml) 
Human recombinant epidermal growth factor (hEGF) 0.5 
Human fibroblast growth factor- basic (hFGF-b) 2.0 
Vascular endothelial growth factor (VEGF) 0.5 
Ascorbic Acid 0.5 
Human recombinant insulin like growth factor (hr-IGF) 0.5 
Gentamicin and Amphoteracin 0.5 
Hydrocortisone 0.2 
Table 2.2 Growth factors and other additions to microvascular endothelial cell growth medium for 
maintenance of HLMVEC 
 
2.3.2. Human pulmonary artery endothelial cells (PAEC) 
Primary human pulmonary artery endothelial cells (PAEC) were purchased from 
Lonza (UK). These cells are established at BioWhittaker’s cell culture facility from post 
mortem normal human tissue and are shipped at passage 3-4. The cells were maintained 
in endothelial cell growth medium-2 (EGM-2®) supplemented with 2% FBS and growth 
factors, antibiotics and other additions listed in table 2.3. They were incubated at 37oC in 
a humidified atmosphere of 5% CO2 in air. Cells were passaged when 60-70% confluent 
using Trypsin/EDTA for between 2 and 5 minutes, until 90% of cells were detached from 
the growth flask. Trypsin activity was stopped using trypsin neutralising solution (TNS). 
The cells were centrifuged at 190g for 5 min at room temperature and re-suspended in 
culture medium. For all experiments cells were used at passages 3-8. 
Supplement Volume (ml) 
Human recombinant epidermal growth factor (hEGF) 0.5 
Human fibroblast growth factor- basic (hFGF-b) 2.0 
Vascular endothelial growth factor (VEGF) 0.5 
Ascorbic Acid 0.5 
Human recombinant insulin like growth factor (hr-IGF) 0.5 
Gentamicin and Amphoteracin 0.5 
Heparin sulphate 0.5 
Hydrocortisone 0.2 
Table 2.3 Growth factors and other additions to microvascular endothelial cell growth medium for 
maintenance of PAEC 
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2.3.3. Ea.hy 926 endothelial cell line 
Ea.hy 926 cells are an EC cell line derived from the fusion of human umbilical vein 
endothelial cells and A549 cells (a type 2 alveolar epithelial cell line derived from human 
bronchial-alveolar carcinoma). They were purchased from the European Collection of 
Cell Cultures (Centre for Applied Microbiology Research, Porton Down, UK) and 
maintained in Dulbecco’s modified eagles medium (DMEM) supplemented with 2mM 
glutamine, 10% FCS (heat inactivated), 100U/ml penicillin and 100µg/ml streptomycin, 
100 M hypoxanthine, 0.4 M aminopterin, and 16 M thymidine. They were incubated 
at 37°C in a humidified atmosphere of 5% CO2 in air. Cells were passaged after reaching 
95% confluence using 0.25% trypsin + 1mM EDTA for 5 minutes. Trypsin activity was 
terminated using 10% FCS supplemented DMEM and cells were pelleted by 
centrifugation for 5 minutes at 190g at room temperature. Cells were counted and seeded 
at appropriate densities in NUNC 6, 24 and 96 well microtitre plates or BioFlex™ 
depending on the required degree of confluence for individual experiments.  
 
2.3.4. Human fetal lung fibroblast and pulmonary arterial smooth muscle cell 
culture 
The human fetal lung fibroblast (HFL-1) cell line was a kind gift of Dr. Rachel 
Chambers (University College London, UK) and pulmonary arterial smooth muscle cells 
(PASMC) were purchased from Lonza (UK). The cells were maintained in DMEM 
supplemented with 2mM glutamine, 100u/ml penicillin and 100ug/ml streptomycin and 
incubated at 37oC in a humidified atmosphere of 5% CO2 in air. PASMC also required the 
addition of non-essential amino acid (NEAA) to medium. HFL-1 cells were cultured in 
DMEM supplemented with 10% FCS, but PASMC were grown in DMEM with 15% 
FCS. Cells were passaged using 0.25% trypsin/ 1mM EDTA after reaching 95% 
confluence for 5 minutes. Trypsin activity was then stopped using 10% FCS 
supplemented DMEM. The cells were centrifuged at 190g for 5 min at room temperature 
and resuspended in culture medium. Morphology of sub-confluent HFL-1 cells is shown 
in figure 2.7. 
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2.3.4.1. Human fetal lung fibroblast-1 and pulmonary artery smooth muscle 
cell proliferation experiments 
HFL-1 cells or PASMC were plated on 96 well plates at 5000 cells/well and 
incubated for 24 hours or until approximately 50% confluent. Cells were then quiesced in 
serum-free medium for 24 hours. Once quiesced cells were washed and treatments added 
to wells in triplicate. Serum-free DMEM was added to wells as a negative control and 
DMEM supplemented with 10% (HFL-1) or 15% (PASMC) added to wells as a positive 
control. Cells were cultured for a further 24 hours, supernatants aspirated to dryness and 
plates frozen at -800C until determination of cellular number by CyQUANT assay 
(section 2.2.5.2). 
2.3.4.2. Cellular differentiation experiments 
HFL-1 cells or PASMC were plated onto a 6 well plate at 2.5 – 3 x105 cells per well. 
Cells were grown for 24-48 hours until fully confluent. Cells were then washed and 
quiesced in serum-free DMEM for 24 hours. Cells were washed again and treatments 
added. Serum-free DMEM was used as a negative control and DMEM supplemented with 
10% (HFL-1 cells) or 15% (PASMC) FCS were used as positive controls. 
Figure 2.7 Approximately 80% confluent HFL-1 cells 
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After 24 hours of treatment supernatants were removed and total RNA extracted from 
cells (section 2.4.1.1). RNA was reverse transcribed to cDNA and gene expression for 
markers of cellular differentiation (alpha smooth muscle actin (SMA), vimentin, 
procollagen-1 (PC1), desmin) was determined by qPCR. 
2.3.5. Cell seeding densities 
Table 2.4 summarises the cell seeding densities for the different cell types in different 
well/ dish sizes unless otherwise state in the specific methods for each chapter. 
 









     
     
     
     
     
Table 2.4 Seeding densities for different cell types on cell culture plates 
Abbreviations: N/A- not applicable; HFL-1- human fetal lung fibroblast-1 cells; PASMC- pulmonary artery 
smooth muscle cells; HLMVEC- human lung microvascular endothelial cells; PAEC- pulmonary artery 
endothelial cells 
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2.4. Molecular Biology Protocols 
2.4.1. Ribose nucleic acid extraction  
2.4.1.1. Ribose nucleic acid extraction from isolated cells 
Total ribose nucleic acid (RNA) was extracted from cultured cells using RNeasy 
mini Kit (Qiagen) according to the manufacturers protocol. Cells were scraped from the 
surface of the well in buffer supplied (RLT buffer) and dissolved in equal volumes of 
70% ethanol. The mixture was then added to an RNeasy mini spin column and 
centrifuged to fix total RNA to the column. The RNA in the column is then washed with 
further buffers and then eluted using RNase free water into an eppendorf and used or 
stored at -20oC (figure 2.8). 
 
 
 
 
 
 
Figure 2.8 Protocol for RNA extraction using RNeasy spin columns 
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2.4.1.2. Ribose nucleic acid extraction from lung tissue 
RNA was extracted from lung tissue using a modified TriZol® and RNeasy protocol 
(figure 2.9). Between 50 and 100mg of tissue was homogenised using an electric 
homogeniser and suspended in 1ml TriZol®. The sample is processed as described in 
figure 2.9, once these steps were completed the remainder of the protocol is identical to 
that shown for cellular RNA extraction (i.e. from step 4 onwards; figure 2.9). 
The RNA concentration and purity were determined by measuring 
spectrophotometric absorption at 260 nm to 280 nm. This was undertaken on either the 
Shimadzu UV-VIS spectrophotometer 1201 (Milton Keynes, UK) or the nano-drop 
ND1000 spectrophotometer (Lab tech International, East Sussex). The quality of the 
RNA was additionally checked by agarose gel electrophoresis on a 1.5% gel (figure 2.10). 
The integrity of total RNA can be measured using an agarose gel.  Total RNA was 
run on agarose gel containing ethidium bromide in 1x TBE buffer using horizontal gel 
electrophoresis apparatus: 24cm x24cm gel HU13 (Thistle Scientific, Glasgow, UK) and 
visualised using a UV transilluminator (figure 2.11). Good quality RNA should exhibit 
Figure2.9 Protocol for ribose nucleic acid extraction from whole lung tissue 
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well-defined large and small ribosomal RNA bands (figure 2.11), and the ratio of the 
band density of 28S:18S for mammalian total RNA should be approximately 2.  
Additional bands or a smear between the two rRNA bands or below the small rRNA 
band, are indicative of degradation in the total RNA sample. 
 
 
 
 
 
Figure 2.10 Protocol for the determination of extracted ribose nucleic acid quality by agarose 
gel electrophoresis 
Figure 2.11 Agarose gel showing electrophoresis of ribose nucleic acid extracted from whole 
rat lung 
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2.4.2. The polymerase chain reaction 
2.4.2.1. Basic principles of reverse transcription polymerase chain reaction 
(RT-PCR) 
2.4.2.1.1. Reverse Transcription 
RNA is converted into complementary DNA (cDNA) by reverse transcription (RT), 
which is then specifically amplified by PCR. mRNA is non-specifically transcribed into 
cDNA using a polyT primer (oligo dT) or specifically transcribed using gene-specific 
primers. Moloney Murine Lukaemia Virus reverse transcriptase (MMLV-RT) is the most 
commonly used reverse transcriptase and is used in this thesis. The RT primer used in 
conjunction with MMLV-RT in this thesis is an oligo dT that hybridised with the poly(A) 
end of mRNA. Polymerisation commences from this primer and proceeds in a 5’-3’ 
direction. In this situation all mRNA is reverse transcribed into cDNA (figure 2.12) 
 
2.4.2.1.2. Polymerase chain reaction (PCR) 
The polymerase chain reaction, first described by Saiki in 1985 (Saiki et al. 1985) 
allows amplification of  DNA from a selected region of the genome or specific short 
fragments of DNA. Similarly RNA sequences may be amplified after reverse 
Figure 2.12 The principle of reverse transcription 
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transcription to cDNA. Specificity of amplification is provided by designing synthetic 
oligonucleotides complementary to DNA sequences surrounding the region of interest. 
These primers are able to bind to the DNA in the presence of a Taq (heat stable DNA) 
polymerase and an excess of deoxynucleotides. 
The PCR then follows 3 main stages. Firstly heating the DNA denatures the double 
stranded helix allowing the formation of ionic bonds between the single-stranded primer 
and the now single-stranded template. These ionic bonds are temporary and are 
continually formed and broken, but stable bonds form when the primers attach to their 
complementary region on the single-strand of DNA. With these more stable bonds 
formed the Taq polymerase is able to attach and copies the template. As a few bases are 
constructed in the newly synthesised chain stable ionic bonds form between the template 
and the primer. Continued incubation with the DNA polymerase and the four 
deoxyribonucleotide triphosphates facilitates the synthesis of DNA downstream from the 
primers. This process is termed annealing. A subsequent extension step enables the 
polymerase to increase the amount of DNA by attracting bases to attach to it. Each 
consecutive cycle doubles the amount of DNA present, amplifying the area or gene of 
interest (figure 2.13). 
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Figure 2.13 Schematic representation of polymerase chain reaction. 
P1 / P2- Primer 1 or 2; ds- double stranded; ss- single stranded.  
2.4.2.1.3. Real time RT-PCR 
“Real-time” analysis of the PCR product as amplification occurs has been made 
possible by the introduction of dual-labelled oligonucleotide probes (which emit as 
fluorescence signal on cleavage) and dsDNA binding dyes. The specific products of PCR 
can be monitored based on fluorescence-kinetics after each cycle. Here the Rotor-Gene 
3000TM four channel multiplexing system (Corbett Research, Mortlake, Sydney, 
Australia) was used. This system used four separate light sources (blue, green, orange and 
red) to span the visible spectrum. SYBR Green I is a DNA binding dye that has 
undetectable fluorescence when in its free form, but which fluoresces when it 
incorporates into dsDNA. This is a relatively simple and cheap method of dsDNA 
quantification, but has the disadvantages of binding to any dsDNA, including the specific 
target DNA, non-specific PCR products and primer dimers. The fraction of fluorescence 
originating from primer dimers or non-specific products can be distinguished from the 
fluorescence of target products by setting up a melt curve as the reference (chapter 
118 
 
2.4.2.1.4). The basic principle of real-time PCR using SYBR Green is summarised in 
figure 2.14 
 
Figure 2.14 The basic principle of real-time PCR using SYBR Green 
SYBR Green I was used for all real-time RT-PCR in this study. All real-time RT-
PCR was carried out by the QuantiTect SYBR Green PCR Kit. This kit provides accurate 
real-time quantification of DNA and cDNA targets. 
 
2.4.2.1.4. Melt Curves 
The melt curve is a post PCR analysis tool that is used to estimate the specificity of 
amplified products. The end products are incubated through a range of increasing 
temperatures.  The amplicon is then melted from a double stranded to single stranded 
state. At low temperatures the DNA is double stranded and so a high fluorescence is 
recorded whereas at high temperature the strands dissociate and a low fluorescence is 
recorded due to release of the dye. Melt curves are presented as a derivative plot showing 
rate of change of fluorescent signal.  The x-axis represents temperature and the y-axis is 
the negative derivative (rate of change) of fluorescence (F) with respect to temperature 
(T), shown as dF/dT (figure 2.15). The melting temperature depends on the length of 
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DNA, sequence and G:C content.  The peak of the plot represents the melting point (Tm) 
at which 50% of the DNA is single stranded.  More than one peak indicates more than 
one amplified product. Primer dimers denature into single strands at high temperatures. 
 
Figure 2.15 Melt Curve showing single amplification product 
 
2.4.2.2. Reverse transcription protocol 
Total mRNA (0.6µg) diluted in RNase free water (7µl) was used for reverse 
transcription and incubated with oligo(dT)12-18 primer (1µl) at 65°C for 10min. The 
reverse transcriptase mixture containing first strand buffer (5×, 2.8µl), DTT (0.1M, 2µl), 
dNTP (10mM, 2µl), RNase free H2O (1.7µl), RNasine (0.5U/µl, 0.5µl) and MMLV 
(200U/µl, 1µl) was added (10µl for each sample) and incubated for 1 hour at 37°C then 
subsequently at 65°C for 5min. The synthesized cDNA could be used immediately or 
stored at -20°C for several months until required. 
2.4.2.3. Polymerase chain reaction 
2.4.2.3.1. Selection of primers 
Gene accession number and mRNA and DNA sequences for genes of interest were 
obtained from the National Centre for Biotechnology Information (NCBI) GenBank 
database. Primers were either purchased as premixed forward and reverse primers 
(Qiagen, UK), or were selected with the aid of Primer3 software (http://frodo.-
wi.mit.edu/). All in house designed primers were synthesized by the Life Technologies 
Company and are listed in Table 2.5. Designed primer pairs were evaluated using the in 
silico assay evaluated module of RTPrimerDB (http://medgen.ugent.be/rtprimerdb/) to 
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avoid the presence of SNPs in primer annealing sites. The hairpin structure and primer 
dimerization were analyzed by NetPrimer (http://www.premierbiosoft.com/net-primer/). 
Gene Primer Pair Size Gene Sequence 
IL-8 Fwd: TCAGGGAGGCTACCACTTC 
Rev: TACTCCAAACCTTTCCACCC 
157 BC013615 
ET-1 Fwd: TCAGTTTGAACGGGAGGTTT 
Rev: CAAGCCACAAACAGCAGAGA 
83 NM_001955 
IL-6 Quantitect (Qiagen )  NM_000600 
MCP-1 Fwd: GATCTCAGTGCAGAGGCTCG 
Rev: TGCTTGTCCAGGTGGTCCAT 
85 NM_0002982 
ETAR Fwd: CTCCCACACCCAAGAAGAAA 
Rev: TCGTAGATGTTGTGGGTGGA 
72 NM_001957 
ETBR Fwd: AAGAACAAGTGCATGCGAAA 
Rev: GGATGTCAATGACGATGTGC 
85 NM_000115 
ECE Fwd: ATACTACCGTGCGTGCATGA 
Rev: CGAGCCTCTCAATCAACTCC 
80 NM_001397 
SMA Fwd: AGCCAAGCACTGTCAGGAAT 
Rev: AGAGCCATTGTCACACACCA 
88 NM_001613 
PC1 Fwd: AGCCAGCAGATCGAGAACAT 
Rev: CAGAGTGGCACATCTTGAGG 
88 NM_000302 
Desmin Fwd: CAGGTGGAGGTGCTCACTAAC 
Rev: TGTTCTCTGCTTCTTCCTTCAAC 
127 NM_001927 
Vimentin Fwd: CAGGACTCGGTGGACTTCTC 
Rev: CAGCTCCACCTTCTCGTTG 
81 NM_003380 
Table 2.5 Real-time PCR primers for human genes  
Acc. No.- accession number;; IL-8- Interleukin-8; EDN-1- Endothelin-1; IL-6- interleukin-6; MCP-1- 
monocyte chemoattractant protein-1; ETAR- endothelin a receptor; ETBR- endothelin B receptor; ECE- 
endothelin converting enzyme; SMA- alpha smooth muscle actin; PC1- procollagen-1. 
2.4.2.4. Selection of reference genes 
Fourteen reference genes were selected from those known to be stable in other cell 
systems (Vandesompele et al. 2002; Radonic et al. 2004). Their gene accession number 
and sequences were obtained from the NCBI (National Centre for Biotechnology 
Information) GenBank database. The primers were designed with the aid of Primer3 
software (http://frodo.wi.mit.edu/) and evaluated as above (section 2.4.2.3.1). All primers 
were synthesized by the Life Technologies Company (Paisley, UK). The length of the 
primers was from 19 to 21 mer, GC content was from 43% to 57%, and the expected PCR 
products ranged from 70 bp to 98 bp (table 2.7- Appendix B). 
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2.4.2.5. Analysis of gene stability and expression levels 
The stability of investigated genes was evaluated using the geNorm software 
program (http://medgen.ugent.be/~jvdesomp/geNorm/). This method of comparing the 
stability of gene expression relies on analysis of the variation between gene expression 
under the same experimental conditions and the variation between experimental 
conditions for the same gene (Vandesompele et al. 2002). The software calculates an 
index of the stability of gene expression (M), which is the mean pair-wise variation for a 
specific candidate reference gene compared with all other tested candidates (figure 2.16). 
After each round of analysis, the least stable reference gene is excluded in a stepwise 
manner thereby deriving the most stable pair of reference genes. A gene with a higher M 
value indicates a higher variation. The most stably expressed gene with lowest M value is 
then used to create a normalization factor (NF) against which the other genes under the 
same experimental conditions are ranked. The pair-wise variation (V) of sequential 
normalisation factors was calculated to determine the optimum number of reference genes 
to use for each cell type (figure 2.16). A V score of 0.15 was set as the cut-off value, 
below which reference genes were assumed to provide adequate normalisation (Pinhu et 
al. 2008){Vandesompele, 2002 #617. 
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GeNorm calculated (A) Average gene expression stability value (M) and Pairwise variation value (V) for 
HFL-1 subjected to cyclic mechanical strain (CMS). 
 
 
 
 
 
 
 
 
 
 
Figure 2.16 Example of GeNorm output graphs 
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2.4.2.6. PCR amplification 
PCR amplification was performed in a 20l reaction solution containing QuantiTect 
SYBR Green PCR Master Mix (2x, 10l), forward primer (10M, 1l), reverse primer 
(10M, 1l), template cDNA (1m, 1l), RNase-free water (7l). All reagents and 
materials were prepared as described below. The loading volume of reagents and samples 
were based upon duplicate measurement of each sample. (figure 2.17). Table 2.6 
summarises the amplification prolfiles of primers. 
 
 
Figure 2.17 Sample loading procedure for real time PCR 
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Table 2.6 Temperature profile for the investigation of human gene products 
2.4.2.7. Quantification of gene expression from a standard curve and melting 
curves 
Target PCR products may be quantified by absolute or relative methods after 
amplification. Absolute quantification uses external standards containing the same DNA 
sequence as the target region to produce external standards from which the absolute copy 
number of target products can be calculated. Relative quantification uses a standard curve 
constructed from the expression of standard or reference gene and describes the 
expression of the target gene relative to this standard. Consequently the reference gene 
should not vary under experimental conditions. 
A relative quantification method was used. One condition (usually non-stimulated 
e.g. unstretched cells) was selected as the original standard concentration and given an 
arbitrary value of 1. From this dilutions were made to 1:10, 1:30 and 1:100 and a standard 
curve is generated by the Rotor Gene 3000TM system software after amplification. From 
this relative expressions were calculated for other experimental samples and a report 
including sample labels, template amounts, cycle threshold (Ct) values and standard 
deviations was generated by the software.  
After completion of PCR a melting step was performed to verify specificity of PCR 
products. All the primers used in this study achieved single peaks  
 
 
Cycle  Cycle Point 
Denature @ 95ºc, 15 min 0 second  
Cycling (65 repeats) Step 1 @ 94ºc, hold 20 seconds 
 Step 2 @ 60ºc, hold 20 seconds, acquiring to Cycling A(FAM/SYBR, SYBR) 
 Step 3 @ 72ºc, hold 20 seconds 
Hold @ 72ºc, 0 min 15 seconds  
Melt (70-99ºc) , hold 5 seconds on 1st step, hold 15 
seconds on next steps, acquiring to Melt A(FAM/SYBR)  
Hold 2 @ 25ºc, 1 min 0 second  
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2.4.3. RNA interference 
2.4.3.1. Basic principle 
RNA interference is the mechanism for silencing the mRNA transcript of an active 
gene. Physiologically RNAi is used by most eukaryotes for anti-viral defence and gene 
regulation. Short double stranded RNA (dsRNA; less than 30 nucleotides) can cause gene 
specific silencing in mammalian cells {Caplen, 2001 #793;Elbashir, 2001 #792}. The 
introduction of long double-stranded RNA (dsRNA, typically >200 nucleotides) into 
mammalian cells initiates a vigorous non-specific anti-viral response: RNAi. (figure 
2.17). Transcription and translation are shut down, resulting in non-specific inhibition of 
protein synthesis and RNA degradation. An RNAse III enzyme, termed dicer, binds to the 
dsRNA and cleaves it into short pieces of ~20 nucleotide pairs in length, known as small 
interfering RNA (siRNA). The siRNA duplex products are recruited into a multi-protein 
siRNA complex, known as RNA-induced silencing complex (RISC). The RISC then 
guides the siRNA to bind to other single stranded RNA molecules of complementary 
sequence. Once bound endonucleases within the RISC cleave the mRNA strand 
complementary to the bound siRNA, thus mediating catalytic cleavage of the 
complementary RNA, degrading it and silencing expression of the viral gene (figure 
2.17). 
Figure 2.18 Mechanism of non-specific gene silencing by long dsRNAs 
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Introduction of synthetic siRNAs (less than 30 nucleotides long) induced highly 
specific gene silencing in mammalian cells bypassing the anti viral response and have 
since allowed the identification of genes of importance in biological pathways (figure 
2.18) (Elbashir et al. 2001). 
 
 
2.4.3.2. siRNA protocol 
2.4.3.2.1. Solutions and reagents 
The reagents and solutions are summarised in table 2.7. 
Reagents for siRNA  
siRNA Buffer (5x) Made up to 1x with RNase free water 
siRNA stock (20uM) Stored at -20oC in aliquots 
Control siRNA Stored at -20oC in aliquots 
DharmaFECT si RNA Transfection reagent 
OptiMEM-I medium Reduced serum medium 
Table 2.7 Reagents for short interefering RNA (siRNA) transfection 
The volumes of reagents required (per well) for a 24 well plate are summarised in 
table 2.8. Experiments for protein levels in supernatants were performed in 24 well plates. 
Figure 2.19 Mechanism by which siRNA bypass the anti-viral response 
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Experiments for determination of gene expression were performed in 6 well plates and 
those for intracellular protein expression were performed in 6cm dishes. Volumes were 
scaled up appropriately.  
Volumes for siRNA ( per well 24 well plate)   
 Eppendorf A (µl) Eppendorf B (µl) 
OptiMEM-I 49 50 µl – siRNA volume 
DharmaFECT-1 1  
*siSmad-4  0.38 
*si Smad-2  0.25 
*siControl  0.25 
Table 2.8 Volumes of reagents required per well of a 24 well plate for short interfering (si) RNA 
transfection experiments 
 
2.4.3.2.2. Protocol for siRNA 
Target-specific siRNAs against Smad-4 (siSmad-4) and Smad-2 (siSmad2) were 
designed and synthesised by Dharmacon. PAEC were seeded in 24 well plates at a 
density of 40x104.ml-1 in EGM-2 with all supplements. After 48 hours the cells were 50-
60% confluent, the optimal concentration for transfection of adherent PAEC.  The cell 
supernatants were removed, washed twice with optiMEM-I and replaced with 400l of 
fresh pre-warmed antibiotic free medium. The plate was then returned to the incubator. 
DharmaFECT-1TM reagent was prepared by the addition of DharmaFECT-1TM to 
OptiMEM-I, the serum free transfection medium. This was mixed gently and kept at RT 
for 5 minutes. The siRNA solution was prepared by mixing thawed siRNA stock, and 
transfection medium. This was mixed by pipetting up and down and also incubated at RT 
for 5 minutes. The siRNA solution was then added to the gene silencer solution and 
incubated at RT for a further 20 minutes to form the siRNA/siRNA transfection reagent 
complex. During this incubation period the optiMEM-I medium was aspirated off the 
cells, the cells were washed twice in optiMEM-I and then 400µl of fresh optiMEM-Iwas 
added to each well. After the 20 minute incubation period 100l of siRNA/Dharmafect 
mixture was added to the appropriate well and incubated at 37ºC for 30 hours. The 
process was identical for the negative control wells which contained scrambled control 
siRNA or the transfection reagent alone.  
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After 4-6 hours the siRNA/Dharmafect mix was replaced with fresh EGM-2 with 
all supplements and incubated for another 24 hours. At this stage cells were quiesced in 
EGM-2 supplemmented with 0.1% FCS and cells were ready for treatment 16 hours later 
i.e approximately 40 hours from removal of siRNA/Dharmafect mixture. The protocol is 
summarised in figure 2.20 
Abbreviations: RT- room temperature, PAEC- pulmonary artery endothelial cell; EGM-2 endothelial growt 
medium-2; FCS- fetal calf serum 
A simultaneous set up using the same cells and transcription reagents was used to 
confirm successful gene silencing by protein detection in 6cm dishes. Immunoblotting 
was used to assay the specific target protein following transfection. The optimal 
transfection durations and siRNA concentrations were based on work by our collaborators 
(Morrell, University of Cambridge School of Clinical Medicine Cambridge, UK). Cells 
were treated for 24 hours for assay of protein level in supernatants by ELISA and for 1 
hour prior to collection of whole cell lysate to determine intracellular protein levels. 
 
Figure 2.20 siRNA transfection protocol for pulmonary artery endothelial cells 
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2.4.4. Dominant negative gene delivery by adenoviral vector 
2.4.4.1. Basic principle 
Viral vectors have been used alongside transfection techniques as a method to 
deliver a gene to a cell (figure 2.21), in this case leading to the over-expression of a non-
functioning version of the gene. Adenoviral vectors are useful for gene transfer due to a 
number of key features: 1) they rapidly infect a broad range of human cells and can 
achieve high levels of gene transfer compared to other available vectors; 2) adenoviral 
vectors can accommodate relatively large segments of DNA (up to 7.5kb) and transduce 
these transgenes into nonproliferating cells; and 3) adenoviral vectors are relatively easy 
to manipulate using recombinant DNA techniques (Vorburger and Hunt 2002). Other 
vectors of interest include adeno-associated virus, herpes simplex virus, retroviruses and 
lentiviruses, a subset of the retrovirus family. Lentiviruses (e.g., HIV-1) are of particular 
interest because they are well studied, can infect quiescent cells, and can integrate into the 
host cell genome to allow stable, long-term transgene expression (Anson, 2004). 
Viral gene therapy vector entry into the mammalian cell. Viral vectors bind to cell surface receptors, 
initiating endocytosis through a clathrin dependent process. Once internalised, the viral particles avoid 
degradation via the lysosomal pathway and direct endosome trafficking to the cell nucleus. Adenoviral and 
adeno-associated viruses are released from the endosome in the perinuclear region, and the viral particles 
‘‘dock’’ on the nuclear envelope membrane pores. The viral particle capsid coat dissociates, and the 
genome is delivered into the cell nucleus. Retroviral and lentiviral vectors require further processing in the 
cytoplasm, including reverse transcription, prior to arrival in the nucleus. (figure was created by the US 
National Library of Medicine.) 
Figure 2.21 Principle of gene delivery using a viral vector 
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As with all gene transfer methods, there are drawbacks. For adenoviral vectors, 
packaging capacity is low, and production is labour-intensive (Vorburger and Hunt 2002). 
With retroviral vectors, there is the potential for activation of latent disease and, if there 
are replication-competent viruses present, activation of endogenous retroviruses and 
limited transgene expression. 
2.4.4.2. Protocol for viral gene transfection 
Abbreviations: MOI- multiplicity of infection; FCS- fetal calf serum; CMS- cyclic mechanical strain; PFU- 
plaque forming units  
 
 
2.5. Antibody –based assays 
2.5.1. Protein Assay 
The Bradford assay is a colorimetric assay based on the principle of binding 
brilliant blue to protein (Bradford 1976). Protein standards (BSA at 400g/ml) were 
prepared between 5 and 400µg/ml in distilled water. Standard or diluted samples (100µl) 
were added to 96-well micro-titre plate in triplicate. Bio-Rad Bradford Reagent (200µl) 
Figure 2.22 Protocol for dominant negative viral gen transfection into Ea.hy 926 cells 
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diluted reagent was added to each well. Absorbance was measured at 620nm using a plate 
reader. The absorbance of cell lysis buffer alone was measured to exclude the possibility 
of interference with the assay. Unknown protein concentrations were calculated using a 
standard curve (figure 2.23). 
 
Figure 2.23 Protocol for measuring protein concentration 
 
2.5.2. Whole cell extract 
Cells were washed with ice cold PBS then harvested. Cell lysates were stored at –
80oC. The protein content was determined as previously described in chapter 2.5.1.  
 
Determination Of Protein In Samples
Add 100µl of sample (or appropriately diluted sample) or standards
to triplicate wells on a microtitre plate
?
Add 200µl of diluted Bradford to each well, mix by gentle tapping
?
Read the absorbance at 620nm 
?
Undertake 4 parameter regression of control curve
Calculate unknown protein concentrations
Protocol
Reagents
4ml of Bradford + 16ml of distilled water for a 96 well plateBradford solution
Make up standard according to instruction to concentration of 400µg/ml of BSA, 
then make serial dilutions as following
Protein standard
Composition of working solutionSolution
1ml of 5 µg/ml12.5 µl of 400 µg/ml + 987.5 µl
1ml of 10 µg/ml25 µl of 400 µg/ml + 975 µl
1ml of 25 µg/ml62.5 µl of 400 µg/ml + 937.5 µl
1ml of 50 µg/ml125 µl of 400 µg/ml + 875 µl
1ml of 75 µg/ml187.5 µl of 400 µg/ml + 812.5 µl
1ml of 100 µg/ml250 µl of 400 µg/ml + 750 µl
1ml of 200 µg/ml500 µl of 400 µg/ml + 500 µl
1ml of 300 µg/ml750 µl of 400 µg/ml + 250 µl
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2.5.2.1. Preparation of the whole cell extract 
The whole cell extracts were prepared by harvesting the cells in 1× cell lysis buffer 
including 20mM Tris-HCl (pH 7.5), 150mM NaCl, 1mM Na2EDTA, 1mM ethylene 
glycol tetraacetic acid (EGTA), 1% Triton, 2.5mM sodium pyrophosphate, 1mM -
glycerophosphate, 1mM Na3VO4, 1g/ml leupeptin and 1mM phenylmethylsulfonyl 
fluoride (PMSF). The whole cell extract was kept at -20ºC until required. Samples were 
then centrifuged and supernatants collected as described in figure 2.24.  
Abbreviations: CLB- 1x cell lysis buffer. 
2.5.2.2. Preparation of protein extract from whole lung 
Whole lungs (or segments of whole lung) were snap frozen in liquid nitrogen at the 
time of euthanasia and stored at -800C until analysed. 50-100mg of sample was 
homogenised in a pestle and mortar in the presence of liquid nitrogen. Homogenates were 
then added to 1ml cell lysis buffer (as above) with protease inhibitors added. Samples 
were then processed using the same protocol used for cells grown in culture. 
Figure 2.24 Protocol for intracellular whole cell protein harvest. 
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2.5.3. Preparation of nuclear extract 
The cells were harvested in the presence of protease and phosphatase inhibitors. 
Nuclear extracts were used to detect the presence of components of the MAPK signalling 
pathway in the nucleus by Western blotting. In order to separate cytoplasmic proteins 
from the nuclear extract, hypotonic buffer was added to the cells followed by detergent 
causing leakage of the cytoplasmic proteins into the supernatant. The cytoplasmic fraction 
was collected after centrifugation. The nuclear proteins were lysed in lysis buffer with a 
cocktail of protease inhibitors. Nuclear extraction was performed using a nuclear 
extraction kit purchased from Active Motif (figure 2.25). Nuclear extraction was only 
performed using Ea.hy 926 cells and hence the protocol shown is adapted to suit these 
cells. 
Figure 2.25 Protocol of preparation of nuclear extract for Ea.hy 926 cells 
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2.5.4. Enzyme linked immunosorbent assay (ELISA) 
2.5.4.1. Basic Principles  
Enzyme linked immunosorbent assay (ELISA) is an immunologic assay that uses 
specific antibodies to detect and quantify solid phase bound proteins on a membrane, and 
proteins in solution. There are two common types of ELISA (figure 2.26). Sandwich 
ELISAs detect proteins in solution using an immobilized capture antibody. A washing 
step removes non-specifically bound material and an enzyme-marked secondary antibody 
with a second epitope to target protein is added. An enzyme-substrate reaction is used to 
amplify the signal (figure 2.27A). Alternatively, the target protein is immobilized and 
captured by the antibody in solution (figure 2.27B). The basic methodology of a sandwich 
ELISA is described in Figure 2.27. 
 
Figure 2.26 Two common types of Enzyme Linked Immunosorbent Assay (ELISA). Courtesy of L. 
Pinhu. 
A: Sandwich ELISA, capture antibody is immobilized on a solid support and captures target antigen in 
solution. B: Target protein is immobilized (such as expressed on the cell surface) and captures antibody in 
solution.  
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Figure 2.27 Basic principle of sandwich ELISA. Courtesy of L. Pinhu  
Ab- antibody 
 
2.5.4.2. Duoset ELISA 
Sandwich ELISAs for detection of a variety of proteins were performed using a 
generic ELISA protocol according to the guidelines provided by the supplier of the paired 
antibodies (Duoset ELISAs: R&D Systems). Supernatants were examined immediately 
after experiments or frozen at -80oC and used when necessary. The constituents of the 
reagents for the ELISA and ELISA protocol are shown in table 2.11 and figure 2.28. The 
duoset ELISAs were used to analyse for MCP -1 (human and rat), IL-6 (human and rat), 
angiopoeitin -2 and Il -8.  
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Table 2.9 Composition of ELISA reagents  
Figure 2.28 Duoset ELISA protocol and reagents 
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2.5.4.3. Specific ELISA: Endothelin-1 (ET-1)  
ET-1 ELISA kits were purchased from R&D Systems. Supernatants were removed 
for cytokine analysis following 24 hours incubation after stretch. Samples were stored at 
minus 80oC or assayed immediately for ET-1 following the supplied protocol. The 
reagents used and protocol are summarised in figures 2.29 and 2.30. 
 
 
Figure 2.29 Reagent preparation for ET-1 ELISA 
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2.5.5. Western blotting 
Western analysis or immunoblotting is a direct method for identifying and 
quantifying specific proteins in complex mixtures such as cell lysates. The complex 
protein mixture is fractionated according to molecular weight by gel electrophoresis. 
Separated proteins are transferred and blotted onto a membrane made of nitrocellulose, 
most commonly polyvinylidene fluoride (PVDF) or nylon. The membrane is incubated 
with a blocking reagent to shield non-specific binding sites. The primary antibody 
captures the target protein on the membrane. After washing steps to remove the unbound 
primary antibody, horseradish peroxidase conjugated secondary antibody binds to the 
primary antibody immobilized on the membrane with the specific protein. Horseradish 
peroxidase secondary antibodies are utilized in conjunction with specific 
chemiluminescent substrates to generate a light signal. The amount of peroxidase activity 
present is related to the amount of the target protein fixed to the membrane. The general 
principle for western blotting is summarised in Figure 2.31. 
Figure2.30 Protocol for ET-1 ELISA 
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Figure 2.31 The general principle of western blotting (courtesy of L. Pinhu) 
 
2.5.5.1. Gel electrophoresis, blotting and immunodetection of proteins 
The preparation of cell lysates is described in Chapter 2.5.2. The protocol for 
electrophoresis and immunodetection of proteins is shown in Figure 2.32. Samples were 
boiled with Dithiothreitol (DTT) to reduce oxidised disulphide bonds and loaded onto 
Sodium dodecyl sulphate (SDS) gels for electrophoresis. Molecular weight markers were 
also added to one well on each gel to monitor the progress of the electrophoresis. Details 
of the antibodies used are shown in table B.2 (Appendix B). The membrane was 
incubated with LumiGLO (0.5ml 20× LumiGLO, 0.5ml 20× peroxide and 9ml Milli-Q 
water) with gentle agitation for 1-5 minutes at room temperature following incubation of 
secondary antibody. Duration of exposure to x-ray film varied between antibodies and 
was dependent upon the amount of the investigated protein in the sample.  
+
_
2. Electrophoresis
1. Complex  
protein 
mixture 
3. Transfer to membrane
MembraneGel
Electric
Current
Cell lysate
or extract 
4. Bind 1st antibody
Primary antibody
5. Bind 2nd antibody
Secondary antibody
6. Chemiluminescent
Substrates – light 
X-ray film
Light 
140 
 
 
Western Blot Protocol 
Reagents 
 
1x Cell Lysis Buffer:  20mM Tris-HCl (pH 7.5), 150mM NaCl, EGTA, 1mM EGTA, 1% Triton, 
2.5mM sodium pyrophosphate, 1mM glycerophosphate, 1mM Na3VO4, 
1µg.ml leupeptin. 
 Add 1mM PMSF immediately before use. 
 
1x SDS Sample Buffer 62.5mM Tris HCl (pH 6.8 at 25°C), 2% w/v SDS, 10%  
for sample loading glycerol, 50mM DTT, 0.01% w/v bromophenol blue or phenol red.  
 
Running buffer For 2L- Trizma base 12.11g, SDS 2g, Glycine 57.65g, H2O 2L.  For 1L 
Trizma base 6.055g, SDS 1g, Glycine 28.825g, H2O 1L. 
 
Transfer Buffer 25mM Tris base, 0.2M glycine, 20% methanol (pH 8.5). For 1.5L- Trizma 
base 4.5g, Glycine 21.525g, distilled H2O 1200mls, methanol 300mls. 
 
Blocking Buffer 1x TBS, 0.1% Tween-20, 5% w/v non-fat dry milk. (100mls TBS and 5g 
milk powder) 
 
TBS- for washing 20mM Tris base, 137mM NaC, 0.1% Tween  
 
Gels  
For 2x 10% gels 
Separation gel 
-      8.3mls protogel 
- 6.5mls protogel buffer 
- 10.2mls water 
- 300µl APS Ammonium persulphate (10% 0.1g in 1ml H2O) – must premake 
- 30µl TEMED – add last 
 
Stacking gel:  
- 1.3ml protogel 
- 2.5ml protogel buffer (stacking) 
- 6.1mls H2O 
- 150µl APS 
- 30µl TEMED – add last 
Protocol 
1. Make SDS gel and load into western kit 
2. Add 950µl of loading buffer to 50µl of mercaptoethanol 
3. Add loading buffer to volumes of cell lysate containing 20-50µg protein in a 1:1 or 2:1 ratio.  Boil for 
5 mins at 100°C. 
4. Load 30µl sample and 10µl biotinylated protein marker onto gel. Add loading buffer to any empty 
wells.  
5. Run gel at 100V for 15 min followed by 150V for 40 min to 1 hour in running buffer until 
sufficiently advanced (dye reached bottom of gel). 
6. Transfer separated proteins onto nitrocellulose membranes using a TE22 transfer unit (Amersham 
Biosciences, UK) filled with transfer buffer set at 100V for 1 hr. 
7. Incubate membrane in blocking buffer for 1hr at room temperature on rocking platform (25rpm). 
8. Incubate membrane in the appropriate primary antibody diluted in blocking buffer for 1 hr at room 
temperature or overnight at 4°C on rocking platform. 
9. Wash membrane three times in TBS (10min per wash). 
10. Incubate membrane in appropriate HRP conjugated secondary antibody and anti-biotin antibody for 1 
hr at room temperature on rocking platform. 
11. Wash membrane three times in TBS (10min per wash). 
12. Incubate membrane in equal volumes of D1 and D2 with gentle agitation for 1-3 minutes. Expose to 
light sensitive film for appropriate time period. 
Figure 2.32Protocol for western blotting (courtesy of Dr. S. Leaver) 
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2.6. Rodent left coronary artery ligation model of chronic heart failure 
2.6.1. Rat Myocardial Infarction Surgical Protocol 
Lung tissue from rats at 16 weeks post left coronary artery ligation was made 
available through a collaboration with Dr. A. Lyon at the National Heart and Lung 
Institute (Imperial College, London, UK). Our collaborators induced left coronary artery 
(LCA) ligation as described (Lyon et al. 2009) Briefly, adult male Sprague-Dawley (SD) 
rats (250-350g) were anaesthetised and left thoracotomy was opened through the 4th 
intercostal space, and the pericardial sac was divided. The LAD was ligated proximal to 
the first diagonal using a 7.0 Prolene suture at a point 1-2mm distal to the left atrium 
inferior border along an axis parallel to the atrioventricular groove. Blanching and 
cyanosis of the myocardium confirmed effective ligation-induced myocardial ischaemia. 
After successful coronary occlusion, maintenance isoflurane was reduced to 1.0% during 
chest closure.  
 
Bleeding from the needle puncture was treated with gentle swab pressure, and 
further subcutaneous fluids were administered as necessary for fluid resuscitation. Phase 
1 ischaemic-induced ventricular fibrillation was treated by either a short phase of CPAP 
delivered for 2-3 ventilatory cycles, flicking the fibrillating heart, or compressing the 
fibrillating heart between two forceps handles. 
 
2.6.2. Lung and plasma harvest protocol at 16 weeks post left coronary artery 
ligation 
An initial group of animals (n=7) were studied to confirm the effectiveness of this 
model of CHF. In this initial group a wet lung weight only was recorded, due to the need 
for a prolonged period of ventilation required for haemodynamic recordings.  
Subsequent to this group the lungs of animals at 16 weeks post LCA, or age 
matched controls (AMC), were harvested for wet:dry weights, protein or RNA harvest, 
bronchoalveolar lavage and measurement of lung “dynamics” (figure 2.33). At the time of 
euthanasia animals were anaesthetised and ventilated, and the heart and lungs accessed 
via the abdominal cavity and diaphragm. This was to allow the heart to be approached in 
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a method which identified any pericardial adhesions to the anterior thoracic wall and for 
these to be dissected without damage to the heart. In addition a venous blood sample was 
collected from the inferior vena cava into a heparinised syringe (1-2 ml). 
Once the pericardium was clear of the anterior chest wall the heart and lungs were 
exposed by making two large lateral cuts along the lateral aspects of the anterior chest 
wall. The animals heart, lungs, mediastinum and great vessels were then removed en bloc. 
The organs were immediately immersed in ice cold Krebs Henseleit solution and the 
lungs dissected away from the heart along the plane of tissue between the aorta and 
trachea. A whole lung wet weight was immediately recorded and the lungs divided 
according to the protocol below (figure 2.33). 
Abbreviations: LCA- left coronary artery; BAL- broncoalveolar lavage 
 
 
 
 
 
Figure2.33 Protocol for the collection and use of the lungs and serum from rats at 16 
weeks post left coronary artery ligation, or age matched controls 
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2.6.2.1. Plasma collection for protein measurements 
The blood was transferred to a 2ml vial containing EDTA, and underwent 
centrifugation at 3000 revolutions per minute for ten minutes. The serum was aspirated, 
stored at -80oC and defrosted immediately prior to analysis. 
2.6.2.2. Whole lung wet weight and wet:dry weight ratio 
The whole lung wet weight was recorded at the time of euthanasia. To determine a 
wet:dry weight ratio a lobe of the right lung was removed and immediately removed and 
snap frozen in liquid nitrogen for RNA and protein analysis. The remainder of the lung 
was chilled on ice. Main airways, components of the mediastinum and other contaminants 
were dissected off and the lung homogenised in a 7ml bijou. Once homogenised a wet 
weight was recorded. The sample was then cooled by suspending the bijou in liquid 
nitrogen and placed in the freeze dryer for 24 hours, after which a dry weight was 
recorded. A wet dry weight ratio was calculated: 
 Wet:dry weight = (Wet weight/dry weight) *1000 
2.6.2.3. Dry weight body weight ratio 
The wet:dry weight ratio is adequate for determining the presence of pulmonary 
oedema but does not provide the ability to compare dry weight between animals because 
the starting amount of tissue being homogenised was not standardised between animals 
(the residual amounts of right lung varied depending upon which lobe had been snap 
frozen). Dry weight:body weight ratio is a more reliable measure of lung weight which 
allows comparison between animals (Dixon et al. 2009). In a subsequent group of 
animals the left lung was harvested solely for the recording of a wet weight and a dry 
weight. The left lung in the rat comprises of only one lobe and hence this allows for a 
standardisation between animals and the comparison of a measure of dry weight. 
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2.6.2.4. Protein and RNA collection 
Segments of right lung (weighing 50-100mg) were immediately snap frozen in 
liquid nitrogen and stored at -800C for later analysis of protein and RNA content. Samples 
were processed as described in sections 2.4.1, 2.4.2.2 and 2.4.2.3. 
2.6.2.5. Measurement of lung “dynamics” 
This work was based on the hypothesis that CHF in animals showed post infarction 
would show evidence of structural remodelling. To quantify this, a mechanism for 
determining lung dynamics was established. Left lungs of animals were divided from the 
right lung at the left main bronchus immediately below the carina. The lung was then 
briefly stored in a chilled sterilin for transfer to the laboratory. The left main bronchus 
was then cannulated with a 16G cannula (Abbocath, UK) and secured with a 2.0 silk 
suture. Once securely cannulated a manometer was attached and 0.5ml increments of ice 
cold normal saline instilled. After each instillation the airway pressure (cm H2O) was 
recorded using the manometer. The initial volume required to produce a recordable 
pressure in the manometer, termed the “opening volume”, was noted and felt to represent 
lung compliance- the more volume required, the harder the lungs were to open and hence 
the less compliant they were. Once a pressure recording was made further 0.5ml aliquots 
of ice cold normal saline were instilled and the pressure in the manometer recorded for 
each increment. Hence a volume/pressure curve was generated for each animal (figure 
2.24). Instillation was continued until 7mls of normal saline was instilled (or the lung 
showed evidence of volumetric trauma). Once the maximum volume was reached the 
manometer was removed and the saline expelled from the lung collected as a BAL into a 
sterile 10ml falcon. 
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2.6.2.6. Collection of bronchoalveolar lavage and cytospin and staining of 
lavage leucocytes 
2.6.2.6.1. Pelleting of cells from bronchoalveolar lavage and cytospin protocol 
The BAL was centrifuged at 200 rcf for 5 minutes at 40C to pellet any cells present 
in the BAL. The supernatant was aliquotted and stored at -800C for analysis at a later 
date. The cell pellet was then re-suspended in 500ul of ice cold PBS. 10µl of the re-
suspended cell mix was removed and mixed with 10µl of kimura stain and left to stand 
for 1-2 minutes. 10µl of this stained mix was then withdrawn and added to a 
haemocytometer and a total cell count made. 
The remaining 490µl of the re-suspended cell mix was then centrifuged onto a 
labelled slide using the cell cytospin (4500 rpm for 3 minutes). 
 
  
Figure 2.34 Pictoral representation of method for recording lung “dynamics” in ex-vivo rat lung. 
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3. Characterisation of  the effects of cyclic mechanical strain 
delivered by the Flexercell 4000 apparatus on human lung 
microvascular endothelial cells and establishment of the 
model of fibroblast proliferation and differentiation 
 
3.1. Introduction 
The aims of this initial work were to determine the effect of mechanical strain 
delivered by the FlexercellTM 4000 apparatus on human lung microvascular endothelial 
cells (HLMVEC) and to optimise experimental conditions. This work was necessary 
because we had not used the Flexercell™ device with this cell type or with a static 
protocol of mechanical strain before. Furthermore, I aimed to establish a model for the 
determination of fibroblast (human fetal lung fibroblast -1 cell line; HFL-1) proliferation 
and differentiation in response to supernatants from strained or unstrained HLMVEC. 
The specific objectives were:  
a. to determine the optimal seeding density and growth conditions for human 
lung microvascular endothelial cells and Ea.hy 926 cells on BioFlex™ 6 
well plates  
Work from our group has previously addressed the response of an immortalised 
pulmonary epithelial cell line (A549) to cyclic mechanical strain (CMS) as a model for 
ventilator associated lung injury (VALI). The intention in this thesis was to model raised 
pulmonary venous pressure on the lung microvasculature and as such mechanical strain 
protocols required optimisation for HLMVEC. Cyclic, as opposed to static, strain 
provides a more injurious stimulus to cells and thereby a greater output signal (Vlahakis 
and Hubmayr 2000). Although the pulmonary microvasculature will still be subjected to 
pulsatile flow from both the right ventricle and left atrium (back pressure), I also aimed to 
investigate the effect of static strain in order to abolish any effects of supernatant flow 
over the cells which is unavoidable in CMS. 
b. to determine the effect of static mechanical strain on cell viability 
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It is possible that mechanical strain applied to HLMVEC may cause cell death or 
detachment, producing misleading results. For example apparent mediator down-
regulation may simply be due to decreased cell number due to cell detachment or death. 
c. to select an appropriate reference gene for human lung microvascular 
endothelial cells, Ea.hy 926 and fibroblast cells whose expression was 
unaffected by cyclic mechanical strain.  
Real time reverse transcription PCR (RT-PCR) is a sensitive, reproducible method 
for expression profiling of selected genes. A proper internal control gene for 
normalization is critical in quantifying mRNA expression levels between different 
samples. However, reference gene expression may vary among tissues or cells, and may 
change when conditions vary (Dheda et al. 2004; Pachot et al. 2004). For example, in 
human T-cells the expression of common housekeeping genes was highly variable 
(Dheda et al. 2004). Similarly -actin is a commonly used housekeeping gene, but it is 
also known that mechanical strain deforms the basic cell structure and it is feasible that 
the expression of this gene could alter as the cell responds. (Chien 2007; Yamada and 
Ando 2007). Although reference gene expression has been reported to vary considerably, 
it has not been determined which gene is most suitable for SMS or CMS experiments 
with HLMVEC or Ea.hy 926 cells.  
d. to determine the optimal parameters for stimulating the robust production 
of a chosen mediator in human lung microvascular endothelial cells and 
Ea.hy 926 cells exposed to static mechanical strain 
ET-1 is increased by human umbilical vein endothelial cells (HUVEC) in response 
to CMS (Cheng et al. 2001). Endothelin-1 (ET-1) is an attractive target mediator in 
mechanical strain induced ACM remodelling in light of known pro-fibrotic and mitogenic 
properties, alongside observed increases in animal models and patients with CHF (Dawes 
et al. 1996; Dupuis et al. 1998; von Lueder et al. 2004; Koda et al. 2006). Other 
mediators released by EC in response to mechanical strain, raised in patients or animal 
models of CHF, and have pivotal roles in inflammation are: monocyte chemoattractant 
protein-1 (MCP-1), interleukin-6 (IL-6) and intercellular adhesion molecule-1 (ICAM-
1)(Tsutamoto et al. 1995; Aukrust et al. 1998; Cheng et al. 1998; Deswal et al. 2001; 
148 
 
Wung et al. 2001; Sasamoto et al. 2005). These are therefore also attractive target 
mediators.  
e. to establish a model to assess the effect of supernatants from stretched 
endothelial cells on fibroblast proliferation and differentiation 
The ACM in CHF is thickened by deposition of ECM, termed structural 
remodelling. To determine whether mechanical strain at the pulmonary microvasculature 
is implicated in this process I intended to investigate the effect of supernatants from 
stretched EC on fibroblast proliferation and differentiation.  
3.2. Specific Methods 
3.2.1. Determination of optimal cell seeding density and the effect of mechanical 
strain on cell viability and membrane integrity 
HLMVEC and Ea.hy 926 cells were plated on BioFlex™ 6 well plates to assess 
the production of IL-8. Cells were seeded at densities ranging from 3 to 8x105 cells/well 
and exposed to 2 hours of 30% CMS (0.33Hz). This regimen was chosen because it 
previously resulted in robust production of IL-8 from A549 and primary human alveolar 
type 2 (AT2) cells by our group (data not shown). IL-8 appears to be almost universally 
produced by cells in vitro in response to mechanical strain (Okada et al. 1998; Oudin and 
Pugin 2002; Yamamoto et al. 2002; Jafari et al. 2004; Harada et al. 2005). Cells were 
plated on BioFlex™ membranes at increasing densities and grown to confluence for 24 
hours with growth medium replaced with serum free medium 16 hours, and just prior to, 
CMS. Cells were exposed to 0% or 30% CMS for 2 hours at 0.33Hz and then incubated 
for 24 hours prior to the removal of supernatants for the assessment of IL-8 levels by 
ELISA.  
For cell viability and membrane integrity studies cells were seeded at the chosen 
optimal seeding density and subjected to mechanical strain as above. Cell viability was 
determined by MTT assay at 24 hours after cessation of CMS (chapter 2.2.5.1). Cell 
damage was quantified by measuring lactate dehydrogenase release (LDH) into 
supernatants at 10 minutes after CMS. 
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3.2.2. Determination of optimal reference genes for gene expression studies of 
mechanical strain in human lung microvascular endothelial and Ea.hy 926 cells  
HLMVEC were seeded at 5x105 cells / well 48 hours prior to mechanical strain to 
allow for cells to come to confluence. Cell growth medium was refreshed with serum-free 
medium 16 hours prior to, and again immediately before mechanical strain. A regimen of 
CMS was used for these experiments because this degree of strain is known to produce 
changes in gene expression, is a more powerful stimulus than static mechanical strain 
(SMS) and hence is a greater test of reference gene stability.  
Ea.hy 926 cells were plated BioFlex™ plates at a density of 4 x 105 cells per well. 
Cells were incubated for 24 hours in DMEM containing 10% FCS. After this time 
medium was replaced with serum free medium for 16 hours and again immediately prior 
to strain. 
Fibroblasts were plated onto 6 well BioFlex™ plates at a density of 3 x 105 cells 
per well. Cells were incubated for 48 hours in 10% FCS DMEM. After this time medium 
was replaced with 0% DMEM for 16 hours and again immediately prior to strain. 
All cells were subjected to mechanical strain for 2, 4 and 6 hours and RNA 
harvested immediately after strain or also at 2, 4 and 6 hours after 2 hours CMS. RNA 
was also harvested from cells grown on BioFlex™ plates but not subjected to CMS at 2 
hours in parallel with strained cells.  
Fourteen reference genes were selected from those known to be stable in other cell 
systems (Vandesompele et al. 2002). Their gene accession number and sequences were 
obtained from the NCBI (National Centre for Biotechnology Information) GenBank 
database. The primers were selected with the aid of Primer3 software 
(http://frodo.wi.mit.edu/)(Rozen S 2000). All primers were synthesized by the Life 
Technologies Company (Paisley, UK) and are listed in table B2 (appendix B). Designed 
primer pairs were evaluated to exclude single nucleotide polymorphisms from primer 
annealing sites with the public database for primer and probe sequences used in real-time 
PCR assays (RTPrimerDB: http://medgen.ugent.be/rtprimerdb/). The primers were 
analysed using NetPrimer (http://www.premierbiosoft.com/netprimer/) to exclude the 
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development of secondary structures, such as hairpins and primer dimers. The length of 
the primers was from 19 to 21 mer, GC content was from 43% to 57%, and the expected 
PCR products ranged from 70 bp to 98 bp (table 2.7 Appendix B). Gene expression was 
determined by real-time quantitative (qPCR) and the stability of investigated genes was 
evaluated using the geNorm software program (http://medgen.ugent.be/-
~jvdesomp/geNorm/; chapter 2.4.2.5). 
3.2.3. Determination of optimal parameters for stimulating the production of the 
chosen mediator in human lung microvascular endothelial cells and Ea.hy 926 cells 
exposed to cyclic mechanical strain 
HLMVEC and Ea.hy 926 cells were seeded at 4-5 x 105 cells / well and grown to 
confluence. Cells were then serum starved overnight and medium refreshed with serum 
free medium prior to CMS. RNA was extracted for gene expression by qPCR 
immediately after increasing durations of CMS. Supernatants were collected for ELISA 
assay after 24 hours incubation post CMS. 
3.2.4. Determination of fibroblast proliferation and differentiation in response to 
supernatants from strained and unstrained human lung microvascular endothelial 
cells and the role of endothelin-1 
To investigate the role of EC strain in ACM structural remodelling fibroblasts were 
cultured in the presence of supernatants from strained and non-strained HLMVEC. Cell 
proliferation was determined using the CyQUANT assay (chapter 2.2.5.2) and 
differentiation by alpha smooth muscle actin (SMA) gene expression (chapter 2.3.4.2). 
Furthermore to address the importance of ET-1 in fibroblast differentiation and 
proliferation, SMS induced ET-1 release was attenuated by phopshoramidon and HFL-1 
cells were then incubated in supernatants from HLMVEC exposed to 0% and 20% SMS 
in the presence of phosphoramidon or a vehicle control, as summarised in figure 4.1.  
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HLMVEC were grown to confluence on BioFlex™ 6 well plates and quiesced overnight in medium 
containing 0.1% fetal calf serum (FCS). HLMVEC were then subjected to 4 hours of 0% or 20% static 
mechanical strain (SMS) in the presence or absence of phosphoramidon or vehicle control. Cells were 
incubated for 24 hours post SMS and then harvested for measurement of ET-1 level by ELISA or added to 
confluent quiesced fibroblasts (HFL-1) cells cultured either in 6 well plates (for mRNA) or 96 well plates 
(for CyQUANT). HFL-1 cells were also incubated in DMEM containing 0% or 10% FCS alongside “strain-
supernatants” as positive and negative controls respectively. After 24 hours of further incubation HFL-1 
RNA was extracted for gene expression or supernatants were aspirated from 96 well plates, plates were 
frozen at -80oC for later determination of relative cell number by CyQUANT proliferation assay. 
 
3.3. Results 
3.3.1. Optimal seeding density for application of mechanical strain to human lung 
microvascular endothelial cells and Ea.hy 926 cells 
HLMVEC (A) and Ea.hy 926 (B) cells were seeded at varying densities, grown for 24 hours, quiesced and 
subjected to 30% cyclic mechanical strain (0.33Hz; 4hours). Supernatants were collected at 24 hours post 
stretch and analysed for IL-8 using ELISA. Data presented as mean ± SEM from 3 independent 
experiments.  
Figure 3.1 Schematic representation of protocol to assess “strain supernatant” induced fibroblast 
proliferation and differentiation 
Figure 3.2 Effect of CMS on Interleukin-8 (IL-8) release by (A) HLMVEC and (B) Ea.hy 926 Cells at 
different cell seeding densities
 Both cell types increased IL
Ea.hy 926 cells expressed lower levels of IL
increase was still seen. An optimal seeding density of 5 x 10
Ea.hy 926 cells based upon the largest difference between strained and unstrained cells. 
The same density was chosen for HLMVEC based upon the increase in IL
seeding densities of 4 and 6 x 10
subsequent experiments identified this density to give the optimal confluence at 24 hours 
after plating (figure 3.
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Confluent human lung microvascular endothelial cells on BioFlex™ plates immediately 
prior to stretch 
-8 levels in supernatants at 24 hours after CMS 
-8 when compared to HLMVEC, but an 
5 cells / 
5 cell / well. Visual inspection of
3). 
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3.3.2. Effect of mechanical strain upon human lung microvascular endothelial and 
Ea.hy 926 cell viability and lactate dehydrogenase release 
Confluent HLMVEC (A) and Ea.hy 926 (B) cells were subjected to 30% cyclic mechanical strain (0.3Hz; 4 
hours). Cell viability was measured 24 hours after CMS by MTT assay. Data presented as mean ± SEM 
from 4 independent experiments. The results were expressed as optical density (OD) at 550nm.  
Supernatants were collected 10 minutes after 30% CMS (0.33Hz; 4 hours). The lactate dehydrogenase 
(LDH) activity was assayed in 100µl samples using the cytotoxicity detection Kit (Roche), 
spectrophotometrically determining the amount of reduced formazan at O.D. 650 nm. Data are presented as 
the mean ± SEM of five (A) and six (B) independent experiments. 
 There was no significant effect of static or cyclic mechanical strain upon cell 
viability in either cell type (figure 3.4). Similarly there was no change in LDH levels in 
response to CMS (figure 3.5). 
 
 
Figure 3.4 Effect of CMS on cell viability in HLMVEC (A) and Ea.hy 926 (B) cells 
Figure 3.5 Effect of cyclic mechanical strain on lactate dehydrogenase activity in HLMVEC (A) and 
Ea.hy 926 (B) cell supernatants 
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3.3.3. Selection of reference genes for gene expression studies of cyclic mechanical 
strain by quantitative real time polymerase chain reaction  
Quantitative real-time PCR (qPCR) is a sensitive and reliable method of determining 
gene expression. The accuracy of quantitative mRNA expression analysis is influenced by 
the choice of reference genes. Reference gene expression is used to control for factors 
including the starting concentration and quality of mRNA, the uniformity of cDNA 
synthesis and efficiency of the PCR reactions. An ideal reference gene is expressed 
constantly, however, the expression of commonly used reference genes may vary 
considerably between cell and tissue types and under different experimental conditions 
(Dheda et al. 2004; de Jonge et al. 2007). It was therefore vital to find genes that were 
unaffected by mechanical strain. In addition, this system was used to determine reference 
genes for HFL-1 cell “fibrogenesis” experiments. Fourteen genes were identified from the 
available literature as candidate reference genes. Stability was determined using the 
geNorm software, as already described (chapter 2.4.2.5). The approach relies on the 
principle that the expression ratio of two perfect reference genes would be identical in all 
samples in all experimental conditions. Genes were allocated a stability value (M), with a 
higher value representing a lower stability. An arbitrary cut off value for M of 0.5, below 
which genes were deemed to be suitably stable, was selected. The program also 
calculated a pairwise variation (chapter 2.4.2.5), which determined the optimal number of 
housekeeping genes for a system. Figure 2.16 illustrates the graphical representation of 
the average stability values (the most stable genes on the far right) and the pairwise 
variations given for each cell type. The data (Appendix C) reveal a pairwise variation 
below the threshold value (0.15) for two compared to three reference genes and hence the 
use of two reference genes for each cell type is acceptable. Table 3.1 summarises the 
most stable reference genes for each cell type. 
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Cell type / tissue Most Stable Genes M Value Optimal number of 
genes 
Ea.hy 926 GUSB 
TUBB 
0.309 
0.288 
2 
HLMVEC GAPDH 
HRPT 
0.210 
0.213 
2 
HFL-1 GUSB 
PPIB 
0.170 
0.182 
2 
Whole Rat Lung ARBP 
HRPT 
0.393 
0.386 
2 
Table 3.1 Summary of GeNorm results of reference gene stability for cell types and whole rat lung 
Abbreviations: HPRT- hypoxanthine phosphoribosyltransferase 1; GUSB -glucuronidase, beta; GAPDH- 
Glyceraldehyde-3-phosphate dehydrogenase; TUBB, tubulin, alpha 1b; PPIB- peptidylprolyl isomerase B; 
ARBP- acidic ribosomal phosphoprotein 
 
 
3.3.4. Time course for the effects of mechanical strain on mediator gene expression 
by human lung microvascular endothelial cells and Ea.hy 926 cells 
(A) HLMVEC and (B) Ea.hy 926 cells were grown to confluence on BioFlex™ 6 well plates and quiesced. 
Growth medium was refreshed and mRNA harvested from unstretched cells at 2 hours or cells stretched for 
2/4/6/ hours.  The expression levels of Il-8, MCP-1 and ET-1 quantified by qPCR, normalized to the 
average expression of two housekeeping genes (HKG; A: GAPDH, HRPT; B: GUSB, TUBB) and 
compared to expression levels in unstretched cells. (A) HLMVEC n=3; (B) Ea.hy n=4. Kruskal Wallis with 
Dunns post test: *p<0.05. 
 These gene expression data show that both cell types increase expression of MCP-
1 and IL-8, with a peak expression for IL-8 at 4 hours by HLMVEC and 2 hours by Ea.hy 
(figure 3.7). MCP-1 peak expression was maximal at 2 hours for HLMVEC, but 4 hours 
for Ea.hy 926 cells. ET-1 peak expression was at 4 hours in HLMVEC. ET-1 expression 
Figure 3.7 Effect of cyclic mechanical strain for increasing duration on interleukin-8 (Il-8), monocyte 
chemotractant protein (MCP)-1 and endothlein (ET)-1 gene expression by human lung microvascular 
endothlelial and Ea.hy 926 cells 
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is not presented for Ea.hy cells because expression of ET-1 mRNA by these cells was so 
low that Ct numbers were very high and primer efficiency was unacceptable. 
3.3.5. Endothelin production by human lung microvascular endothelial cells 
exposed to CMS and fibroblast responses 
ET-1 is an important mediator in idiopathic forms of PAH that may eventually lead 
to right heart failure. ET-1, and its precursor big endothelin, are raised in serum of 
patients with CHF (Cody et al. 1992; Tsutamoto et al. 1995) and correlate with severity 
of disease and prognosis (Pacher et al. 1996). The lung is an important producer and 
regulator of ET-1, and gene expression and protein are increased in the lungs of rodents 
with CHF (Dupuis et al. 1998; Dupuis et al. 1998; Tonnessen et al. 2003).  ET-1 is not 
only a potent vasoconstrictor, but also stimulates fibroblast proliferation and 
differentiation in vitro (Dawes et al. 1996). HUVEC subjected to CMS upregulate ET-1 
in a ras, raf and ERK-dependent manner (Cheng et al. 2001). Given that HLMVEC 
increased ET-1 mRNA in response to mechanical strain (figure 3.7) this mediator was 
identified as a potential stimulator of structural remodelling of the ACM in CHF and its 
release and effect on fibroblast biology was addressed. 
 
3.3.6. Static mechanical strain increases ET-1 gene transcription and protein 
release by human lung microvascular endothelial cells 
ET-1 gene expression was significantly increased at 4, 12 and 24 hours after SMS 
(figure 3.8A). A four hour time point was chosen for further experiments as this was felt 
to most probably represent a direct effect of mechanical strain, rather than the production 
of another mediator in response to mechanical strain that was feeding back to increase 
ET-1 expression. Supernatants were subsequently collected at 24 hours after SMS and 
ET-1 levels analysed by ELISA. SMS lead to an increase in ET-1 levels in supernatants at 
24 hours after strain (figure 3.8B).  
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HLMVEC were grown to confluence on BioFlex™ 6 well plates and quiesced for 16 hours in medium 
containing 0.1% fetal calf serum (FCS). Medium was then refreshed and cells subjected to SMS (20%, 4 
hours or duration as indicated). (A) RNA was extracted immediately post SMS and gene expression 
determined by qPCR. Gene expression was normalised to the average expression of 2 housekeeping genes 
and is shown relative to unstimulated controls (0% SMS, 4 hours). (B) Cells were incubated for 24 hours 
post SMS and supernatants harvested for the analysis of ET-1 levels (ELISA) *p<0.05; Kruskal Wallis with 
Dunn’s post test (A; n=4), and Wilcoxon signed rank test (B; n=6). Values shown are mean ± SEM. 
 
3.3.7. Supernatants from human lung microvascular endothelial cells subjected to 
static mechanical strain increase fibroblast proliferation and differentiation 
To assess the importance of SMS induced ET-1 in HLMVEC, fibroblast (HFL-1) 
cells were incubated in supernatants from strained and non-strained HLMVEC, and also 
with DMEM containing 0% and 10% FCS as positive and negative controls. Proliferation, 
relative to negative controls, was increased in cells incubated with supernatants from 
strained HLMVEC, but a significant effect was not seen in cells incubated with 
supernatants from unstrained cells (figure 3.9A). Similarly myofibroblast differentiation 
of HFL-1, as determined by SMA gene expression, was increased in cells incubated with 
“strain-supernatants”, although this did not reach significance (figure 3.9B). Another 
marker of fibroblast differentiation, procollagen-1, also increased non-significantly 
(figure 3.9C). 
 
 
 
Figure 3.8 Effect of static mechanical strain (SMS) on pre-pro-endothelin-1 (ppET-1) gene 
transcription and endothelin -1 (ET-1) protein release by HLMVEC 
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HFL-1 cells were grown to 60% confluence on 96 well plates (A) or 100% confluence on 6 well plates (B 
& C) and quiesced for 24 hours in DMEM supplemented with 0% fetal calf serum (FCS). Cells were then 
incubated for a further 24 hours in DMEM containing 0% (clear bar) or 10% FCS (black bar) or 
supernatants from HLMVEC subjected to 0% or 20% static mechanical strain (4hrs; 0.33Hz: HLMVEC 
supernatant; SMS %). Supernatants were aspirated at 24 hours and cells frozen at -80oC for cellular 
proliferation (A) or RNA extracted for gene expression (B&C).  (A) Relative cell number was determined 
using CyQUANT proliferation assay and expressed relative to unstimulated controls (0% FCS: allocated 
value of 1). Alpha smooth muscle actin (SMA; B) and procollagen 1(PC1; C) gene expression were 
determined by qPCR normalised to the average of 2 housekeeping genes (HKG: GUSB, PPIB) and 
expressed relative to unstimulated controls (0% FCS). *p<0.05, **p<0.01 Kruskal Wallis with Dunn’s post 
test. Proliferation experiments: n=5; differentiation experiments: n=3. Values shown are mean ± SEM. 
 
3.3.8. Is endothelin-1 an important mediator in fibroblast proliferation and 
differentiation in response to supernatants from stretched human lung 
microvascular endothelial cells? 
To answer the question whether ET-1 was the important mediator driving HFL-1 
proliferation and differentiation in supernatants from strained HLMVEC, HLMVEC were 
incubated with phosphoramidon, an endothelial converting enzyme (ECE) inhibitor, for 
30 minutes prior to and during SMS. Attenuation of strain-induced ET-1 release by 
phosphoramidon was confirmed, and then HFL-1 cells were incubated with supernatants 
from HLMVEC subjected to 0 or 20% SMS, with or without phosphoramidon or vehicle 
control (figure 3.10).  
Figure 3.9 Effect of supernatants from stretched and non- stretched HLMVEC on fibroblast 
proliferation and differentiation. 
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Figure 3.10 Effect of phosphoramidon on strain induced endothelin-1 release and “strain-
supernatant” induced fibroblast proliferation and differentiation 
(A) HLMVEC were grown to confluence on BioFlex™ 6 well plates and quiesced for 16 hours in medium 
containing 0.1% fetal calf serum (FCS). Cells were then subjected to 0 or 20% static mechanical strain 
(SMS; 4 hours 0.33Hz) with 0, 0.5 or 5µM phosphoramidon. Supernatants were collected at 24 hours post-
strain and ET-1 levels determined by ELISA. (B) Fibroblasts (HFL-1) were grown to 60% confluence on 96 
well plates and quiesced in DMEM containing 0% FCS for 24 hours. Cells were the incubated in DMEM 
containing 0 or 10% FCS or supernatants from HLMVEC subjected to 0 or 20% SMS with or without 5µM 
phosphoramidon for a further 24 hours. Supernatants were then aspirated to dryness and cells frozen to be 
thawed at a later date when relative proliferation was determined using CyQUANT cell proliferation assay. 
(C&D) HFL-1 cells were cultured to confluence on 6 well plates and quiesced for 24 hours in DMEM 
containing 0% FCS. Cells were then incubated for a further 24 hours in DMEM containing 0 or 10% FCS, 
endothelial growth medium MV-2 (EGM) containing 2% FCS, or supernatants from HLMVEC subjected to 
0 or 20% SMS with or without 5µM phosphoramidon . RNA was harvested and alpha smooth muscle actin 
(SMA; C) and procollagen 1(PC1; D) gene expression were determined by qPCR normalised to the 
average of 2 housekeeping genes (HKG: GUSB, PPIB) and expressed relative to unstimulated controls (0% 
FCS). *p<0.05 **p<0.01 (A) Kruskal Wallis with Dunns post test. (A) n=3; (B) n=5 except EGM: n=3; 
(C&D) n=2. Values shown are mean ± SEM. 
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Phosphoramidon attenuated strain induced ET-1 release (figure 3.10A) and also 
inhibited both strain-induced HFL-1 proliferation (figure 3.10B) and potentially, but non-
significantly, differentiation (figure 3.10 C&D).  
 
3.3.9. Mechanical strain induced endothelin-1 release did not persist across cell 
donors 
Thus far experiments have been from HLMVEC at passages 4-8, from one donor. 
HLMVEC are commercially available primary cells and have a finite life span before 
cells either fail to continue to proliferate or alter their morphology. At passage 9 the cells 
used in the above experiments showed significantly different morphology and slowed 
growth rate. Consequently new cells were obtained. Unexpectedly, two subsequent sets of 
cells from different donors, grown under, and exposed to, the same experimental 
conditions did not release endothelin-1 when subjected to SMS (figure 3.11). 
HLMVEC were grown to confluence, quiesced in medium containing 0.1% FCS for 16 hours and subjected 
to 20% static mechanical strain for 4 hours (0.33Hz) in medium containing 5% FCS. Supernatants were 
collected at 24 hours after mechanical strain and assayed for endothelin-1 by ELISA. n=4. Values shown 
are mean ± SEM. 
 
Several possible reasons for this difference were considered: 
1. Due to an undetected alteration in the Flexcell apparatus, strain was no longer 
being effectively applied to the cells. 
2. The cells were not sensing the strain. 
Figure 3.11 Endothelin-1 protein levels in supernatants from subsequent donor cells at 24 hours 
after static mechanical strain 
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3. The level of FCS (5%) was masking the ET-1 response. 
4. There was a fundamental difference in the cells between donors. 
 
3.3.9.1. Was the stimulus enough and was the dose of fetal calf serum 
appropriate? 
Having repeated the static mechanical strain experiments three times and found no 
ET-1 response from the cells from two different donors and two different suppliers 
(figure 3.11), I subsequently performed the experiments at low dose FCS (0%) and at the 
previous dose of FCS (2%, the dose in which the cells normally grow). Furthermore, I 
increased the mechanical strain level to 30%, applied cyclic mechanical strain (CMS). 
The reasons for this were:  
a. I wanted to increase the level of strain to ensure the cells were sensing the stimuli 
and to maximise any response.  
b. A greater elongation CMS system is effective in other cell types (i.e. the lung 
epithelial cell line A549) and that, from previous work in our lab, interleukin-8 
(Il-8) is robustly released in response to CMS across several cell types and could 
be used as a positive control for cells sensing the mechanical stimulus. 
162 
 
HLMVEC cells were grown to confluence on BioFlex™  6 well plates and quiesced overnight in medium 
containing 0.1% fetal calf serum (FCS). Medium was then refreshed with medium containing 0% or 2% 
FCS 1 hour prior to 20% static mechanical strain (SMS). RNA was then harvested immediately for gene 
expression (A&C) or supernatants were collected 24 hours later for endothelin-1 (ET-1) or Interleukin-8 
(IL-8) protein determination by ELISA (B&D). Gene expression was normalised to the average of two 
housekeeping genes and expressed relative to unstrained controls. n=3 for all experiments. Values shown 
are mean ±SEM. 
 
 These data illustrate that the cells did transduce mechanical strain, as evidenced 
by an increase in IL-8 protein release and gene transcription. There was a larger increase 
in IL-8 gene expression by cells in serum free medium compared to medium with 5% 
FCS. Protein release however was greater in cells subjected to SMS in medium 
containing 5% FCS (figure 3.12 C&D). Samples from the same experiments increased 
ET-1 gene expression in cells stretched in medium containing 5% FCS, but there was no 
subsequent increase in protein levels at either FCS concentration (figure 3.12 A&B). 
Figure 3.12 Endothelin-1 and interleukin-8 gene transcription and protein release after static mechanical 
strain at different doses of fetal calf serum. 
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HLMVEC were grown to confluence on BioFlex™ 6 well plates and quiesced for 16 hours in medium 
supplemented with 0.1% fetal calf serum (FCS). Medium was then refreshed with medium containing 2% 
FCS and cells were subjected to 30% CMS for 4 hours (0.33Hz). Supernatants were collected 24 hours after 
CMS and analysed for ET-1 and Il-8 by ELISA. Values shown are mean ± SEM. n=3 
 
 Furthermore on increasing the amplitude and pattern of mechanical strain so that 
cells were subjected to 30% cyclic mechanical strain (at the same rate of 0.33Hz) protein 
levels of IL-8 in post-strain supernatants were increased, without an accompanying 
increase in ET-1 levels (figure 3.13). 
3.3.9.2. The effect of prostaglandin release on strain induced endothelin-1 
release 
Increased expression of inducible cyclooxygenase (Cox-2) and its product 
prostaglandin (PGE2) can inhibit the production of ET-1 by smooth muscle cells (SMC) 
(Wort et al. 2002). I therefore questioned whether cells released prostaglandins in 
response to strain and if inhibiting this release with indomethacin, a cox-2 inhibitor, 
would alter strain induced ET-1 levels. If this were found to be true, then the differences 
seen in endothlein-1 expression in response to SMS or CMS might be as a result of 
different levels of Cox-2 expression by donor cells. 
HLMVEC exposed to SMS released PGE2 in a time dependent fashion, but 
inhibition of COX and hence strain induced PGE2 did not increase strain-induced ET-1 
expression (figure 3.14). 
Figure 3.13 Cyclic mechanical strain (CMS) induced endothelin-1 (ET-1) and interleukin-8 (Il-8) release by 
human lung microvascular endothelial cells
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HLMVEC were grown to confluence on BioFlex™ 6 well plates and quiesced in medium containing 0.1% 
fetal calf serum (FCS) for 16 hours. (A) Cells were then subjected to SMS for increasing durations (as 
indicated) and supernatants collected immediately for analysis of PGE2 levels by ELISA. n=1 (B) Cells 
were pre-treated with Indomethacin, a COX inhibitor, and then subjected to SMS (4 hours, 20%, 0.33Hz). 
Supernatants were collected at 24 hours after strain for analysis of ET-1 protein by ELISA. Mean ± SEM; 
n=2. 
 
3.3.9.3. Experiment to ensure cells were plated at an appropriate seeding 
density for the detection of mechanical strain 
The density of EC in culture is important for two reasons. Firstly cells at the time 
of mechanical strain must be confluent to allow cell-cell interaction, which may 
contribute to mechanotransduction. Over confluence on the other hand may diminish the 
sensation of mechanical strain. Furthermore, endothelial cells grown in culture if 
confluent for too long will growth inhibit themselves and may therefore alter their 
responses. In our experience when confluent for too long on BioFlex™ collagen coated 
plates HLMVEC become detached and cell death occurs. Throughout these experiments 
cells had looked confluent and not detached, but it was possible that the new cells, despite 
looking appropriately confluent, were growing at a different rate and the initial 
experiment protocol was not providing the appropriate seeding density. Therefore, I 
repeated the experiments at different initial seeding densities. This would also provide 
samples in which to measure different mediator release to investigate for alternative strain 
induced mediators. In all cases cells were stretched (4 hours, 0.33Hz), incubated for a 
further 24 hours and protein release determined by ELISA. As an alternative cell type, 
HUVEC (Lonza, UK) were grown and subjected to CMS. These cells did not grow well 
on the collagen-1 coated BioFlex™ cell culture plates and all cells detached on applying 
Figure 3.14 Prostaglandin (PGE2) release by human lung microvascular endothelial cells (HLMVEC) 
subjected to static mechanical strain (SMS) and the effect of indomethacin on strain induced endothelin-1 
(ET-1) release.
165 
 
CMS (30% elongation, 0.33Hz). Further experiments using these cells were consequently 
not pursued. 
HLMVEC were seeded at increasing cell densities on BioFlex™ 6 well plates and cultured for 24 hours. 
Cells were then quiesced in medium containing 0.1% fetal calf serum (FCS) for 16 hours, medium 
refreshed and subjected to CMS (30%, 4 hours, 0.33Hz). Supernatants were collected at 24 hours after 
strain for determination of endothelin-1 (ET-1, A), interleukin-8 (Il-8, B) and monocyte chemotatic protein-
1 (MCP-1, C). Immediately after the collection of supernatants cells were treated with 1mg/ml MTT and 
incubated for a further 60 minutes. Supernatants were then aspirated off the cells and cells lysed with 
DMSO for five minutes. These supernatants were then collected, 200µl aliquots pipetted into 5 wells of a 
96 well plate per condition and the optical density read at 550 nm (D). For each condition the average 
reading from 5 wells were recorded. n=4. Values are shown as mean ±SEM. 
 
 IL-8 was again used as a positive control for EC sensed CMS. A seeding density 
of 4-5 x105 cells/well resulted in the largest increment in protein after CMS and hence 
appeared to be the optimal seeding density, in keeping with 5 x105 cells/well that cells 
had been seeded at in previous experiments (figure 3.15B). There was no increase in ET-1 
post- CMS at any seeding densities (figure 3.15A). Interestingly strained and non-strained 
ET-1 levels decreased as seeding density increased, without any decrease in cell viability 
(figure 3.15D).  
Figure 3.15 Experiments to address cell seeding density in human lung microvascular endothelial cells 
exposed to cyclic mechanical strain (CMS).
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 In order to establish an alternative strain induced mediator, subsequent cells were 
exposed to mechanical strain for increasing durations (2, 4,and 6 hours) and the 
expression of alternative genes determined by qPCR. Candidate genes were selected 
based on literature describing genes altered in animal models of CHF and genes induced 
by strain in other EC (chapter 1.5). The genes investigated were: ICAM-1, IL-6, 
angiopoeitins (Ang) 1 and 2 and MCP-1. CMS-induced increases in gene expression were 
seen for IL-6, Ang 2 and MCP-1 (data not shown). Protein levels were subsequently 
analysed by ELISA in supernatants from cell-seeding-density experiments. The most 
robust upregulation was seen for MCP-1 (figure 4.9C). Further work was consequently 
carried out to investigate CMS induced MCP-1 expression by EC. This work forms the 
basis of the next chapter. 
3.3.9.4. Effect of fetal calf serum concentration upon monocyte 
chemoattractant-1 expression by human lung microvascular endothelial cells and 
Ea.hy 926 cells 
Chapter 4 of this thesis concentrates on MCP-1 expression by EC subjected to 
CMS. Experiments in which ET-1 was released by cells were carried out in growth 
medium containing 5% fetal calf serum (FCS). Others have subjected EC to mechanical 
strain in serum-free medium or medium containing low concentration of FCS (0.1%) 
(Wang et al. 1993; Wung et al. 1997; Cheng et al. 1998; Cheng et al. 2001). To 
determine the optimal conditions for investigation of CMS-induced MCP-1 expression by 
both EC types, cells were stretched in increasing concentrations of FCS (figure 3.16). The 
greatest response was seen in cells stretched in 0.1% FCS. 
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Confluent, quiesced HLMVEC (A) and Ea.hy 926 (B) cells were subjected to 30% cyclic mechanical strain 
(0.33Hz; 4 hours) in the presence of increasing doses of fetal calf serum. Supernatants were collected at 24 
hours after stretch. Data are represented as mean ± SEM; (A) HLMVEC: n=3; (B) Ea.hy: n=1. 
 
 
3.4. Discussion 
3.4.1. Summary of important findings in this chapter 
The work in this chapter established optimal conditions for assessing the effect of 
mechanical strain on the Ea.hy 926 endothelial cell line and HLMVEC. The optimal cell 
seeding density was established and found to be consistent for both initial experiments 
(figure 3.2) and repeat experiments (figure 3.15). Mechanical strain did not have a 
deleterious effect on cell viability. 
IL-8 and MCP-1 were identified as being robustly upregulated by mechanical strain 
in both Ea.hy 926 and HLMVEC. Strain induced ET-1 upregulation did not however 
persist between donor pools of HLMVEC. This variation in response was not due to 
increased levels of PGE2 release by subsequent cells. 
Supernatants from stretched cells increased fibroblast proliferation and differentiation 
in initial experiments in an ET-1 dependent manner.  
 
Figure 3.16 Effect of fetal calf serum concentration on cyclic mechanical strain  induced release of 
MCP-1 by HLMVEC (A) and Ea.hy 926 (B) cells 
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3.4.2. Establishment of a model for investigating the effects of mechanical strain 
upon endothelial cells 
The experiments in this chapter were designed to characterise the effects of CMS on 
HLMVEC and Ea.hy 926 cells, and to optimise experimental conditions. The results 
indicate that CMS applied to HLMVEC ands Ea.hy 926 cells at 30% does not 
significantly alter cell respiration, as determined by MTT assay. Neither does subjecting 
the cells to CMS cause significant membrane damage, as quantified by LDH assay. 
Both cell types increase expression of IL-8 and MCP-1 in response to mechanical 
strain, but only HLMVEC, in initial experiments, express more ET-1. Optimal time points 
to collect mRNA were determined for all 3 mediators and two reference genes (table 3.1) 
identified to allow accurate gene expression comparison for future experiments. 
3.4.3. Selection of reference genes for gene expression studies of cyclic mechanical 
strain by quantitative real time polymerase chain reaction  
Accurate normalization of gene expression in PCR is essential to control for 
variation in sample extraction, input, reaction efficiencies and to compare the effects of 
differing experimental conditions (Vandesompele et al. 2002; Radonic et al. 2004; 
Radonic et al. 2005). Normalisation depends on the stable expression of reference or 
“housekeeping” genes under the pertinent experimental conditions. CMS is a powerful 
stimulus that alters the expression of a wide variety of genes and components of the cells 
cytoskeleton (Kaunas et al. 2005; Chien 2007). It is therefore important to ensure that the 
reference genes selected are stable to prevent inaccurate results. The geNorm software 
(http://medgen.ugent.be/~jvdesomp/geNorm/) provides a validated tool for assessing the 
stability of housekeeping genes under experimental conditions and using this method we 
have identified stable housekeeping genes for a variety of human pulmonary cells 
subjected to mechanical strain (Pinhu et al. 2008). This work confirms our previous data 
and also identifies stable genes for Ea.hy 926 cells exposed to mechanical strain. The 
importance of confirming housekeeping gene stability in each experimental system is 
shown in the results obtained. Genes traditionally used as stable housekeeping genes (e.g 
GAPDH, beta-actin, beta-2-microglobulin and 18S) were amongst the least stable genes 
in Ea.hy 926 and HFL-1cells subjected to CMS (appendix C) . 
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3.4.4. Human lung microvascular endothelial cells subjected to mechanical strain 
increase endothelin-1 expression and supernatants from strained cells increase 
fibroblast proliferation. 
These findings that HLMVEC release ET-1 when subjected to mechanical strain 
are not unprecedented. Cheng et al found that HUVEC exposed to CMS released ET-1 in 
a ras/ raf/ ERK dependent manner. Due to the inability to reproduce these results in cells 
from different donors, I was unable to interrogate the pathways underlying SMS induced 
ET-1 production by HLMVEC.  
Initial results revealed that supernatants from strained HLMVEC increased 
fibroblast proliferation and a non-significant increase in differentiation was also seen. 
Attenuation of ET-1 levels in strain supernatants by phosphoramidon also attenuated 
these responses, suggesting a role for ET-1 in the fibroblast stimulation. In keeping with 
these findings fibroblast proliferation is increased by direct treatment with ET-1 via the 
endothelin A receptor (ETAR) (Dawes et al. 1996). 
It is difficult to determine why subsequent cells did not replicate these initial 
findings. The same system for the application of mechanical strain was used as Cheng et 
al (Flexercell 4000), the only differences in this protocol was that Cheng et al seeded 
cells at a lower density and grew them to confluence over 3 days prior to stretch. Their 
cells were grown, quiesced and stretched in medium-199 (M199; Sigma), rather than the 
EGM2-MV (Lonza) used here. In addition their cells were strained in medium containing 
2% FCS, whereas here 5% FCS was used (as per the manufacturer’s instructions for 
normal HLMVEC growth). Interestingly, in subsequent experiments there was an 
increase in ET-1 gene expression by cells subjected to SMS in 5% FCS, but this did not 
translate into increased protein levels. Of note, although there was a significant increase 
in protein levels from strained cells at 24 hours after strain in the Cheng paper, this 
difference increased out to 50 hours. A longer incubation post strain might therefore be 
required to identify an increase in ET-1 protein. It must also be considered that this first 
batch of cells may have been genetically different and were more sensitive to strain or 
more resistant to supplements in the growth medium that might have inhibited SMS 
induced ET-1 release. 
It is therefore unknown whether the initial finding that HLMVEC produce ET-1 in 
response to SMS is a true finding. Future work could utilise more sensitive determinants 
170 
 
of gene regulation, including reporter constructs, to determine if there is increase in ET-1 
gene transcription after SMS. If this is found to be true then further assessment of protein 
release could elucidate the optimal time of supernatant harvest post-strain to identify a 
difference in peptide levels. Another vial of cells from the same initial donor was 
requested to determine if initial results could be replicated within donor, but these were 
no longer available. There is considerable expense involved in purchasing and growing 
these primary cells and consequently, after a comprehensive attempt to ensure the lack of 
response was true, other potential mediators released in response to strain were 
investigated. 
3.4.5. Monocyte chemotatic protein-1 is released by human lung microvascular 
endothelial cells subjected to cyclic mechanical strain 
In order to test further the hypothesis that mechanical strain at the PMV has an 
important role in the generation of inflammation and ACM remodelling in CHF, other 
potential CMS induced mediators were sought. A review of the literature identified 
several other potential candidates that were upregulated by CMS in other EC or other cell 
lines, including MCP-1, IL-6, Ang 1 and 2, and ICAM-1 (Wung et al. 1997; Cheng et al. 
1998). MCP-1 and IL-6 serum levels were raised in patients with CHF (Damas et al. 
2000; Gaertner et al. 2003).  
In addition to addressing the response by HLMVEC, due to the considerable 
expense of growing and maintaining these cells, the response to CMS by Ea.hy 926 cells, 
an endothelial cell line was determined. Using a cell line would more robustly allow 
interrogation of the signalling mechanisms underlying CMS induced responses. Findings 
would then be confirmed in the primary cells. From the above list of potential mediators, 
MCP-1 was robustly upregulated by CMS in both cell types. and was therefore chosen as 
a target chemokine for investigation, described in chapter 4. 
3.5. Future Directions 
Although the SMS induced release of ET-1 by HLMVEC was thoroughly re-
investigated, there are, as mentioned above, other strategies that could be used to 
determine whether there is a real response by these cells. Firstly, the protocol could be 
adapted to exactly match that of Cheng et al, specifically with respect to using medium-
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199 and straining the cells in medium containing 0.1% FCS or 2% FSC. Also, the time 
course of protein release could be established in more detail, specifically at longer time 
points than used here- in HUVEC there is an increase in ET-1 release by strained 
compared to unstrained cells beyond 50 hours after CMS(Cheng et al. 2001).  
Gene expression of ET-1 appeared to still be increased in later experiments 
subjecting HLMVEC to CMS (figure 4.6), despite no concurrent increase in protein 
levels. It is possible that supernatants were being harvested too early after CMS. 
Alternatively, there may be increased gene expression, but this is not translating into 
release of mature ET-1 peptide. Further investigations could address the effect of CMS on 
gene transcription using ET-1 gene reporter constructs and subsequently constructs with 
attenuations of the promoter region to identify the important transcription factor binding 
site (Rodriguez-Pascual et al. 2003). Post transcriptional components of the ET-1 
synthesis pathway, including mRNA stability, could then be interrogated to establish why 
increases in gene expression do not lead to increased mature peptide levels. 
For the practical purposes of the thesis this line of work was not felt to be cost or 
time effective. Hence, MCP-1 was chosen as an alternative mediator and subsequent work 
concentrated on the biology of this chemokine in relation to mechanical strain applied to 
HLMVEC. 
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4. Chapter 4: MCP-1 and signalling 
4.1. Introduction  
The aim of the work in this chapter was to investigate the impact of mechanical strain 
on the production of MCP-1 by pulmonary microvascular EC and the role of mitogen 
activated protein kinases (MAPK) in this.  
The specific objectives were: 
a. to investigate the effect of CMS on MCP-1 gene expression and protein 
release by Ea.hy 926 cells and HLMVEC 
b. to investigate the effect of CMS on the activation of MAPK and the role of 
MAPK on CMS-induced MCP-1 expression 
c. to determine the importance of this system in functional studies of 
fibroblast and PASMC proliferation and differentiation, and monocyte 
migration 
Chronic heart failure is associated with increased blood levels of chemokines and 
cytokines, including TNF-, interleukin-6 (IL-6), MCP-1, and endothelin-1 (ET-1) 
(reviewed in (Cody et al. 1992; Munger et al. 1996; Carlstedt et al. 1997; Aukrust et al. 
1998; Roig et al. 1998; Sharma et al. 2000; Mari et al. 2002; Tan et al. 2006)). The 
exact source of these inflammatory mediators is not clear and it is postulated that they 
are either directly produced by the failing myocardium or in response to translocation of 
bacteria and their cell wall components across an oedematous gut wall (Habib et al. 
1996; Torre-Amione et al. 1996; Anker et al. 1997; Kapadia et al. 1997; Mari et al. 
2002). Activation of the neurohormonal system and direct effects of pressure or volume 
changes on other organs, particularly the lungs, liver and kidneys may also stimulate the 
production of inflammatory mediators.  
The pulmonary endothelium is an immediate upstream target of raised LAP. 
Acutely, this may result in stress failure leading to pulmonary oedema, but the chronic 
effects are less well studied, despite shortness of breath being the predominant symptom 
of this syndrome (Townsley et al. 1995; West 2000). Others have identified increased 
expression of cytokines and chemokines in lungs of rodents with experimentally 
induced heart failure (Gaertner et al. 2003; Tonnessen et al. 2003). In addition the lung 
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has an important role in the production of inflammatory mediators and their clearance in 
other disease states (Kobayshi et al. 1998; Gaertner et al. 2003; Selimovic et al. 2009). 
Here, it is proposed that the lungs are an important source of inflammatory mediators in 
CHF, including MCP-1, and that raised LAP imparts a mechanical strain or stretch on 
the pulmonary microvasculature stimulating the expression of inflammatory mediators.  
The indications for exploring a potential role for MCP-1 are: MCP-1 is raised in 
the serum of patients with CHF and gene expression is increased in lungs of a rodent 
model of CHF (Aukrust et al. 1998; Tonnessen et al. 2003). Furthermore, MCP-1 is 
released by several cell types, including endothelial cells, in response to CMS (Wung et 
al. 1997; Okada et al. 1998; Jiang et al. 1999; Wung et al. 2001; Gruden et al. 2005).   
The role of MAPK in mechanotransduction has already been discussed in detail 
(chapter 1.6 and 1.10). Specifically, CMS induced MCP-1 release by endothelial cells 
involves the small g-protein Rac, reactive oxygen species (ROS) and a subsequent 
increase in AP-1 dependent gene expression (Wung et al. 1997; Wung et al. 2001). It is 
established that ROS can activate MAPK and that MAPK in turn can influence gene 
transcription via the AP-1 promoter region (Guyton et al. 1996). Indeed, CMS activates 
ERK, p38 and JNK in EC and this activation has an important role in transcriptional 
activation of AP-1(Ikeda et al. 1999; Kito et al. 2000). Furthermore, non-CMS stimuli 
increase MCP-1 expression through ERK and AP-1 signalling pathways (Cho et al. 
2002; Takaya et al. 2003). Therefore, the role of MAPK in CMS-induced MCP-1 
expression in EC was investigated. 
 
4.2. Specific methodsCyclic mechanical strain and sample collection protocol 
The effect of CMS on the release of MCP-1 by EC was determined using the 
CMS protocol previously described (chapter 2.2.2.2). RNA was extracted immediately 
after 4 hours of CMS (30%, 0.33Hz), or cells were incubated for a further 24 hours prior 
to the collection of supernatants for chemokine measurement by ELISA. 
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4.2.2. Role of mitogen activated protein kinases 
MAPK activation was assessed by comparing the expression of phosphorylated 
and total forms of ERK1/2, JNK and p38 after CMS in whole cell lysates using western 
blotting. To address the importance of the respective MAPK in CMS-induced MCP-1 
production cells were pre-treated with UO126 (3 or 10µM; MEK 1/2 inhibitor), PD 
98059 (3 or 10µM; MEK 1/2 inhibitor), SP600125 (3 or 10µM; JNK inhibitor) and SB 
203580 (3 or 10µM; p38 inhibitor), or the equivalent drug diluent in the same volume as 
the vehicle control, for 60 minutes prior to 30% CMS. RNA and whole cell lysates were 
collected immediately after CMS for analysis of gene expression and MAPK 
phosphorylation respectively, or cells were incubated for a further 24 hours prior to 
collection of supernatants for MCP-1 measurement by ELISA. 
4.2.3. Dominant negative Ras and I-2 transfection  
In order to determine the role of Ras as an upstream component involved in 
CMS-induced MCP-1 release, Ea.hy 926 cells were transfected with a viral vector 
expressing dominant negative Ras. Adenoviral infection of cells Recombinant 
adenovirus (AdV-dnIKK2) and control virus were a gift kindly from Dr. Rainer de 
Martin (University of Vienna, Vienna, Austria). Adenovirus vectors were produced as 
previously described  
For effective transfection cells required initial seeding at half the normal seeding 
density (i.e. 2.5 x 105 cells per well) to achieve 50% confluence. Cells were then treated 
as for previous strain experiments (figure 4.1).  
To establish the optimum multiplicity of infection (MOI, the number of viral 
copies per cell required to produce an effective result) cells were seeded onto BioFlex 
6TM well plates at a lower density to allow a confluence of 40-50% at the time of 
transfection 24 hours later. Cells were then transfected with an increasing MOI and 
whole cell extracts harvested at the point of the experiment at which CMS would have 
been commenced (i.e. 24 hours later). Protein from the lysates (20µg) was probed with 
specific antibodies for Ras by western blotting. RNA and whole cell lysates were 
collected immediately after CMS for determination of MCP-1 gene expression and 
175 
 
MAPK phosphorylation respectively, and supernatants collected at 24 hours post-strain 
for MCP-1 protein measurement by ELISA. 
 
Figure 4.1 Adapted strain protocol for dominant negative Ras and I viral transfection. 
Cells were plated at half normal density to establish 50% confluence at transfection 24 hours later. Cells 
were subsequently quiesced for 16 hours in DMEM medium containing 0.1% fetal calf serum (FCS) once 
fully confluent. Cells were then subjected to cyclic mechanical strain (CMS) for 10 minutes and whole 
cell lysates collected for phosphorylated ERK 1/2 or I  expression by western blotting, or for 4 hours 
and RNA collected immediately for gene expression. Supernatants were also collected at 24 hours post 4 
hours CMS for determination of MCP-1 levels by ELISA. 
 
The same protocol was used for transfection of a dominant negative I-2 using a 
MOI of 100 based on work by collaborators. 
 
4.2.4. Functional Assays 
To address the importance of CMS induced MCP-1 in the model of CHF induced 
inflammation and fibro-proliferation, the effect of supernatants from cells subjected to 
0% or 30% CMS on fibroblast (HFL-1 cells) and PASMC proliferation and 
differentiation were assessed (chapter 2.3.4.1 and 2.3.4.2). 
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4.3. Results 
4.3.1. The effect of cyclic mechanical strain on MCP-1 gene expression and 
protein release by Ea.hy 926 cells and HLMVEC.Cyclic mechanical strain resulted in 
a time dependent increase in MCP-1 gene expression in both Ea.hy 926 cells and 
HLMVEC with a peak expression at 4 hours of CMS. There was also a significant 
increase in protein levels in the supernatants at 24 hours post-CMS compared to 
supernatants from unstimulated cells (figure 4.2) 
Ea.hy926 (A) and HLMVEC (C) were grown to confluence on BioFlex 6 well plates, quiesced for 16 
hours and mRNA extracted (RNeasy; Qiagen) from cells exposed  to CMS (30%, 0.33Hz) for  2, 4 or 6 
hours and unstretched cells (0% CMS) at 2 hours. 0.6µg RNA was reverse transcribed and MCP-1 gene 
expression quantified using quantitative RT-PCR relative to the average expression of 2 housekeeping 
genes (HKG: GUSB, TUBB). Expression shown is relative to unstimulated cells at 2 hours. Supernatants 
were collected at 24 hours post-stretch from Ea.hy926 (B) and HLMVEC (D) grown under the same 
conditions and exposed to CMS (0 or 30%; 4 hours; 0.33 Hz). MCP-1 was assayed using ELISA. Data 
represent four independent experiments analysed by one-way ANOVA (gene expression) and students t-
test (protein); *p<0.05; **p<0.001). 
 
 
 
 
 
 
Figure 4.2 Effect of cyclic mechanical strain (CMS) upon MCP-1 gene expression and protein release 
by endothelial cells 
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4.3.2. The role of MAPK in mechanotransduction in Ea.hy 926 cells 
4.3.2.1. The time course of activation of MAPK by cyclic mechanical strain 
 
Ea.hy 926 cells were collected at 0, 5, 10, 30 and 60 minutes of 30% CMS. A: Western blot was 
performed to detect the phosphorylated and total ERK1/2, p38 and JNK in 20µg of cell lysate protein. 
The developed blots were analysed using the Image J to quantitate the density of the bands and the values 
for the relative expression of phosphorylated to total forms of ERK p42 (B), ERK p44 (C), JNK p46 (D), 
JNK p54 (E) and p38 (F) expression. Comparison between conditions was made by Kruskal Wallis with 
Dunns post test: *p<0.05. Asterisks on top of bars refer to comparison with the appropriate control 
condition (0% CMS). The results are representative of four (ERK) or three (JNK, p38) independent 
experiments.  
 
A 
Figure 4.3 Phosphorylation of ERK1/2, p38 and JNK1/2 in Ea.hy 926 exposed to cyclic mechanical 
strain 
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Western analysis was performed to demonstrate activation of MAPK by CMS 
using specific antibodies against phosphorylated ERK1/2, p38 and JNK (figure 4.3). 
Cyclic mechanical strain increased the ratio of phosphorylated to total ERK1/2, JNK 
and p38, with a peak phosphorylation of JNK and p38 at 10 minutes of CMS, although 
there was minimal increase in the phosphorylation of the p54 JNK isoform (figure 
4.3A/D/E). ERK 1/2 peak phosphorylation occurred at 30 minutes (figure 4.3A/B/C). 
The activation of JNK returned to baseline by 60 minutes of CMS and the 
phopshorylation of p38 and ERK1/2 are diminishing, but had not completely returned to 
levels seen in unstimulated cells. Despite incubating cells in medium containing only 
0.1% FCS for 16 hours prior to CMS, a high baseline phosphorylation of JNK and to a 
lesser extent  ERK was seen in unstimulated cells. Strain induced ERK 1/2 
phosphorylation followed a similar pattern in HLMVEC, peaking at five minutes and 
diminishing from 30 minutes (figure 4.4). 
 
HLMVEC were grown to confluence on 6 well plates and quiesced for 16 hours in medium containing 
0.1% fetal calf serum (FCS). Medium was refreshed 1 hour prior to CMS and whole cell lysates collected 
at 0, 5, 10, 30 and 60 minutes of 30% CMS. Western blot was performed to detect the phosphorylated and 
total ERK1/2 in 20µg of cell lysate protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Phosphorylation of ERK 1/2  in human lung microvascular endothelial (HLMVEC) 
cells subjected to cyclic mechanical strain (CMS) 
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4.3.2.2. The effect of MAPK pathway inhibitors on cyclic mechanical strain 
induced MCP-1 release from Ea.hy 926 cells 
Ea.hy 926 cells were pre-incubated with U0126 (A, 3 and 10µM) for 2 hours, or PD98059 (B, 3 and 
10µM), SP600125 (C, 3 and 10µM) or SB203580 (D, 3 and 10µM) 1 hour prior to 4 hours, 30% 
elongation, 0.33Hz CMS. MCP-1 protein was assayed by ELISA 24 hours after CMS. MTT assay was 
used to assess the cell viability. Data are presented as mean ± SEM. Comparison between conditions was 
made by Kruskal-Wallis with Dunns post test, * p<0.05. Asterisks on top of the bar refer to comparison 
with the appropriate control condition (non-CMS, 0). Asterisks above lines refer to comparison between 
indicated conditions.  
 
To determine the role of MAPK in CMS-induced MCP-1 release, specific 
inhibitors of the three signalling pathways were used. The ERK 1/2 pathway inhibitors 
UO126 and PD98059 completely attenuated the CMS-induced MCP-1 protein release 
(figure 4.5A/B). SB 203580, a p38 inhibitor, did not prevent CMS stimulated MCP-1 
release (figure 4.5D) and, despite reducing levels of MCP-1 in stretched supernatants 
the JNK inhibitor SP600125 also appeared to reduced levels of MCP-1 in supernatants 
from unstretched cells in a dose-dependent manner (figure 4.5C). Cell viability was also 
reduced at the higher (10µM) dose of SP600125 as determined by MTT assay (data not 
shown) and cells showed an obvious morphology change with increased detachment by 
Figure 4.5 Effect of MAPK pathway inhibitors on stretch-induced MCP-1 release in response to 
cyclic mechanical strain (CMS) 
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strained versus unstrained cells. This is likely to reflect the differences in MCP-1 levels 
seen at the higher concentration. At 3µM doses of SP600125 there was a small but 
insignificant decrease in metabolic activity in both strained and unstrained cells.  
 
4.3.2.3. ERK 1/2 pathway inhibitors attenuate strain induced MCP-1 protein 
release by human lung microvascular endothelial cells 
To test the role of the ERK pathway in strain induced MCP-1 release in primary 
cells HLMVEC were subjected to mechanical strain in the presence of UO126, the 
MEK1/2 inhibitor. Figure 4.6 shows that UO126 attenuated the release of MCP-1 
protein by HLMVEC subjected to mechanical strain. 
HLMVEC were grown to confluence on BioFlex 6TM well plates and quiesced in medium containing 
0.1% fetal calf serum (FCS) for 16 hours. Medium was then refreshed with medium containing 0.1% FCS 
and UO126 (3µM) or vehicle control 1 hour prior to cyclic mechanical strain (CMS 30%, 4 hours, 
0.33Hz). Supernatants were harvested at 24 hours post CMS and MCP-1 protein levels assayed (ELISA). 
n=2. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 Effect of MEK1/2 inhibitor on strain induced MCP-1 protein release by human lung 
microvascular cells (HLMVEC). 
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4.3.2.4. The effect of MAPK inhibitors on ERK1/2 phosphorylation 
Ea.hy 926 cells were pre-treated with U0126 (3µM) for 2 hours prior to, or SP600125 (3µM) for 1 hour 
prior to, 10 minutes of 30% cyclic mechanical strain. Cell lystates were collected.  Phosphorylated 
ERK1/2 was detected in 20µg of cell lysate protein using western blotting. The results are representative 
of two independent experiments.  
 
In order to ensure that the UO126 was appropriately inhibiting ERK 1/2 
phosphorylation, p-ERK 42/44 level was analysed in whole cell lysates from cells 
subjected to 0% or 30% CMS in the presence and absence of these inhibitors (figure 
4.7). Furthermore, in light of the results showing a global decrease in MCP-1 protein 
levels in supernatants after CMS, the effect of SP600125 on ERK1/2 phosphorylation 
was determined to ensure that this inhibitor was not cross inhibiting ERK1/2 
phosphorylation. Western blotting of protein from total cell lysates harvested after 10 
minutes of CMS showed that UO126 completely abolished CMS induced ERK 1/2 
phosphorylation and that SP600125 had no effect on ERK 1/2 phosphorylation (figure 
4.7). 
 
4.3.2.5. The effect of ERK 1/2 pathway inhibition on cyclic mechanical strain 
induced MCP-1 gene transcription by Ea.hy 926 cells 
To determine the effect of CMS induced ERK 1/2 phosphorylation on MCP-1 
transcription, the effect of the UO126 and PD98059 on MCP-1 gene transcription 
was assessed. Both inhibitors dramatically reduced the expression of MCP-1 mRNA 
after 4 hours of strain compared to non-strained controls (figure 4.8).  
Figure 4.7 Effect of MEK1/2 and JNK inhibitors on stretch induced ERK1/2 phosphorylation in 
Ea.hy 926 exposed to cyclic mechanical strain 
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Ea.hy 926 cells were pre-incubated with U0126 (3µM) for 2 hours, and PD90359(3µM), SP600125 
(3µM) and SC514(3µM) for 1 hour  prior to 4 hours 0 or 30% CMS. MCP-1 mRNA levels were 
determined by quantitative real-time PCR normalised to the average level of expression of two house-
keeping genes HKG in the same sample and expressed relative to unstimulated controls. Data are 
presented as mean ± SEM for the ratio of MCP-1/HKG. Comparison between conditions was made by 
one-way ANOVA with Bonferroni test, * p<0.05, ** p<0.01, *** p<0.001. Asterisks on top of bars 
refer to comparison with basal expression (CMS 0%), asterisks above lines refer to comparison 
between indicated conditions. Numbers of experiments are shown in the appropriate non-stretched 
bars. 
 
4.3.2.6. Phophorylated ERK1/2 and phosphorylated ribosomal-s6-kinase 
(p90RSK) enter the nucleus of Ea.hy 926 cells after CMS 
To determine whether phosphorylated ERK and RSK, a kinase downstream of 
ERK 1/2, enter the nucleus after CMS, nuclear extracts were analysed using western 
blotting. Phosphorylated p90RSK and phosphorylated-ERK 42/44 were detectable in 
nuclear extracts from cells harvested at 10-30 minutes after CMS (figure 4.9).  
Figure 4.8 Effects of MEK 1/2, JNK, p38 and I inhibition on stretch-induced MCP-1 
mRNA expression by Ea.hy 926. 
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(A) Nuclear extracts were collected at 0, 10, 30 and 60 minutes of 30% CMS. Phosphorylated p90RSK 
(phos-p90RSK), phosphorylated ERK 1/2 and lamin A/C were detected in 17ug of nuclear extract protein 
by western blotting. Blot representative of three experiments. (B) The developed blots were analysed 
using the Image J to quantitate the density of the bands and the values for the relative expression of 
phosphorylated p90RSK to Lamin C. 
 
4.3.2.7. Determination of the role of Ras as an upstream component of the 
ERK 1/2 pathway 
In order to determine the role of Ras upstream from ERK 1/2 in CMS induced 
MCP-1 release Ea.hy 926 cells were transfected with a virus carrying dominant negative 
(dn) Ras with the intention of rendering the cellular Ras response ineffective. An 
increasing level of Ras protein by western analysis was seen with an increasing 
multiplicity of infection (figure 4.10). A MOI of 500 was used to address the effects of 
dnRAS on CMS induced MCP-1 release.  
 
 
Figure 4.9 phospho-p90RSK and phosphor ERK 1/2 expression in nuclear extracts 
from Ea.hy 926 cells exposed to cyclic mechanical strain 
A 
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Ea.hy 926 cells were infected with dominant negative Ras at increasing multiplicity of infection (MOI, 
plaque forming units per cell) expressing viral vector and grown to confluence. Cells were serum starved 
(0.1%FCS) for 16 hours and collected. (A)Western blot was performed to detect total Ras expression. (B) 
The developed blots were analysed using the Image J to quantitate the density of the bands.  
Ea.hy 926 cells were transfected with dominant negative Ras (dnRas; MOI 500pfu/cell) or Empty Vector 
(EV) or not transfected 24 hours after plating on Bioflex 6 well plates and grown to confluence. Cells 
were quiesced overnight (0.1%FCS) and exposed to CMS (0 or 30%). Cells were harvested after 10 
minutes. Western blot was performed to detect total Ras, and total and phosphorylated ERK1/2 and is 
representative of 3 independent experiments (A). MCP-1 protein levels were assayed in supernatants at 24 
hours after stretch by ELISA (B), n=3. MCP-1 mRNA levels were quantified by real time PCR compared 
with the average level of expression of two house-keeping genes (HKG) GUSB and TUBB in the same 
sample and shown relative to unstimulated control (C). n=1.  
A B 
A 
Figure 4.10 Ras protein expression by EAHY for dominant negative Ras viral multiplicity of 
infection 
Figure 4.11 Effect of dominant negative Ras transfection (500 MOI) on ERK1/2 phosphorylation. 
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Cells were subsequently transfected as described above and subjected to CMS 
(30%, 0.33Hz). In addition, cells were transfected with an empty viral vector (EV) or 
left untreated to provide negative and positive controls respectively. After 10 minutes, 
CMS whole cell lysates were extracted for analysis of Ras and phopsho- and total 
ERK1/2 expression by western blotting. Immediately after 4 hours of CMS, RNA was 
extracted and MCP-1 gene expression determined using qPCR. MCP-1 protein 
expression was analysed in supernatants collected at 24 hours after CMS (figure 4.11). 
The results show that whilst Ras levels were higher in dnRas transfected cells, there was 
no effect upon CMS induced phosphporylation of ERK 1/2, indeed the dnRas and the 
EV appeared to increase phosphorylation of ERK 1/2 in this system. Furthermore, 
dnRas did not attenuate either CMS induced MCP-1 gene transcription nor protein 
release.  
 
4.3.3. Determination of the role of I-2 as an upstream component of strain 
induced MCP-1 transcription. 
Nuclear kappa factor beta (NFB) is implicated in the signalling pathway 
inducing MCP-1 transcription by EC in response to other stimuli. To determine its role 
in strain-induced MCP-1 expression Ea.hy 926 were both strained in the presence of 
SC514, a specific I-2 inhibitor, and transfected with a virus carrying dnI-2 using 
the same protocol as for dnRas (figure 4.12). Neither the pharmacological inhibitor nor 
the transfection appeared to affect MCP-1 release in this preliminary work, although 
firm conclusions cannot be made due to the small number of experiments (n=2). 
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(A) Ea.hy 926 cells were plated on BioFlexTM 6 well plates and grown to confluence. Cells were then 
quiesced for 16 hours in medium containing 0.1% fetal calf serum (FCS). Cell were then pre-incubated 
with SC514 (10µM) or vehicle control for 1 hour prior to 4 hours CMS (30%; 0.33 Hz). Supernatants 
were collected at 24 hours post CMS and MCP-1 levels assayed (ELISA); n=4.  
(B) Ea.hy 926 cells were transfected with dominant negative I (dnI; MOI 100pfu/cell) or Empty 
Vector (EV) or not transfected (vehicle) 24 hours after plating on Bioflex 6 well plates and grown to 
confluence. Cells were quiesced overnight (0.1%FCS) and exposed to CMS (0 or 30%). MCP-1 protein 
levels were assayed in supernatants at 24 hours after stretch by ELISA. n=2.  
 
4.3.4. Functional studies 
4.3.4.1. Supernatants from endothelial cells exposed to cyclic mechanical 
strain increase pulmonary arterial smooth muscle cell (PASMC) and fibroblast 
proliferation 
 To determine the role of products from EC subjected to CMS in stimulating 
PASMC and fibroblasts to proliferate, cells of both types were grown to 60% 
confluence, quiesced and then treated with medium containing 0% or 10% FCS (as 
positive or negative controls) and supernatants from Ea.hy cells subjected to 0% or 30% 
CMS for 24 hours. Relative cell number was then determined using the CyQUANT 
assay and cell numbers relative to the unstimulated controls (i.e. 0% FCS). These data 
show that both types of cells proliferated more than unstimulated controls following 
treatment with supernatants from stretched compared to non-stretched cells (figure 
4.13). The increase in relative proliferation reached statistical significance for PASMC 
(0% CMS (median (interquartile range): 1.378 (1.291-1.459), 30% CMS 1,582 (1.399-
2.00)), but not for HFL-1 (0% CMS: 1.345 (1.3-1.481), 30% CMS: 1.590 (1.41-1.66)). 
Figure  4.12 Effect of SC514 (a specific I-2 inhibitor) and viral transfection of dominant negative 
I on CMS induced MCP-1 protein release by Ea.hy 926 
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HFL-1 (A) and PASMC (B) were grown to confluence and serum starved for 24 hours. Cells were then 
incubated for a further 24 hours in medium containing 0% or 10% fetal calf serum (FCS) or supernatants 
from non-stretched (0) or stretched (30) Ea.hy 926 cells. Cell proliferation was assessed by CyQUANT 
proliferation and expressed relative to unstimulated cells (0% relative proliferation =1). n=5; Friedmans 
test with Dunn’s post test * p<0.05.  
 
 
4.3.4.2. Supernatants from endothelial cells exposed to cyclic mechanical 
strain stimulate fibroblast but not pulmonary arterial smooth muscle cell 
differentiation 
To establish the effect of mechanical strain applied to endothelial cells upon 
fibroblast and PASMC differentiation, HFL-1 cells and PASMC were grown to 
confluence on 6 well plates, quiesced and then incubated for a further 24 hours with 
supernatants from stretched or non-stretched EC.  
The expression of markers of myofibroblast differentiation, alpha smooth 
muscle actin (SMA), procollagen 1 (PC1), connective tissue growth factor (CTGF) and 
vimentin, were determined in cells incubated with supernatants from strained and 
unstrained EC. These data revealed that the expression of SMA and vimentin increased 
in HFL-1, a fibroblast cell line, on incubation with supernatants from strained rather 
than non-strained EC (figure 4.14 A/C), whilst, PASMC did not (figure 4.15 A/B). In 
summary, supernatants from stretched EC increased PASMC and HFL-1 proliferation, 
but only promoted cellular differentiation in HFL-1 cells. 
Figure 4.13 HFL-1 and PASMC proliferation in response to supernatants from non-stretched and 
stretched Ea.hy 926 cells and positive (10% FCS) and negative (0% FCS) controls 
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HFL-1 cells were grown to confluence on 6 well plates and serum starved for 24 hours. Cell were then 
incubated with supernatants from unstretched (0) or stretched (30) EaHy.926 cells or DMEM 
supplemented with 0% or 10% fetal calf serum (FCS). RNA was extracted and gene expression (A: alpha 
smooth muscle actin (SMA), B: procollagen-1 (PC1), C: vimentin, D: connective tissue growth factor 
(CTGF)) determined by qPCR. Expression was normalised to the average expression of 2 housekeeping 
genes (HKG: GUSB, PPIB) and data are shown relative to unstimulated controls (0% FCS), given an 
expression value of 1.*p<0.05 Kruskal Wallis with Dunns post test; n=4. 
 
 
 
Figure 4.14 Fibroblast differentiation in response to incubation with supernatants from Ea.hy 926 
cells exposed to mechanical strain. 
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HFL-1 cells were grown to confluence on 6 well plate and serum starved for 24 hours. Cell were then 
incubated with supernatants from unstretched (0) or stretched (30) EaHy.926 cells or DMEM 
supplemented with 0% or 10% fetal calf serum (FCS). RNA was extracted and gene expression (A: alpha 
smooth muscle actin (SMA), B: procollagen-1 (PC1), C: vimentin, D: connective tissue growth factor 
(CTGF)) determined by qPCR. Expression was normalised to the average expression of 2 housekeeping 
genes (HKG) and data are shown relative to unstimulated controls (0% FCS), given an expression value 
of 1.*p<0.05 Kruskal Wallis with Dunns post test. n=3. 
 
 
4.3.4.3. Supernatants from endothelial cells exposed to cyclic mechanical 
strain increase monocyte migration. 
The major physiological role of MCP-1 is monocyte recruitment, and 
consequently potential propagation of the inflammatory response. To determine whether 
the increase in MCP-1 seen in supernatants from stretched EC is of physiological 
Figure 4.15 Pulmonary artery smooth muscle cell (PASMC) differentiation in response to incubation with 
supernatants from Ea.hy 926 cells exposed to mechanical strain. 
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significance, their effect on monocyte migration was also assessed. Preliminary data 
reveal that a greater number of monocytes migrated into the membranes of 
Transwells™ suspended in supernatants from stretched compared to non- stretched 
wells (figure 4.16). This supports the hypothesis that in vivo stretch induced MCP-1 
production might be important in monocyte recruitment and persistence of the 
inflammatory response seen in CHF. 
THP-1 cells were seeded into hanging inserts with porous (8um) membranes suspended in supernatants 
from stretched or non-stretched cells for 2 hours. Membranes were then cleaned of loose cells, fixed with 
4% paraformaldehyde and stained with brilliant blue. Cells were counted under light microscopy in 5 
random fields of view (B). Data represent the number of cell in five random fields of view in 2 
independent experiments  
4.4. Discussion 
4.4.1. Summary of important results in this chapter 
The experiments in this chapter examined the effect of CMS on MCP-1 gene 
expression and protein release by EC and the role of MAPK in this system. The results 
presented demonstrated that both the Ea.hy 926 cell line and the commercially available 
HLMVEC when subjected to CMS increased gene transcription and protein levels of 
MCP-1 after 4 and 24 hours respectively.  
In Ea.hy 926 cells CMS activated p38, pJNK and ERK 1/2 with a peak 
phosphorylation at 10 minutes for JNK and p38, but at 30 minutes for ERK1/2. Peak 
ERK 1/2 phosphorylation occurred earlier in the primary cells at 5 minutes. For all 3 
MAPKs the degree of phosphorylation was returning to, but had not reached, baseline 
levels by one hour. Nuclear translocation of phosphorylated p90RSK occurred after 30 
minutes of mechanical strain returning to baseline by 60 minutes. Cyclic mechanical 
Figure 4.16 THP-1 migration into supernatants from non-stretched (NS) and stretched (S) 
Ea.hy 926 cells. 
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strain-induced MCP-1 mRNA transcription and protein release were blocked by the 
MEK 1/2 inhibitors (UO126 and PD98059- both 3µM), but protein release was not 
affected by p38 inhibition (SB203580) nor by JNK inhibition (SP600125). Upstream of 
ERK1/2 dominant negative Ras transfection did not attenuate phosphorylation of 
ERK1/2 and consequently did not inhibit MCP-1 mRNA transcription or protein 
release. 
Neither the specific inhibitor of I (SC514) nor viral transfection of dominant 
negative I attenuated strain induced MCP-1 protein release by Ea.hy 926. 
Supernatants from strained compared to unstrained Ea.hy 926 cells increased 
both HFL-1 and primary PASMC cell proliferation. Differentiation of HFL-1 cells into 
a myoproliferative phenotype, as determined by alpha-smooth muscle actin (SMA) and 
vimentin gene expression was potentiated by supernatants from strained compared to 
unstrained cells. This was not the case with PASMC which expressed less SMA, 
vimentin and connective tissue growth factor (CTGF), a third marker of SMC 
differentiation into a myoproliferative phenotype. Indeed, SMA levels were reduced in 
the presence of “strained” supernatants, whilst vimentin and CTGF levels remained 
unchanged. 
Preliminary data revealed that supernatants from Ea.hy 926 cells exposed to 
mechanical strain did increase migration of monocyte cells, suggesting that EC strain 
may be important in monocyte recruitment and tissue inflammation. 
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Cyclic mechanical strain (CMS) activated all 3 of the MAPK pathways, but only inhibition of the ERK 
1/2 pathway attenuated stretch stimulated MCP-1 protein and gene expression (thick green arrow). 
Inhibition of the NFkB pathway had no effect on strain induced MCP-1 expression  
Abbreviations: JNK- c-Jun NH2- terminal protein kinase; ERK- extracellular signal related protein 
kinase; NFkB- nuclear factor kappa B; MCP-1- monocyte chemoattractant protein-1; AP-1- activator 
protein-1; p90RSK- ribosomal protein S6 kinase. 
 
 
4.4.2. MCP-1 gene expression and protein release in response to cyclic mechanical 
strain in endothelial cells 
Mechanical strain induced MCP-1 gene transcription and protein release in 
both Ea.hy 926 cells, an endothelial cell line, and primary human lung microvascular 
endothelial cells (HLMVEC). Such findings are consistent with data from other 
endothelial cell types (human umbilical endothlelial cells (HUVEC)) as well as non-
endothelial vascular cells (renal mesangial cells, aortic smooth muscle cells (SMC)) 
and non vascular cells (bladder SMC, myometrium (Shynlova et al. 2008) (Okada et 
al. 1998; Jiang et al. 1999; Wung et al. 2001; Gruden et al. 2005; Yang et al. 2008). 
Figure 4.17 Summary of the proposed pathway of mechanical strain induced monocyte 
chemoattractant protein-1 expression by endothelial cells. 
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These data therefore support previous findings that MCP-1 is produced in response to 
CMS by EC, but moreover are the first to show this finding in HLMVEC. This is 
important for two reasons: firstly, EC from different vascular beds have differing 
responses to stimuli, including mechanical strain, with differences even seen between 
EC from pulmonary arteries and pulmonary microvascular EC (Adkison et al. 2006). 
Secondly, these findings support the hypothesis that the pulmonary microvasculature, 
as the immediate upstream target of raised LAP, is a potential source of inflammatory 
mediators and an active contributor to the pathophysiology of CHF.   
 
4.4.3. The role of MAPK in mechanical strain induced MCP-1 release  
The decision to interrogate the role of the MAPK in CMS induced MCP-1 
production is based on two streams of evidence: Firstly, MAPK (specifically ERK1/2 
and p38) are involved in MCP-1 synthesis by EC in response to stimuli other than 
mechanical strain (Goebeler et al. 2001; Sutcliffe et al. 2009). Secondly, all three 
MAPKs are phosphorylated in response to CMS in bovine aortic EC and have an 
important role in AP-1 transcription activity (Kito et al. 2000). In addition, the MAPKs 
are implicated in mechanotransduction in other cell types and in CMS stimulated EC 
production of other mediators (Okada et al. 1998; Ikeda et al. 1999; Wung et al. 1999). 
There is no previous work specifically addressing the role of the MAPKs in EC strain 
induced MCP-1 production.  
We show that all three MAPK are phosphorylated in a time dependent manner 
with peak phosphorylation at 10 minutes for JNK and 30 minutes for ERK 1/2 and p38. 
This is in agreement with the work of others who showed a similar time dependent 
response stretching bovine aortic EC using the same apparatus (Ikeda et al. 1999; Kito 
et al. 2000).  
In both whole cell lysates and nuclear extracts the baseline levels of 
phosphorylated ERK were higher than expected. Reviewing the available literature, the 
baseline levels of ERK1/2 phosphorylation are similar to those seen by other groups 
applying CMS to bovine aortic EC using the same technique (Kito et al. 2000). One 
difference in method is that here cells only quiesced for 16 hours in medium containing 
0.1% FCS. Other groups quiesced their cells for longer (48 hours) prior to 
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experimentation and then strained the cells in serum-free (0% FCS) medium (Ikeda et 
al. 1999) or quiesced and treated the cells in serum-free (0% FCS) medium (Kito et al. 
2000). A third possible explanation in Ea.hy 926 is the use of DMEM as a quiescence 
medium. This medium has a relatively high glucose concentration, which can itself 
stimulate MCP-1 expression and hence potentially activate ERK 1/2 at baseline. 
Medium M199 has a lower glucose concentration and is used by others for quiescence 
in EC and experimentation and is an alternative that could be used to investigate this in 
the future.  
 
4.4.3.1. Strain-induced MCP-1 expression is only inhibited by MEK 1/2 
inhibition and not by the inhibition of JNK or p38 pathways 
Only inhibition of the ERK 1/2 pathway had a significant effect upon CMS 
induced MCP-1 release and gene transcription in Ea.hy 926 cells. Our work is the first 
to directly determine the relative importance of the MAPK in strain induced MCP-1 
expression in endothelial cells. ERK1/2-dependent MCP-1 expression has been 
demonstrated in other cell types (glomerula mesangial cells, VSMC) in response to 
other stimuli, including ET-1, TNF- and barometric pressure. Extensive work has 
addressed the role of MAPK signalling in the regulation of MCP-1 expression in 
endothelial cells. Activation of the MAPK pathways in EC appears to be stimulus 
specific, as indeed is the regulation of MCP-1 gene expression. For example MCP-1 
transcription was abolished by SB203580 but not UO126 in EC stimulated by 
homocysteine and TNF-, whilst vascular endothelial growth factor (VEGF) induced 
MCP-1 expression by HUVEC was specifically attenuated by MEK 1/2 inhibition with 
PD98059 (Goebeler et al. 1999; Goebeler et al. 2001; Sung et al. 2001). It is postulated 
that this differential MAPK recruitment and subsequent transcription factor activation 
provides a regulatory mechanism by which chemokines can be selectively expressed in 
a cell type-specific and stimulus-specific manner (Roebuck et al. 1999). This may be 
reflected by the different susceptibility of specific areas of the vascular tree to 
atherosclerosis, dependent upon relative exposure of the endothelium to laminar flow 
and circumferential stretch.  
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It is important to note that roles for the JNK or p38 pathways in CMS induced 
MCP-1 production have not been rigorously excluded. Two different inhibitors of the 
ERK 1/2 pathway were used, with UO126 effectively abolishing ERK 1/2 
phosphorylation. The JNK pathway inhibitor (SP600125) did not significantly attenuate 
strain induced MCP-1 expression at the lower dose of 3µM, but had deleterious effects 
on cell respiration at the higher dose (10µM). A second less toxic JNK inhibitor or 
molecular inactivation of the pathway would ideally be used at the higher 
concentrations to support further the redundancy of this pathway in this system. The 
specific p38 inhibitor also did not show any significant effect on CMS induced MCP-1 
expression at either 3µM or 10µM. It must be noted that the doses of both SB203580 
and SP600125 are lower than those used by some other groups in other systems and we 
cannot ruled out an effect of SB203580 at higher doses (Cho et al. 2002) (Goebeler et 
al. 1999). In rat aortic SMC, strain induced MCP-1 expression occurs via both ERK 1/2 
and p38 pathways (Guest et al. 2006). Therefore, although our data strongly support a 
role for ERK 1/2 in CMS induced MCP-1 production, the roles of the other pathways 
would require the use of second inhibitors and more rigorous and specific techniques.  
 
4.4.3.2. Upstream and downstream components of mechanical strain 
induced signalling pathway leading to ERK 1/2 phosphorylation and MCP-1 
expression 
CMS induced MCP-1 release by HUVEC was dependent on the actin 
cytoskeleton and involves ROS, PLC, PKC and tyrosine kinases (TK), also seen to be 
important in other cell types (SMC) (Wung et al. 1997; Okada et al. 1998; Wung et al. 
2001). The same authors also demonstrated a role for AP-1 transcription factors. Work 
by Wung et al has confirmed a role of Ras, Rac and ROS upstream of ERK1/2 in bovine 
aortic EC subjected to CMS. We therefore postulated a role for the small protein Ras in 
our system and attempted to interrogate this by transfecting a dominant negative Ras 
(dnRas). Unexpectedly, this did not alter either ERK1/2 phophorylation or MCP-1 
protein release. These data would suggest that either the transfected construct was not 
inactive as intended, or that in this system ERK1/2 is activated by a Ras independent 
mechanism. Further work would be required to elucidate this. 
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4.4.3.3. Phosphorylated p90RSK translocates to the nucleus after cyclic 
mechanical strain 
 Our data show that p90RSK, a canonical component of the ERK 1/2 pathway, 
enters the nucleus from 30 minutes after CMS in Ea.hy 926. This is in keeping with our 
proposed view that ERK1/2 is the predominant pathway involved in CMS induced 
MCP-1 expression. It does not, however, exclude the possibility of other pathways 
being important. HUVEC subjected to CMS increased MCP-1 expression in a redox 
sensitive manner involving AP-1 transcription factors binding at the TRE promoter 
site(Wung et al. 1997). More recently in an in vivo model of arteriolar stretch in the 
context of arteriogenesis, circumferential wall tension increased VSMC MCP-1 gene 
expression in an AP-1 dependent manner (Demicheva et al. 2008). Furthermore, ERK 
1/2 is known to activate AP-1 in response to stretch, and to other stimuli leading to the 
production of MCP-1(Kito et al. 2000; Takaya et al. 2003). Cytokines and other stimuli, 
however, increase MCP-1 gene transcription via either AP-1, or NFB or both 
transcription factors in MAPK dependent or independent manners (see figure 1.8). 
Figure 4.18 outlines a proposed signalling pathway based on the data from these 
experiments.  
Abbreviations: ERK- extracellular signal related protein kinase; MCP-1- monocyte chemoattractant 
protein-1; AP-1- activator protein-1; p90RSK- ribosomal protein S6 kinase 
 
Figure 4.18 Summary of the proposed pathway of mechanical strain induced monocyte 
chemoattractant protein-1 expression by endothelial cells. 
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4.4.4. Fibroblast and vascular smooth muscle cell proliferation and differentiation 
In keeping with our hypothesis, supernatants from strained compared to non-
strained Ea.hy 926 cells stimulated HFL-1 cells and PASMC to proliferate. This finding 
concurs with previous data using supernatants from strained HLMVEC (chapter 3.3.7, 
figure 3.9). What is interesting about the results using the endothelial cell line are that 
one difference between Ea.hy 926 cells and the primary cells is that they release 
comparable low levels of ET-1 compared to the primary cells. Consequently it is 
unlikely that ET-1 is driving this proliferation, but instead an alternative mediator is 
important.  
Interestingly, the differentiation data revealed a divergent picture between the 
two proliferating cell types. Whilst HFL-1 cells increased SMA expression and 
vimentin on incubation with strained supernatants, PASMC decreased SMA 
expression and vimentin expression remained unchanged.  Whilst these results are 
surprising, there may be valid explanations for them. Firstly our model of gene 
expression was based upon a time course of SMA expression by HFL-1 cells in 
response to incubation in medium with 10% FCS. This time point may not be the 
optimal time point for addressing expression of other genes or for gene expression in 
PASMC. Indeed work addressing hepatic fibroblast differentiation revealed only a small 
increase in SMA expression in response to MCP-1 stimulation at 1 day, but a much 
more pronounced response at 6 days (Kruglov et al. 2006). Our limitation was that to 
incubate the cells for 6 days in “strained supernatant” would require refreshing of the 
supernatant and this would require the application of strain to a considerable number of 
EC. It may also be that fibroblasts (specifically fetal fibroblasts) might behave 
differently from PASMC in response to mediators including MCP-1. 
Differences between cell proliferation and expression of markers of 
differentiation are again unexpected, but may reflect that in this system mediators 
released by Ea.hy 926 cells in response to strain may drive cell growth rather than 
differentiation. Again, the time point of 24 hours may in part explain some of the 
differences. This model may reflect an early component of the response (cell 
proliferation) and it could be postulated that at later time points, the increased cell 
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numbers might then undergo differentiation or that as mentioned above the changes in 
markers of differentiation do not become apparent until a later time point.  
 
4.4.5. Monocyte Migration 
Monocyte migration in response to supernatants from strained cells might be 
important in the pathophysiology for CHF for two reasons: firstly, MCP-1 release 
promotes recruitment of monocytes and can directly potentiate the inflammatory 
response in CHF which might, if analogous to other disease states, lead to fibrosis and 
remodelling (Distler et al. 2006). In addition, monocytes that migrate through the 
endothelium can themselves differentiate into fibroblasts in response to MCP-1 
stimulation (Haudek et al. 2009). 
 
4.5. Future Directions 
a. To investigate the role of other MAPK in CMS- induced MCP-1 release and 
the activation of the upstream components of the MAPK signalling pathways 
ERK 1/2, JNK and p38 were all significantly activated by 30% CMS. UO126 and 
PD98059 were the only MAPK pathway inhibitors to significantly attenuate CMS 
induced MCP-1 release and gene expression, supporting a role for ERK1/2 
phosphorylation in CMS-induced MCP-1 expression. This does not exclude a role for 
the other MAPKs and further work should be directed at conclusively excluding role for 
JNK and p38 by employing other pharmacological inhibitors and transfection of viral 
vectors expressing dominant negative components of the respective pathways. This 
would be especially important for the p38 pathway, which has been shown to be 
important in MCP-1 expression in response to other stimuli in EC, both independently 
and alongside ERK1/2 signalling (Guest et al. 2006).  
Attempts to identify the role of Ras as an upstream component of this pathway 
were unsuccessful. Previous work in our lab using siRNA techniques directed at Ras has 
also been unsuccessful due to cell detachment, and so we did not pursue this line of 
investigation either. Future work should be directed at confirming phosphorylation of 
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other upstream components of this pathway and using more specific techniques to 
abrogate their function. Furthermore, pharmacological inhibitors of actin integrity, 
stretch activated ion channels and other potential upstream components of the ERK1/2 
pathway (ROS, PLC, PKC, Rho, Src kinases and TKs) are readily available and would 
help further elucidate the mechanism underlying mechanotransduction in HLMVEC and 
Ea.hy 926 cells and their importance in MCP-1 expression. 
b. To elucidate the down-stream signalling responsible for 
mechanotransduction  
Phosphorylated p90RSK translocated to the nucleus after CMS. Others show that 
both NFB (p65) and AP-1 (c-jun) binding sites in the promoter region are important in 
increased MCP-1 gene transcription in response to other stimuli. Pharmacological 
inhibition of I (SC514) and preliminary data using dnI transfection do not suggest a 
role for the NFB pathway and hence p65 binding sites are unlikely to be involved. It 
would however, be important to determine the role of AP-1 (c-jun) in CMS induced 
MCP1 expression in EC by either using siRNA techniques or by identifying relative 
binding levels on the MCP-1 promoter using choromatin immunopreciritation (ChIP). 
 
c. To confirm the effect of strained supernatants on monocyte migration and to 
determine whether this is MCP-1 dependent 
The primary role of MCP-1 is monocyte recruitment. Preliminary work suggests 
that “strain supernatants” recruit monocytes across porous membranes. To determine if 
CMS induces a relevant physiological change, this work needs to be confirmed and 
experiments performed to determine whether MCP-1 inhibition attenuates the response. 
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5. Chapter 5- BMP-9 and ET-1 
5.1. Introduction 
Pulmonary arterial hypertension (PAH) secondary to left heart failure is 
common: 40-60% of patients with isolated diastolic dysfunction or left ventricular 
(LV) systolic dysfunction have PAH at presentation (Moller et al. 2005). Development 
of secondary PAH in CHF worsens prognosis and pulmonary artery systolic pressure 
was an independent predictor for the need for cardiac transplant (Abramson et al. 
1992; Hulsmann et al. 1998). 
The bone morphogenetic proteins (BMP) and their receptor, bone 
morphogenetic protein receptor type 2 (BMPR2) are postulated to have an important 
role in the pathophysiology of PAH (Chapter 1.4.1). Heterozygous germline mutations 
in BMPR2 have been identified in familial forms of PAH, although there is incomplete 
penetrance (Deng et al. 2000; Lane et al. 2000). Mutations in the BMPR2 gene have 
been identified in approximately 80% of cases of familial PAH (Machado et al. 2006). 
Expression of BMPR2 is also decreased in lungs of patients with idiopathic PAH with 
no detectable mutation in the BMPR2 gene, and in human and animal lungs in diverse 
forms of acquired PAH (Atkinson et al. 2002). It has been proposed that the 
subsequent imbalance in TGF- and BMP signalling pathways is an important 
component in the pathophysiology of PAH.  Work specifically addressing PAH 
secondary to increased left atrial pressure has identified alterations in the BMPR 
signalling pathways, although no difference in BMPR2 expression was seen (Du et al. 
2003). Instead decreased levels of the type 1 receptor (BMPR1A) were observed, 
potentially secondary to the upregulation of angiopoeitin-1 (Ang-1). The incomplete 
penetrance of BMPR2 mutations has lead to the suggestion of a “two-hit” hypothesis 
of PAH- a second insult to the lungs, such as inflammation, being required for the 
manifestation of clinical disease. What is likely is that dysfunction of the BMPR 
signalling, be it due to an induced or inherited decrease in receptor expression or 
function is critical in the pathogenesis of PAH (Davies and Morrell 2008). 
BMP-9 stimulated cytokine release from pulmonary arterial endothelial cells 
(PAEC), signalling through Smad 1/5 and unexpectedly also through Smad-2/3 (Upton 
et al. 2009). TGF-1 stimulates ET-1 release via Smad-2/3 phosphorylation in EC. It 
is therefore plausible that BMP-9 is able to induce ET-1 release via a similar 
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mechanism. Recently published data showed that human lung microvascular 
endothelial cells (HLMVEC) released ET-1 in response to BMP-9 (Star et al. 2010). 
Given that ET-1 and other inflammatory mediators are implicated in the 
pathophysiology of both CHF and PAH, BMP-9 signalling might have an important 
role in both of these disease states. In this chapter the effect of BMP-9 on release of 
ET-1 and MCP-1 by PAEC is investigated.  
 
5.1.1. Smad independent signalling by bone morphogenetic proteins 
The mitogen activated protein kinase (MAPK) cascades are an alternative 
signalling pathway for BMPs that is Smad-independent: BMP-4 phosphorylates both 
p38 and ERK 1/2 MAPK, with haemoxygenase-1 (HO-1) induction being p38 
dependent (Yang et al. 2007). BMP-2 induced apoptosis occurs in a p38 dependent 
manner and this effect is negatively regulated by Smad-6 (Kimura et al. 2000). 
Furthermore, BMP-2 is able to signal through either Smads or p38 MAPK dependent 
on the localization of BMPR1 and BMPR2 at the cell surface (Nohe et al. 2002). Both 
p38 and ERK 1/2 were phosphorylated in HLMVEC stimulated with BMP-9. 
Inhibitors of the two pathways had no effect on BMP-9 stimulated ET-1 release.  
Tumour necrosis factor (TNF-)- stimulated pulmonary artery smooth muscle 
cells (PASMC) release ET-1 via the NFB signalling pathway. BMP-4 treated 
coronary artery endothelial cells (CAEC) and, to a lesser extent, PAEC also activate 
the NFB signalling pathway (Csiszar et al. 2008). Furthermore, the BMPR1a is able 
to recruit the NFB and MAPK signalling pathways (Matluk et al. 2010). 
 
5.1.2. Specific aims 
The specific aims of this chapter were: 
1. To determine the effect of BMP-2, 4, 6 and 9 on ET-1 and MCP-1 
release by PAEC. 
2. To investigate the role of Smad signalling proteins and MAPKs in 
BMP-9 stimulated endothelin-1 release. 
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5.2. Specific Methods 
PAEC were initially grown until 80-90% confluent on 96 well plates for BMP 
dose response experiments. Cells were then quiesced for 16 hours in medium 
containing 0.1% fetal calf serum (FCS) and treated with the specific BMP in medium 
containing 0.1% FCS without hydrocortisone. 24 hours after stimulation, supernatants 
were collected and analysed by ELISA. Cell respiration was then determined by MTT 
assay (Section 2.2.5.1). To compare cell number, cells were frozen at -80oC after the 
aspiration of the supernatants and thawed at a later stage to quantify relative cell 
number by CyQUANT proliferation assay (section 2.2.5.2). 
Cells for gene expression experiments were cultured in 6 well plates and for 
experiments to determine levels of intracellular proteins cells were cultured in 6cm 
dishes. In both cases cells were plated as described earlier and grown to 90% 
confluence (24 hours), quiesced in 0.1% FCS for 16 hours and treated in medium 
supplemented with 0.1% FCS without hydrocortisone. 
Cells were transfected with small interfering RNA as outlined previously (chapter 
2.4.3). 
 
5.3. Results 
5.3.1. The effect of bone morphogenetic proteins on release of endothelin-1 by 
pulmonary artery endothelial cells 
The effect of BMP-2,-4,-6 and -9 on the release of ET-1 by PAEC was assessed 
(figure 5.1). BMP-9 produced a significant increase in ET-1 levels at concentrations in 
excess of 0.3g/ml, consistent with reported physiological levels (David et al. 2008). 
BMP-6 stimulated ET-1 release at a much higher, “unphysiological”, dose. BMP-4 
inhibited ET-1 release at lower doses, in keeping with previous reports. The BMP-9 
stimulated ET-1 response was the most dramatic and therefore chosen for further 
investigation. The BMP-9 stimulated ET-1 response reached a plateau at a dose of 
1g/ml, which was within a physiological concentration range and hence used for 
subsequent experiments. 
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PAEC were grown to confluence on 96 well plates and quiesced for 16 hours in 0.1% FCS containing 
M199 growth medium. Medium was then refreshed with 0.1% FCS M199 with increasing 
concentrations of BMP-2 (A), BMP-4 (B), BMP-6 (C) or BMP-9 (D). Supernatants were collected at 24 
hours of treatment and ET-1 level assayed by ELISA. Data are presented as mean ± SEM .n=6 for all 
*p<0.05, ** p<0.01; one-way ANOVA with Bonferroni post test. 
 
 
5.3.2. Is bone morphogenetic protein-9 (BMP-9) induced endothelin-1 (ET-1) 
release by pulmonary artery endothelial cells due to increased cell number? 
PAEC were grown to confluence on 96 well plates, quiesced over night in medium M199 containing 
0.1% fetal calf serum (FCS).  Medium was then replaced with M199 containing 0.1% FCS and 1ng/ml 
BMP-9, or dose as shown.   Supernatants were aspirated at 24 hours of treatment and cell respiration 
determined immediately by MTT assay (A; n=5), or plates were frozen at -80oC for later assessment for 
cell number by CyQUANT assay (B; n=4). Data (mean ±SEM) are presented relative to unstimulated 
controls (given a value of 1). 
 
To determine whether BMP-9 induced an increase in cell number that resulted in 
the increased levels of ET-1 seen, cellular respiration was measured by MTT assay 
Figure 5.1 Endothelin-1 release by pulmonary arterial endothelial cells (PAEC) in response 
to bone morhogenetic peptides (BMP) 
Figure 5.2 Effect of BMP-9 on pulmonary arterial endothelial cell (PAEC) respiration and cell number. 
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(section 2.2.5.1) at the end of the dose response experiments (figure 5.2A). Cellular 
proliferation was also determined after treatment with BMP-9 by CyQUANT assay 
(figure 5.2B). Neither an increase in PAEC respiration nor proliferation was 
stimulated by 1g/ml BMP-9. 
 
5.3.3. Effect of Bone morphogenetic protein-9 on endothelin-1 and monocyte 
chemoattractant protein-1 mRNA expression by pulmonary arterial endothelial 
cells 
To establish whether BMP-9 alters ET-1 gene expression by PAEC, cells were 
treated with BMP-9 and RNA extracted after increasing time points and gene 
expression determined by qPCR. BMP-9 increased ET-1 gene transcription in a 
biphasic manner with a significant increase at 2 and 24 hours (figure 5.3). 
Figure 5.3 Pulmonary arterial endothelial cell (PAEC) endothelin-1 (ET-1) and monocyte 
chemoattractant protein -1 (MCP-1) mRNA expression in response to bone morphogenetic 
protein (BMP-9) stimulation 
PAEC were grown to confluence in 6 well plates and quiesced for 16 hours in M199 medium containing 
0.1%FCS before being refreshed with the same medium containing 1ng/ml BMP-9 or vehicle control. 
RNA was extracted at increasing time points and gene expression determined by q-PCR. ET-1 (A) and 
MCP-1 (B) gene expression were normalised to the average to 2 housekeeping genes (HKG: ACTB , 
GUSB) and shown relative to expression of unstimulated controls at 2 hours. Data are mean ±SEM. * 
p<0.05, ** p<0.01, two-way ANOVA. n=4. 
 
 
5.3.4. Does bone morphogenetic protein stimulate endothelin-1 release via a 
Smad dependent pathway? 
BMP-9 stimulated the release of other inflammatory mediators from PAEC via 
Smad-2/3 or Smad 1/5 (Upton et al. 2009). The pathways both require Smad-4 (a co-
Smad; section 1.9.5) to allow translocation to the nucleus and alterations in gene 
transcription. Therefore, to determine whether BMP-9-induced ET-1 release was via a 
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Smad dependent pathway small interfering RNA (siRNA) were used to knockdown 
Smad-4 (siSmad-4) and BMP-9 stimulated ET-1 protein release assessed (by ELISA; 
figure 5.4A). The effectiveness of the siRNA was determined by western blotting 
(figure 5.4B) and analysis (image J) revealed an average attenuation of Smad-4 by 
78.45%. 
PAEC were grown to confluence in 24 well plates or 6 cm dishes and transfected with siRNA directed 
at Smad-4 (siS4), Smad-2 (siS2), scrambled siRNA (siCP) or vehicle control (DH1). Cells were 
quiesced for 16 hours and then treated with medium BMP-9 (1g/ml) or vehicle control. Supernatants 
were collected at 24 hours (24 well plates) for determination of ET-1 levels by ELISA (A) or whole 
cells lysates were collected at 1hour post treatment (6cm dishes) for determination of transfection 
efficiency by western blotting (B,C) (D) The developed blots (sis4 only) were analysed using Image J to 
quantitate the density of the bands. n=4, except siS2 n=1; *p<0.05; one-way ANOVA. 
 
These data show that BMP-9 stimulated ET-1 release by PAEC is preserved in 
the presence of siSmad-4. This suggests that BMP-9 stimulates ET-1 release in a 
Smad-independent manner. Furthermore, in one experiement Smad-2 was also 
knocked down successfully and there was no effect upon BMP-9 induced ET-1 protein 
release (figure 5.4 A & B). 
 
 
 
Figure 5.4 Effect of Smad-4 and Smad-2 knockdown on bone morphogenetic -9 stimulated 
endothelin-1 release by pulmonary artery endothelial cells. 
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5.3.5. MAPK pathway activation in pulmonary artery endothelial cells 
stimulated with BMP-9 
In order to determine whether BMP-9 could be signalling through the MAPK 
signalling cascades in PAEC to stimulate ET-1 release (figure 5.5) whole cell lysates 
from PAEC treated with BMP-9 were probed by western blotting for the 
phosphorylation of ERK 1/2, JNK and p38 (figure 5.6).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 Postulated mitogen activated protein kinase (MAPK), Smad-independent 
signalling pathway involved in bonemorphogenetic protein-9 (BMP-9) induced endothelin-1 
(ET-1) release by pulmonary artery endothelial cells (PAEC) 
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PAEC were grown to confluence on 6cm dishes and quiesced in M199 containing 0.1%FCS. Medium 
was then replaced with M199 containing 0.1% FCS with 1ng/ml BMP-9 or vehicle control. (A) Total 
cell lysates were collected at 10, 30, 60 and 120 minutes and phosphorylated and total ERK, JNK and 
p38 levels determined in 20µg of protein by western blotting. (B) Developed images were analysed 
using Image J software and density of phosphorylated p38 compared to total p38 presented graphically. 
* p<0.05; t-test. 
 
An increase in p38 phosphorylation was seen at 30 minutes, with no change in 
phosphorylated ERK1/2 or JNK. 
 
5.3.6. The effect of inhibitors of the MAPK pathway on BMP-9 stimulated 
endothelin-1 release in pulmonary artery endothelial cells. 
Given a potential role for MAPK signalling, the effect of pharmacological 
inhibition of the three MAPK pathways on BMP-9 stimulated ET-1 release was 
addressed. Supernatants were collected at 24 hours after addition of BMP-9 to 
previously quiesced PAEC and ET-1 protein levels assayed (figure 5.7). The ERK 
pathway inhibitor UO126 (figure 5.7A) did not have any effect on BMP-9 stimulated 
ET-1 release, but did globally decrease ET-1 release. There was an apparent dose 
Figure 5.6 Effect of BMP-9 on MAPKs phosphorylation 
A 
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dependent reduction in ET-1 release by SP600125, the JNK inhibitor (figure 5.7C). 
The higher (10µM) dose however, reduced cell viability as determined by MTT assay 
(figure 5.7D). The lower doses of 3µM (and 1µM: n=1) did not abrogate the effect of 
BMP-9. Inhibition of p38 MAPK pathway by SB203580 prevented BMP-9 induced 
ET-1 release at both concentrations used (figure 5.7B).  
 
PAEC were grown to 90% confluence on 96 well plates and quiesced overnight in medium containing 
0.1% fetal calf serum (FCS). Cells were then pre-treated for 1 hour with UO126 a MEK 1/2 inhibitor 
(A: 1, 3, 10 µM), SB203580 a p38 inhibitor (B: 3,10µM), and SP600125 a JNK inhibitor (C: 
1,3,10µM). BMP-9 (1ng/ml) or vehicle control were then added to the wells and supernatants collected 
after 24 hours for determination of ET-1 levels by ELISA. After aspiration of supernatants cells were 
assayed for cell viability by MTT assay. No inhibitor except for SP600125 (D) had any detrimental 
effect upon cell viability at all doses used (n=4 for all conditions, except SP 600125: 1µM- n=1). 
*p<0.05 Kruskal Wallis with Dunns post test. 
 
 
5.3.7. Inhibition of the p38 MAPK pathway does not alter BMP-9 induced 
endothelin-1 gene expression at 2 or 24 hours.  
Having established that inhibition of p38 by SB203580 abolishes BMP-9 
induced ET-1 protein release, the effect of p38 inhibition on BMP-9 induced ET-1 
gene transcription was addressed. ET-1 can itself autoregulate ET-1 release and 
Figure 5.7 Effect of MAPK pathway inhibitors on BMP-9 induced endothelin-1 release by 
pulmonary artery endothelial cells. 
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mRNA stability. It is therefore possible that the later 24 hour increase in ET-1 gene 
transcription could be secondary to ET-1 feedback stimulating its own transcription. 
The effect of endothelin A (ETAR) and B (ETBR) receptor antagonists, BQ123 and 
BQ788 respectively, on BMP-9 induced ET-1 gene expression at 24 hours was also 
investigated. In all cases cells were pre-incubated with inhibitors for one hour prior to 
BMP-9 stimulation. 
 
PAEC were grown to confluence on 6 well plates and quiesced for 16 hours in medium M199 
containing 0.1% FCS. Medium was then refreshed with M199 containing 0.1% FCS with or without 
SB203580 (A&B: 3µM), BQ123 (B: 10nM), BQ788 (B: 10nM) or vehicle control. After one hour of 
incubation BMP-9 was added to give a final concentration of 1ng/ml. RNA was harvested at 2 hours 
(A) and 24 hours (B) and gene expression determined by quantitative RT-PCR. Gene expression was 
normalised to the average expression of 2 housekeeping genes (HKG: ACTB, GUSB) and expressed as 
relative expression to unstimulated control at 2 (A) or 24 (B) hours. Values are mean ±SEM and 
represent 3 independent experiments. *p<0.05, **p<0.01, two-way Anova. 
 
p38 inhibition did not attenuate ET-1 gene expression at 2 hours of BMP-9 
stimulation (figure 5.8A). At 24 hours of BMP-9 treatment, again there was no 
attenuation of ET-1 gene expression by SB203580, BQ123 or BQ788 (figure 5.8B). 
This suggests that inhibition of the p38 MAPK pathway does not prevent BMP-9 
induced ET-1 gene transcription. The lack of effect of the p38 and ETAR or ETBR 
antagonists on 24 hour ET-1 gene expression suggests that not only is p38 activation 
not involved in BMP-9 induced ET-1 transcription at this time point either, but also 
that the increase in gene expression seen at 24 hours is not dependent upon ET-1 
feedback or increased ET-1 mRNA stability through the action of released ET-1 via 
ETBR.  
Figure 5.8 Effect of p38 and endothelin receptor antagonist inhibition on BMP-9 stimulated 
endothelin-1 (ET-1) mRNA expression by pulmonary arterial endothelial cells (PAEC). 
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The fact that the use of SB203580 did not decrease ET-1 mRNA levels implies that 
the effect of p38 is not to increase mRNA stability or transcription suggesting that 
inhibition of p38 alters BMP-9 induced ET-1 release at a post transcriptional stage. 
 
 
5.3.8. Does BMP-9 or p38 inhibition affect endothelin B receptor (ETBR) or 
endothelial-converting-enzyme (ECE) gene expression? 
Endothelial-converting-enyme (ECE) is the enzyme responsible for the 
conversion of big endothelin (big ET-1) to ET-1. If p38 acts to stabilise or increase the 
action of ECE then inhibition with SB203580 would reduce activity or availability of 
ECE and hence levels of mature ET-1 protein, but not affect transcription.  
Endothelin B receptor (ETBR) plays an important role in ET-1 protein 
regulation, and endothelial converting enzyme converts the ET-1 precursor to the 
active peptide (section 1.8) (Kobayshi et al. 1998; Cowburn et al. 2005). Furthermore, 
p38 is involved in strain-induced alterations in ETBR gene expression in SMC 
(Cattaruzza et al. 2001). It is therefore possible that BMP-9 or p38 inhibition could be 
affecting the expression of the ETBR and affecting ET-1 clearance.  
PAEC were grown to confluence on 6 well plates and quiesced for 16 hours. Medium was refreshed 
with medium containing SB203580, the specific p38 inhibitor, or vehicle control. 1 hour later cells were 
treated with BMP-9 or vehicle control. RNA was extracted after 24 hours of BMP-9 treatment and 
ETBR (A) and ECE (B) gene expression was determined by qPCR. Expression was normalised to the 
average expression of two housekeeping genes (HKG: ACTB, GUSB) and expressed relative to 
unstimulated controls (no BMP-9 and no SB203580), n=2.  
Figure 5.9 Effect of bone morphogenetic protein-9 (BMP-9) and p38 inhibition on gene expression 
of endothelin receptor b (ETRB) and endothelial converting enzyme (ECE) by pulmonary artery 
endothelial cells (PAEC). 
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Figure 5.9 shows that neither BMP-9 nor treatment with p38 inhibition affect 
gene expression of either ETBR or ECE. 
5.3.9. A potential role for nuclear factor kappa-b (NFB) signalling pathway in 
bone morphogenetic protein-9 induced endothelin-1 release by pulmonary 
arterial endothelial cells. 
The above data do not show a role for p38 in BMP-9 induced ET-1 transcription 
by PAEC, an alternative signalling pathway was therefore sought. SC514, an I 
inhibitor, was used to investigate the role of the NFB pathway. There was a dose 
dependent reduction in ET-1 release that reached significance at the higher 10µM 
dose, implicating a role for NFB in BMP-9 stimulated ET-1 release by PAEC (figure 
5.10). 
PAEC were grown to 90% confluence on 96 well plates and quiesced overnight in medium containing 
0.1% fetal calf serum (FCS). Cells were then pre-treated for 1 hour with SC514 a NFB inhibitor (3, 10 
µM) and BMP-9 (1ng/ml) or vehicle control were then added to the wells. Supernatants were collected 
after 24 hours for determination of ET-1 levels by ELISA. After aspiration of supernatants cells were 
assayed for cell viability by MTT assay. There was no effect upon cell viability at all doses used. n=6; 
*p<0.05, **p<0.01, ***p<0.001; Repeated-measures one way ANOVA. 
 
 
5.4. Discussion  
5.4.1. Summary of important findings in this chapter 
Physiological concentrations of BMP-9 increased ET-1 and inhibited MCP-1 
release by PAEC in a dose-dependent manner. Furthermore, BMP-9 stimulated PAEC 
increased gene expression of ET-1 at 2 and 24 hours of treatment. Smad-4 knockdown 
did not have any effect on ET-1 protein release, suggesting these effects of BMP-9 are 
Figure 5.10 Effect of SC514, a NFB pathway inhibitor, on BMP-9 induced endothelin-1 release by 
pulmonary artery endothelial cells. 
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not mediated through Smad signalling pathways. Preliminary data also revealed that 
Smad-2 knockdown did not diminish BMP-9 induced ET-1 release. Pharmacological 
inhibition of IKK2 signalling suggested a role for the NFκB signalling pathway in 
BMP-9 stimulated ET-1 release (figure 5.10). 
Interrogation of the MAPK pathway components revealed an increase in p38 
phosphorylation at one hour after treatment. Treatment of PAEC with a specific p38 
inhibitor (SB203580, 3µM) attenuated BMP-9 induced mature protein ET-1 release, 
but did not act at the level of transcription or mRNA stability.  
Neither BMP-9 nor p38 inhibition altered gene expression of ECE or ETBR. Further 
work should determine whether the p38 dependent effects of BMP-9 are regulating 
ECE or ETBR function (figure 5.11).  
 
Binding of BMP-9 stimulates phosphorylation of p38 and ET-1 gene transcription via different 
pathways. The data suggest a role for NFB signalling in BMP-9 stimulated ET-1 release and a post-
transcriptional effect of p38 signalling. 
 
 
 
 
Figure 5.11 Postulated pathways involved in bone morphogenetic protein-9 induced 
endothelin-1 expression in pulmonary arterial endothelial cells 
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5.4.2. Bone morphogenetic protein-9 increases protein and gene expression of 
endothelin-1, but inhibits monocyte chemoattractant-1 expression by pulmonary 
arterial endothelial cells. 
To our knowledge this is amongst the first work to date to show that BMP-9 can affect 
ET-1 and MCP-1 release by EC. The increase in ET-1 in response to BMP-9 is not 
unsurprising given that BMP-9 has been shown to phosphorylate Smad-2 via activin 
receptor type II (Actr-II) another of the TGF- superfamily receptors, and this is the 
main pathway through which TGF- stimulates ET-1 release in EC (Upton et al. 
2009). Consequently it was initially hypothesised that BMP-9 was likely to be up-
regulating ET-1 via this pathway. Indeed work has recently been published revealing 
increased ET-1 release by HLMVEC treated with BMP-9 (Star et al. 2010).  
Importantly, concentrations of BMP-9 required to increase ET-1 release by PAEC 
were in keeping with proposed circulating concentrations, compared to those of BMP-
6 which were likely to be in excess of physiological levels (David et al. 2008). The 
small but significant decrease in ET-1 by BMP-4 has been described by others in 
PASMC. In these cells BMP-7 also inhibited ET-1 release, an effect we have not 
looked at in the PAEC (Din et al. 2009).  
The suppression of MCP-1 release by BMP-9 is a unique finding. This work has 
been taken forward by our collaborators (Upton et al, Cambridge) who have shown 
that this response is Smad-4 but not Smad-2 sensitive, hence likely to be dependent on 
Smad 1/5. This effect is only abolished by loss of the activin like kinase-1 (Alk-1) 
receptor (a type 1 TGF superfamily receptor), but not the BMPR2 (data not shown). 
Mutations in Alk-1 are inherited in hereditary haemorrhagic telangectasia (HHT) type 
2. HHT is characterised by a progressive loss of capillaries and the emergence of 
directly-linked dilated arterioles and venules, termed arteriovenous malformations 
(AVMs). Compared to type-1 HHT, AVMs are less common in type-2 HHT, but Alk-
1 mutations are associated with severe PAH in some HHT2 families (Trembath 2001; 
Abdalla et al. 2004; Cottin et al. 2004). This would suggest that loss of BMP-9 
induced inhibition of MCP-1 may be of more importance in HHT2 than in PAH. We 
do not know however, if there are any acquired changes in Alk-1 receptor levels in 
CHF, or if other BMP-9 signalling mechanisms could suppress the presumed Smad 
1/5 dependent MCP-1 inhibition if other receptor levels were altered in CHF. Again 
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these data support a pleotrophic role for BMP-9 and that it is potentially the relative 
balance of its signalling pathways that are important in health and disease. 
Together this and work by others show BMP-9 to effect release by PAEC of a variety 
of vasoactive and inflammatory mediators via different receptors and different 
signalling pathways.  
 
5.4.3. Bone morphogenetic protein-9 stimulates pulmonary artery endothelial 
cells to produce endothelin-1 in a Smad independent and p38 dependent manner 
The action of BMP-9 via a Smad-independent pathway is not unprecedented. 
Other BMPs also signal via all three MAPKs, independently of Smads (Iwasaki et al. 
1999; Nakamura et al. 1999; Yang et al. 2007; Guo and Wang 2009). Furthermore 
MAPKs have a role in ET-1 expression, ET-1 mRNA stability and ETBR expression, 
the latter role potentially being important in ET-1 clearance (Cheng et al. 2003; 
Nilsson et al. 2008). Long-term TGF- treatment may also desensitise ET-1–MAPK 
interactions (Tong and Hamel 2007). Here BMP-9 stimulated an increase in 
phopshorylated p38 at 60 minutes of stimulation. Of the MAPK inhibitors used, only 
the p38 inhibitor SB 203580 attenuated BMP-9 induced ET-1 release. The JNK 
inhibitor at lower doses did not significantly decrease ET-1 release and higher doses 
(10µM) it was toxic to the cells, resulting in a decrease in ET-1 release that was was 
probably not related to JNK pathway inhibition. A role for the JNK signalling pathway 
in BMP-9 induced ET-1 release by PAEC cannot be absolutely excluded. Further 
work would be required using a second, ideally water soluble, JNK inhibitor that 
might be less toxic at the higher doses.  
Attenuation of BMP-9 induced ET-1 production by PAEC is incongruous with 
recently published data (Star et al. 2010). ERK1/2 and p38 MAPKs were 
phosphorylated after BMP-9 stimulation by HLMVEC, but inhibition of either of the 2 
pathways did not prevent ET-1 release.  
The role of p38 in BMP signalling is not a unique finding. BMP-4 induced up-
regulation of HO-1 is p38 dependent and BMP-2 is able to signal through a p38, 
Smad-independent, pathway that involved different oligomerization of the BMPR1 
and 2 on the cell surface when compared to Smad signalling (Iwasaki et al. 1999; 
Nohe et al. 2002; Yang et al. 2007). BMPs 6 & 7 can also signal through p38 MAPK 
(Takahashi et al. 2008). Over-expression of Smad 6 or Smad 7 inhibited BMP induced 
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p38 phosphorylation, and receptor-Smads (r-Smads) have MAPK consensus sites 
resulting in differential phosphorylation of r-Smads by MAPKs, supporting evidence 
of cross talk between the MAPK and Smad pathways (Kimura et al. 2000). The data 
here represent a further potential BMP-MAPK cross talk involving post-translational 
regulation of BMP-9 induced ET-1.  
Our data contradict recently published work showing that ERK1/2 and p38 
MAPKs were phosphorylated after BMP-9 stimulation of HLMVEC, but did not 
mediate ET-1 release (Star et al. 2010). Phosphorylation of Smad 1/5 was seen, but it 
was not confirmed that the ET-1 release was Smad pathway dependent. HLMVEC 
incubated with the p38 inhibitor SB202190 (10µM) decreased both basal and BMP-9 
stimulated ET-1 release, but did not prevent an increase in ET-1 by BMP-9. It is 
unclear why there should be a difference between the two cell types, except that EC 
from different vascular beds might be behaving differently. For example, PAEC and 
HLMVEC respond differently to cyclic mechanical strain (CMS) and PAEC activate 
NFB to a lesser extent than CAEC (Adkison et al. 2006; Csiszar et al. 2008). Other 
differences include the inhibitor used (SB203580 (3µM) vs SB202190 (10µM)) and 
different well sizes for protein and MAPK inhibitor responses (96 well vs 24 well).  
It will therefore be important to replicate these data with a second inhibitor and 
complimentary molecular techniques such as siRNA and dominant negative p38 
pathway transfection. This is particularly important because inhibitors of p38, 
including SB203580, are also able to inhibit TGF- signalling (Inman et al. 2002; 
Laping et al. 2002; Fu et al. 2003). It is unlikely here however that BMP-9 is 
stimulating TGF- release which is subsequently increasing ET-1 levels because 
BMP-9 induced ET-1 release is independent of Smad4 and TGF- induced ET-1 is 
classically acts through the Smad signalling pathway  
 
5.4.4. The role of p38 inhibition in bone morphogenetic protein-9 induced 
endothelin-1 release 
BMP-9 induced ET-1 gene expression at 2 and 24 hours was not attenuated by 
SB203580. This suggests that BMP-9 is neither increasing ET-1 transcription via a 
p38 dependent pathway, nor is p38 activation increasing ET-1 mRNA stability. 
Consequently p38 inhibition interrupts ET-1 release at a point later in the ET-1 
synthesis pathway i.e. post transcription. It was therefore possible that p38 increased 
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ECE expression or activity. Alternatively, ETBR is the main EC receptor present on 
EC and has a role in ET-1 clearance and ET-1 mRNA stability, the latter involving the 
p38 pathway (Dupuis et al. 1996; Cowburn et al. 2005; Goddard et al. 2007; Farhat et 
al. 2008; Nilsson et al. 2008). It is plausible that p38 could reduce ETBR driven ET-1 
clearance. Hence inhibition of p38 would remove this inhibition on ET-1 clearance 
and reduce levels of released mature protein. Neither gene expression of ETBR nor 
ECE were affected by SB203580. Despite not affecting transcription of ECE or ETBR 
these data do not exclude a role for p38 affecting ECE or ETBR availability or function 
and is an area that requires further investigation. 
 
5.4.5. A potential role for NFB signalling pathway in bone morphogenetic 
protein induced endothelin-1 release 
SC-514, an IKK inhibitor, attenuated BMP-9 induced ET-1 release by PAEC 
(figure 5.10), supporting a role for this signalling pathway. NFB is a known 
alternative BMP-Smad-independent signalling pathway. EC activated NFB signalling 
when stimulated with BMP-4, and BMPR1a recruited both the NFB and MAPK 
signalling pathways (Csiszar et al. 2008; Matluk et al. 2010). Furthermore, TNF- 
treated PASMC increased ET-1 expression in an NFB dependent manner (Wort et al. 
2009). It is therefore possible that NFB is activated by BMP-9 through BMPRs to 
increase ET-1 gene transcription, but further work will be required to investigate this 
(section 5.5.1). 
 
5.5. Future Work 
 
5.5.1. Mechanism underlying bone morphogenetic protein-9 induced endothelin-
1 expression in pulmonary artery endothelial cells 
Further work should address the effect of SC514 on ET-1 transcription by PAEC 
in response to BMP-9. If this reveals a decrease in ET-1 gene expression then it would 
suggest that the NFB pathway is the Smad alternative pathway through which BMP-9 
is signalling. Further to this, an ET-1 reporter construct would be used to confirm 
increased transcription and, using truncated promoter regions, determine the important 
transcription factor binding region. 
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5.5.2. Role of p38 inhibition in attenuation of bone morpohogenetic protein-9 
stimulated endothelin-1 release by pulmonary artery endothelial cells 
This work did not identify the point at which SB203580 inhibits BMP-9 
stimulated increase in ET-1. Further work is required to investigate this. In addition to 
the work outline above, using the reporter construct in the presence of SB203580 
should confirm that it is not preventing gene transcription. Other lines of investigation 
can address the protein levels and availability of ETBR and ECE (western blotting and 
immunoprecipitation). 
 
5.6. Summary 
In summary, BMP-9 increased levels of ET-1 released by PAEC and decreased 
expression of MCP-1. BMP-9 induced ET-1 release was Smad independent and was 
attenuated by SB203580, a p38 pathway inhibitor. Further work is required to 
determine the important receptors through which BMP-9 is signalling and the pathway 
involved between the membrane and the nucleus, preliminary work suggested a role 
for the NFB signalling pathway. The exact mechanism by which p38 inhibition 
attenuated ET-1 release also needs to be determined. 
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6. Chapter 6: Investigating inflammation and remodelling 
of the lung using a rat myocardial infarction model 
 
6.1. Introduction 
In vitro, human pulmonary microvascular endothelial cells (HLMVEC) 
released MCP-1 in response to mechanical strain. Supernatants from strained cells 
increased fibroblast and smooth muscle cell proliferation and fibroblast 
differentiation. Monocyte migration was also enhanced by “strain supernatants” 
(chapter 4.3.4). It is important to confirm these in vitro findings in vivo in an animal 
model of chronic heart failure (CHF). To that end, a collaboration was established 
with a local group (AL) investigating the effects of sarco/endoplasmic reticulum 
calcium (SERCA)2a gene therapy in a rodent myocardial infarct-induced model of 
heart failure. Experimental animals were sacrificed 16 weeks after myocardial 
infarction (MI) or a sham procedure and the lungs were harvested immediately. 
Using this model, it was hypothesised that the lungs of animals post MI would show 
evidence of structural remodelling and be a source of fibrogenic and inflammatory 
mediators, including MCP-1. Furthermore, the effect of gene therapy on pulmonary 
changes after MI were determined. 
Animal models with left ventricular failure demonstrate thickening of the 
alveolar capillary membrane, increased collagen and reticulin content and pulmonary 
vascular remodelling (Ben Driss et al. 2000; Kingsbury et al. 2003; Lefebvre et al. 
2006). Lungs from CHF animals are stiffer, heavier and have altered mechanics 
associated with changes in surfactant levels. Bronchoalveolar lavage (BAL) contains 
increased numbers of white blood cells (WBC) (Dixon et al. 2009). Multiple 
inflammatory and neuroendocrine mediators were also increased, including IL-6, 
MCP-1 ICAM-1 and angiotensin-2 (Ang II) amongst others (chapter 1.5). 
Furthermore, rodents post left coronary artery (LCA) ligation had increased pre-
proET-1 mRNA levels with reduced ET-1 clearance across the lungs and a decrease 
in endothelin B receptor (ETBR) expression (Tonnessen et al. 1998; Lepailleur-Enouf 
et al. 2001) (Kobayshi et al . 1998). The models, animals and time scales employed 
to investigate experimentally induced heart failure vary (table A.2; Appendix A). 
With the transition from acute to chronic heart failure, dynamic changes are seen in 
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the levels of mediators involved in vascular tone and remodelling, for example ET-1 
and nitric oxide synthase levels were raised immediately after MI, subsequently 
diminished and then rose again (Tan et al. 2006). Lung structural remodelling, 
increased inflammatory gene expression and variations in expression of components 
of the endothelin system were identified at between 3 and 12 weeks post MI (table 
A.2, Appendix A) (Ben Driss et al. 2000; Kingsbury et al. 2003; Dixon et al. 2009). 
Here animals were sacrificed at 16 weeks post LCA ligation and as such it was 
important to determine whether differences identified by others at earlier time scales 
were also seen at 16 weeks. Histology, lung weights and collagen content provide 
information on aspects of ACM thickening and remodelling, whilst MCP-1 gene 
expression and protein levels in BAL and serum will be measured to assess if the 
lung is a potential source of this inflammatory mediator in CHF. WBC levels in BAL 
are raised at 6 weeks after MI, suggesting increased pulmonary inflammation. 
Analysis of this at 16 weeks will indicate if inflammation persists at this later time 
point. Given the experimental and clinical variations seen in ET-1 expression, and its 
proposed role in the pathophysiology of CHF, it will be pertinent to also determine 
expression of ET-1 and its receptors at 16 weeks post LCA ligation.  
Mechanical strain induced MCP-1 release by EC via ERK 1/2 (chapter 4). 
The evidence for a role of mitogen activated protein kinases (MAPK) in strain 
induced inflammatory mediator release has already been discussed. MAPK are 
postulated to be important in CHF: inhibition of p38 MAPK after MI has beneficial 
effects on left ventricular (LV) remodelling and dysfunction in rodents (See et al. 
2004). ERK 1/2 potentially has a protective role in murine cardiac reperfusion injury 
models, but also induces cardiac hypertrophy (Bueno et al. 2000; Lips et al. 2004). 
Modulation of these pathways might therefore have therapeutic potential and so it 
will be important to understand the role of these pathways in the pulmonary 
pathophysiology of CHF. It is not known whether these pathways are activated it the 
lungs of animals or patients with heart failure and so this will be addressed in this 
model.  
The SERCA2a gene provides a potential target for gene therapy. 
Improvements in haemodynamics have been observed, but affects on the pulmonary 
system have not been investigated. SERCA2a is expressed in the lungs and 
deficiencies have been associated with moderate to severe asthma, and a secretory 
and proliferative SMC phenotype (Lipskaia et al. 2005). SMC proliferation is 
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important in adventitial thickening that is a hallmark of PAH and hence may also be 
important in vascular and parenchymal remodelling in CHF. Hence, the potential 
also exists for a systemically delivered SERCA2a gene therapy to have functional 
consequences in the lungs. It is therefore important to investigate the effect of the 
gene therapy on measures of remodelling and expression of inflammatory and 
fibroproliferative mediators. 
Chronic remodelling of the lung parenchyma and pulmonary circulation in 
CHF protects against hydrostatic pulmonary oedema, but probably contributes to 
shortness of breath. With improvements in therapy and even recovery in left 
ventricular function over time, strategies to prevent or even reverse these pulmonary 
processes would be attractive. It will therefore be important to characterise fully the 
lung response to CHF and to any proposed therapies.  
 
The specific aims of this chapter were: 
1. To characterise lung wet and dry weights and lung histology in this model of 
CHF. 
2. To determine the gene expression of ET-1 and MCP-1 in whole lung from 
CHF animals. 
3. To investigate differences in the level MCP-1 in serum and BAL from 
animals with CHF compared to sham controls. 
4. To investigate the activation of the ERK pathway in whole lungs in this 
model of CHF. 
5. To investigate the effect of CHF on lung dynamics. 
6. To investigate the effect of SERCA2a gene therapy on lung dynamics and 
gene expression in whole lungs from CHF and sham control animals. 
 
6.2. Specific methods 
Preparation of the Sprague-Dawley (SD) LCA ligation model was undertaken 
by our collaborators as previously described and summarised in chapter 2.61 (Lyon 
et al. 2009). Two groups of animals were studied, an initial cohort comparing the 
effect of LCA ligation with sham operated, age matched controls (AMC) and a 
second group of animals, which included an additional cohort of animals injected 
with an adenoviral vector (AAV9) containing the SERCA2a gene. In the latter 
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cohort, animals were injected with the gene at 16 weeks and all animals were 
subsequently sacrificed 4-6 weeks later (figure 6.1). 
After analysing the data from the first two groups it became apparent that 
with the initial protocol dry weight could not be accurately compared between 
animals and groups and to achieve this a consistent amount of lung needed to be 
harvested for wet:dry measurments. Therefore for subsequent available animals the 
left lung was collected for dry weight: body weight (DW:BW) analysis and not used 
for lung dynamics. 
Left coronary artery ligation was performed in male Sprague-Dawley rats via thoracotomy. 16 weeks 
post procedure animals are treated with AAV9.SERCA2a gene therapy via tail vein injection. Animals 
are weighed at 4 -6 weeks post gene injection, sacrificed and samples collected. 
 
6.3. Results 
6.3.1. Haemodynamic measurements and organ weights were used to 
characterise the effectiveness of the model of myocardial infarction (MI) and 
chronic heart failure (CHF). 
An initial cohort of animals were used to characterise the 16 week LCA 
ligation model. At 16 weeks post MI animals were anaesthetised, ventilated and the 
left ventricular end diastolic pressure was recorded using a Millar catheter. Animal 
total body weights were determined at the time of induction of anaesthesia and heart 
weights and total lung weights recorded immediately after euthanasia. Segments of 
the right lung were homogenised for wet and dry weight measurements and a ratio of 
the two is presented (figure 6.3). 
 
Figure 6.1 Protocol for induction of myocardial infarction and SERCA2a gene therapy in adult 
male Sprague-Dawley rats. 
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Male SD rats with left coronary artery ligation (MI) or non-ligated age matched controls (AMC) were 
anaesthetised. Left ventricular end diastolic pressures (A; LVEDP; n=7) were recorded using a 
pressure-volume Millar catheter via direct cardiac puncture after thoracotomy. Total body weights 
were recorded prior to the procedure (E) and heart weights (HW) and lung weights (LW) post 
procedure. HW:BW (B; n=20) and LW:BW(C; n=10) ratios were calculated using: (HW or 
LW/BW)*1000. Wet:dry lung weight (D; n=9 in AMC group and 18 in MI group) was determined by 
weighing a homogenised segment of right lung (wet weight), re-weighing after 24 hours of freeze-
drying (dry weight) and dividing the wet weight by the dry weight . * p<0.05, ***p<0.001 Mann-
Whitney U. 
 
The data show that in  animals subjected to MI there was an increase in left 
ventricular end diastolic pressure and an increased HW:BW ratio suggesting that the 
model is an effective representation of chronic raised left atrial pressure with 
compensatory cardiac hypertrophy (figure 6.2 A,B). A difference was seen in the 
Figure 6.2Heart weight (HW) and lung weight (LW): body weight (BW) ratios, haemodynamic 
parameters and wet:dry lung weights for male Sprague-Dawley rats 16 weeks after left 
coronary artery ligation (MI) or sham operation (AMC). 
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lung weight to body weight ratio (LW:BW), but no difference was seen in the 
wet:dry weight ratio (figure 6.2 C,D). These data suggest that the lungs of CHF rats 
are heavier, but the lack of increase in wet:dry weight implies that the increase in 
weight is due to increased lung tissue rather than pulmonary oedema. 
It is possible that the increase in LW:BW represents a disproportionate loss of 
body weight (cardiac cachexia) by CHF rats rather than an increase in lung weight. 
Total body weights of CHF animals however, were greater than those of AMC 
animals (figure 6.2E) 
 
6.3.2. The effect of chronic heart failure on lung dry weight 
The data confirm an increase in lung weight but not wet:dry lung weight. These 
data do not, however, provide an accurate comparative measure of dry weight 
because the initial protocol used did not standardise the amount of lung at the outset 
of the wet:dry comparison. Dry weight is increased at 6 weeks post MI without 
microscopic changes in the lung parenchyma (Dixon et al. 2009). Hence this 
protocol was adapted to address the dry weights between lungs, with the left lung in 
its entirety used for wet: dry weight measurement (figure 6.3). 
Male SD rats were subjected to left coronary artery ligation or sham operation. At 16 weeks post 
procedure the lungs were harvested and the left lung isolated. After homogenisation the wet weight of 
the lung was recorded and a dry weight was recorded after 24 hours of freeze drying. The dry weight 
was recorded relative to the body weight of the animal. n=4.Mann-Whitney U test. 
These data show a non-significant increase in dry weight: body weight ratio, 
suggesting a trend towards increased tissue, and hence remodelling, in post MI lungs 
Figure 6.3 Dry lung weight to body weight ratio in animals after myocardial infarction 
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6.3.3. Prepro-endothelin-1 (ppET-1) and endothelin A and B receptor gene 
expression are altered in the rodent model of chronic heart failure. 
Despite a variable release of endothelin-1 (ET-1) in response to mechanical 
strain by HLMVEC, whole lung gene expression of ppET-1, the endothelin A and B 
receptors (ETAR and ETBR) and endothelial converting enzyme (ECE) post-MI were 
determined. This was undertaken for two reasons: firstly, others have shown the ET-
1 axis to be altered in an animal model of CHF, but at a shorter interval after LCA 
(Tonnessen et al. 1998; Lepailleur-Enouf et al. 2001; Tan et al. 2006). These 
experiments provided new information on ET-1 expression at this time interval. 
Secondly, ETAR, ETBR and ECE gene expression have been less well studied, but 
are important in the synthesis and regulation of ET-1 activity (chapter 1.8).  
Male SD rats were sacrificed at 16 weeks post left coronary artery ligation (MI) or sham operation 
(AMC).  Segments of lung were immediately frozen in liquid nitrogen and stored at -80oC. RNA was 
extracted using a modified TriZol and RNeasy method. Gene expression was determined using qRT-
PCR, normalised to the average expression of 2 housekeeping genes (HKG: ARBP and HRPT) and 
expressed relative to a randomly selected AMC animal. Values are shown relative to expression in 
aged matched control (AMC).n=5 *p<0.05, **p<0.01 relative to appropriate AMC, Mann Whitney U 
test. 
 
At 16 weeks post LCA ligation ET-1 gene expression is increased compared to 
AMC animals. This is similar to data from earlier time intervals post LCA ligation 
(Tonnessen et al. 1998; Lepailleur-Enouf et al. 2001; Tan et al. 2006). ECE 
expression was not affected by LCA ligation, but the expression of ETAR increased 
and ETBR decreased (figure 6.4). These data suggest that not only is ET-1 expression 
Figure 6.4 Effect of left coronary artery ligation on the expression of Endothelin (ET-1), 
Endothelin A and B receptors (ETAR and ETBR) and endothelin converting enzyme (ECE) 
mRNA 
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altered, but in addition the action and clearance of ET-1 will also be altered due to 
changes in the expression of its receptors (figure 6.5). 
 
Increased endothelin-1 (ET-1), decreased endothelin-B receptor (ETB) and increased endothelin-A 
receptor ETA gene expression result in an increase in ET-1 levels (increased transcription and 
decreased clearance via ETB),  increased ETA mediated effects on VSMC (red plus), and a reduction in 
ETB mediated effects on EC (green minus). 
 
6.3.4. Gene expression of monocyte chemoattractant protein-1 and interleukin-
6 are increased in whole lungs of rodents with left coronary artery ligation 
Further to determining the expression profile of the endothelin system, MCP-
1 gene expression was investigated in this model of heart failure. IL-6 expression 
was also analysed because CMS induced an increase in IL-6 by HLMVEC and IL-6 
was increased in the lung of post MI animals (Gaertner et al. 2003). The data show 
an increase in MCP-1 and IL-6 gene expression in rodents with chronic heart failure 
(figure 6.6).  
 
 
 
 
Figure 6.5 The outcomes of endothelin-1 binding to its different receptors on endothelial cells 
(EC) and vascular smooth muscle cells (VSMC), and the effect on these pathways of altered 
receptor expression post left coronary artery ligation. Adapted from Rich (Rich and 
M L ughli  2003) 
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Male SD rats were sacrificed at 16 weeks post left coronary artery ligation (MI) or sham operation 
(AMC). Segments of lung were immediately frozen in liquid nitrogen and stored at -80oC. RNA was 
extracted using a modified TriZol and RNeasy method. MCP-1 and IL-6 gene expression were 
quantified using quantitative RT-PCR, normalised to the average expression of 2 housekeeping genes 
(HKG: ARBP and HRPT) and are expressed relative to expression in aged matched control (AMC). 
Values are expressed as mean ± SEM. *p<0.05, **p<0.01; one-way ANOVA with Bonferroni’s post 
test. n=5. 
 
 
6.3.5. Monocyte chemoattractant protein (MCP)-1 bronchoalveolar lavage 
(BAL) and serum levels are elevated post myocardial infarction, but only BAL 
levels correlated with heart weight: body weight ratio. 
Both serum and BAL MCP-1 levels were increased in rodents post MI 
compared to AMC (figure 6.7 A and B respectively). BAL increases were significant 
when animals with small MIs (HW:BW ratio <4, HW < 2g and based on visible 
infarct size- as determined by AL) were excluded. BAL but not serum MCP-1 levels 
correlated with HW:BW ratio, an established surrogate for the degree of cardiac 
compensation and hence the extent of MI (figure 6.8). 
 
 
Figure 6.6 Effect of left coronary artery ligation on expression of monocyte chemoattractant 
protein (MCP)-1 and Interleukin (IL)-6 gene expression 
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Figure 6.7 Effect of left coronary artery ligation on protein levels of MCP-1 in serum and 
broncheoalveolar lavage. 
Male SD rats were sacrificed at 16 weeks after left coronary artery ligation (MI) or sham operation 
(AMC).Whole blood was collected on ice in a citrated EDTA tube at the time of euthanasia, 
centrifuged at 660 RCF at 4oC for 10 minutes and serum aliquoted and stored at -80oC for later 
analysis. MCP-1 levels were analysed by ELISA (A). At the time of euthanasia the left lung was 
isolated and stored in ice cold 0.9% normal saline. The lung was then cannulated immediately and 7ml 
of normal saline instilled with the broncheoalveolar lavage (BAL) return collected. Following 
centrifugation at 3500rpm at 4oC for 5 minutes aliquots were stored at -80oC and analysed at a later 
date by ELISA. Data represent AMC, LCA ligation (MI) and LCA ligation with evidence of a large 
MI(B). *p<0.05, # p=0.07 compared to AMC two-tailed t-test. Numbers of animals in each group are 
shown within the appropriate bar. 
Paired serum (A) and BAL (B) MCP-1 levels were plotted against HW:BW ratio for animals that had 
undergone left coronary artery ligation. Spearman’s correlation coefficient was calculated. 
 
 
6.3.6. ERK 1/2 phosphorylation in whole lungs of animals with heart failure  
To determine whether the ERK 1/2 pathway, important in mechanical strain-
induced MCP-1 release by EC (chapter 4.4.3), is upregulated in the lungs of rats post 
MI, ERK 1/2 phosphorylation was determined in whole lungs by western blotting 
(figure 6.9). The data show a non-significant trend to increased expression of p42 
ERK and a significant increase in activation of p44 ERK in lungs of animals post MI.  
 
 
Figure 6.8 Correlation of serum and bronchoalveolar lavage MCP-1 levels with heart 
weight:body weight ratio(HW:BW) from animals with left coronary artery ligation. 
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Male SD rats were sacrificed at 16 weeks post left coronary artery ligation (MI) or sham operation 
(AMC). Lungs were immediately frozen in liquid nitrogen and stored at -80oC. Protein was extracted 
from 0.05-0.1mg of whole lung and expression of phosphorylated (pERK) and total ERK (tERK) 1/2 
assessed in 20µg of protein by western blotting (A). The developed blots were analysed using Image J 
software to quantitate the density of the bands and the relative values of phosphorylated MAPK to 
total MAPK shown (B:p42 ERK, C:p44 ERK). n=4 for each group. *p<0.05, Mann-Whitney U 
 
 
6.3.7. Are lung dynamics affected by CHF? 
To assess the effect of CHF on lung dynamics, pulmonary pressures for given 
volumes of instilled saline were recorded as previously described (chapter 2.6.2.5). 
Two sets of data were recorded: an “opening volume” - the volume that was required 
to first achieve a recordable return on the manometer, and the subsequent pressures 
obtained for each 0.5ml of saline instilled. The opening volume was higher in the 
CHF group compared to the AMC animals (median 3.5 (2.5-4.5) vs 2.5 (2.0-2.5), 
figure 6.10A). Curves showing the pressure of saline returned for a given volume 
instilled into the lungs was shifted down and to the right for lungs in the CHF group 
(figure 6.10B). 
 
Figure 6.9 Effect of left coronary artery ligation on phosphorylation of ERK 1/2 MAPK in 
whole rat lung 
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Intact left lungs were harvested from male SD rats at 16 weeks post MI and AMC. Lungs were briefly 
stored on ice cold saline in a sterilin and the left main bronchus intubated with a 16G catheter. A 
manometer was attached via a 3-way tap and increments of 0.5ml of normal saline injected into the 
lung. After each aliquot of saline the 3-way tap was re-directed and the pressure from the lung 
measured. The volume instilled at which an initial reading on the manometer was obtained was 
recorded (opening volume: A). The manometer reading for each subsequent 0.5ml of volume instilled 
was then recorded (B). Aliquots were added to a total of 7ml and the return BAL collected. *p<0.05, 
Mann-Whitney U, n = 7.  
 
6.3.8. The effect of sarco/endoplasmic reticulum calcium (SERCA2a) gene 
therapy on heart and lung weights 
 
Figure 6.11 The effect of SERCA2a gene therapy on heart and lung weights 
AMC SD rats, or rats with LCA ligation with or without SERCA2a gene therapy at 16 weeks were 
sacrificed at 20-22 weeks post LCA ligation. (A) Heart weights were recorded and expressed as heart 
weight:body weight ratio (HW:BW= (HW/BW)*1000). (B) Total lung weights were recorded at the 
time of euthanasia and expressed as lung weights: body weight ratio (LW:BW= (LW/BW)*1000). (C) 
Left lungs were homogenised and weighed. A dry weight was then recorded after 24 hours of freeze 
drying and expressed as wet weight: dry weight ratio (=wet/dry weight). Total body weights (BW) 
were measured prior to sacrifice (E) n=8 except for AMC and MI groups in wet:dry weight groups 
where n=5. Asterisk above plot signifies difference compared to AMC. *p<0.05; Kruskal-Wallis with 
Dunn’s Multiple comparison post test. 
Figure 6.10 Effect of left coronary artery ligation (MI) on a measure of lung dynamics 
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Animals subjected to MI had increased HW:BW and LW:BW ratios. Animals 
treated with gene therapy (MI+SERCA) also had increased HW:BW ratio compared 
to AMC, but there was no increase in LW:BW. No differences were seen in Dry:Wet 
weight ratios or total body weights (figure 6.11). 
 
6.3.9. The effect of SERCA2a gene therapy on gene expression in the 
endothelin system, monocyte chemoattractant protein (MCP)-1 and interleukin 
(IL)-6 
Adenovirus-mediated gene transfer of SERCA2a improved cardiac 
haemodynamics and increased survival in a rat model of heart failure (del Monte et 
al. 2001). We therefore were interested to determine whether there was any 
difference in the lungs of animals after MI compared to AMC rats. The expression of 
genes of the endothelin system, IL-6 and MCP-1 varied in a similar manner to that 
already seen between AMC and MI animals (figure 6.12). In animals that received 
SERCA2a gene therapy these changes were reversed towards AMC levels for all 
genes examined. 
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mRNA was extracted from 0.05-0.1mg of snap frozen whole lung from male SD rats at 20-22 weeks 
post LCA ligation with or without SERCA2a gene therapy or from AMC litter mates. Endothelin-1 
(ET-1, A), endothelin A receptor (ETAR, B), endothelin B receptor (ETBR, C), endothelin converting 
enzyme (ECE, D) and MCP-1 (E) mRNA expression were analysed by quantitative RT-PCR. 
Expression is normalised against the average of two housekeeping (HKG: ARBP and HRPT) genes 
and is shown relative to a standard composed of cDNA from all animals. n=5 in each group. *p<0.05, 
**p<0.01, Kruskal-Wallis with Dunn’s multiple comparison post test. 
 
 
6.3.10. The expression of human SERCA2a mRNA in gene therapy animals 
 
To determine whether the human SERCA2a gene, delivered by the adenoviral 
vector via the tail vein, was taken up in the lungs of the rats, human SERCA2a gene 
expression was analysed in whole lung RNA samples from AMC animals, CHF 
animals and CHF animals with SERCA2a gene injection by qPCR. Figure 6.13 
Figure 6.12 Effect of left coronary artery ligation with or without SERCA2a gene 
therapy on endothelin-1, endothelin A and B receptors, endothelin converting enzyme 
and MCP-1 mRNA expression in the rat. 
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shows the graphical representation of the PCR plot for the human SERCA2a gene 
(green), the rat SERCA2b gene (blue) and the housekeeping gene ARBP (red).  
 
 
Figure 6.13 Graphical representation of qPCR results for SD rat whole lung gene expression of 
human  SERCA2a (green), rat SERCA2b (blue) and rat ARBP housekeeping (red) genes. 
Whole lung RNA was extracted from AMC animals, animals at 16 weeks post LCA ligation and 
animals at 16 weeks post LCA ligation with human SERCA2a gene delivery via adenoviral vector at 
12 weeks post LCA ligation. 0.05-0.1mg of lung was homogenised and RNA extracted and reverse 
transcribed to cDNA. Gene expression was determined by qPCR, as shown above. 
 
The graph shows that expression of ARBP (HKG) and rat SERCA2b 
(expressed in airways smooth muscle in the lung) are expressed early (i.e. in higher 
quantities) with cycle threshold (CT) values of 15-20 and 20-25 respectively. 
SERCA2a appears to be expressed much later however, suggesting very low 
expression. On further analysis of the PCR curves using the Rotor Gene 6000™ 
software (Corbett, UK) the efficiency of the primer was very poor. The curves are 
also present for all samples, not only the SERCA2a treated animals. It is therefore 
possible that, in keeping with the poor efficiency and high CT values, that the primer 
is binding to another non-specific area in the rat genome. If binding is to human 
SERCA2a then the amounts present are very small and it is not clear why the gene 
should be detected in animals not given the gene therapy. 
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6.3.11. The effects of SERCA2a gene therapy on serum and bronchoalveolar 
lavage MCP-1 protein expression 
 
 
Figure 6.14 The effects of SERCA2a gene therapy on (A) serum and (B) bronchoalveolar lavage 
(BAL) levels of monocyte chemoattractant protein (MCP)-1 in rats post left coronary artery 
(LCA) ligation or age matched controls (AMC) 
AMC rats or rats at 20-22 weeks post LCA ligation with or without SERCA2a gene therapy at 16 
weeks were sacrificed. (A) Serum samples were collected at the time of sacrifice from the IVC, 
centrifuged at 660 rpm for 5 minutes at 100C and stored at -800C until immediately prior to analysis of 
MCP-1 protein by ELISA. (B) The left lung was cannulated and 7ml of ice cold normal saline instilled 
in 0.5ml aliquots. The BAL return was collected and centrifuges to remove blood cells. The BAL was 
stored at -800C until immediately prior to MCP-1 protein analysis (ELISA). Values are shown as 
median and interquartile ranges. n=5 in all groups. Kruskal Wallis with Dunns post test. 
 
In this small group of animals neither LCA ligation nor SERCA2a gene 
therapy had a significant effect on MCP-1 serum or BAL levels (figure 6.14). The 
trends of the graph may be towards an increase in MCP-1 as seen previously in the 
CHF group, with a return towards normal in the gene therapy group, but the numbers 
of samples need to be increased to determine if this is a true finding. 
 
6.3.12. The effect of SERCA2a gene therapy on lung dynamics 
The effect of SERCA2a gene therapy on measures of lung dynamics was 
determined. Only small numbers of animals were available for these experiments. 
The increase in opening volume in CHF animals compared to AMC animals 
appeared to be present, but was not statistically significant (figure 6.15A). SERCA2a 
gene therapy appeared to reduce the “opening volume” towards that seen in the AMC 
group, although again this change was not statistically significant. The subsequent 
curves of “lung dynamics” again appeared similar to those previously seen when 
comparing CHF and AMC animals. Treatment with SERCA2a gene therapy 
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appeared to shift the curve from that seen in the CHF animals towards that seen in 
the AMC animals (figure 6.15B). Again further experiments need to be performed to 
confirm this finding. 
 
 
Figure 6.15 Effect of SERCA2a gene therapy on measures of lung dynamics in age matched 
controls (AMC; black line) rats or animals post left coronary artery  ligation with (MI + 
SERCA; green line) or without (MI; red line) SERCA2a gene therapy 
Intact left lungs were harvested from male SD rats at 20-22 weeks post LCA ligation with or without 
SERCA2a gene therapy at 16 weeks, and age matched controls. Lungs were briefly stored in a sterilin 
on ice and the left main bronchus intubated with a 16G catheter. A manometer was attached via a 3-
way tap and increments of 0.5ml of normal saline injected into the lung. After each aliquot of saline 
the 3-way tap was re-directed and the pressure from the lung measured (cm H20). The volume instilled 
at which an initial reading on the manometer was obtained was recorded (opening volume: A) The 
manometer reading for each subsequent 0.5ml of volume instilled was then recorded (B). Aliquots 
were added to a total of 7ml and the return collected. AMC n=3; MI n=4; MI + SERCA n=5. Kruskal-
Wallis test applied with Dunn’s multiple comparison post test. 
 
6.3.13. The effect of gene therapy on bone morphogenetic protein (BMP)-9 and 
bone morphogenetic protein receptor (BMPR)-2 gene expression in whole rat 
lung 
Work described in chapter 5 identified BMP-9 as a stimulator of ET-1 by 
PAEC. Acquired deficiencies in the BMPRs is associated with secondary forms of 
PAH, although BMPR1a expression was decreased in CHF (Du et al. 2003). It is 
possible that a loss of BMPR expression or function results in unopposed TGF- 
signalling and Smad independent BMP-9 signalling. To determine whether either 
BMPR2 or BMP-9 expression were altered in this model of CHF, gene expression 
levels were analysed in whole lungs of AMC animals and animal post LCA ligation 
with or without SERCA2a gene therapy. BMP-9 gene expression was detected at 
only very low levels in whole rat lungs with poor primer efficiencies rendering it 
impossible to determine whether there is no BMP-9 gene expression in the rat lungs 
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or if the level is simply too low to obtain an accurate evaluation. BMPR2 gene 
expression was not altered by LCA ligation or SERCA2a gene therapy (figure 6.16). 
mRNA was extracted from 0.05-0.1mg of snap frozen whole lung from male SD rats at 20-22 weeks 
post left coronary artery ligation with (MI+SERCA) or without (MI) SERCA2A gene therapy or from 
AMC litter mates. BMPR2 gene expression was determined by RT-PCR, normalised to the expression 
of two housekeeping genes (HKG) and expressed relative to gene expression in a standard DNA 
samples comprising of a mix of DNA from all samples. N=5 in all groups. Kruskal-Wallis test applied 
with Dunn’s multiple comparison post test. 
 
6.4. Discussion 
6.4.1. Summary of important findings 
SD rats subjected to LCA ligation have heavier but not wetter lungs as 
evidenced by an increase in LW:BW ratio without an increase in wet:dry weight ratio 
(figure 6.2). Dry weight: body weight ratio trended towards an increase in CHF 
animals, but did not reach significance (figure 6.3). SERCA2a gene therapy restores 
LW:BW ratio towards normal (figure 6.10).  
Gene expression of components of the ET-1 system and inflammatory 
mediators MCP-1 and IL-6 were increased in whole lung extracts from CHF animals 
compared to AMC animals (figure 6.4 & 6.5), and the effects were attenuated by 
SERCA2a transfection (figure 6.11). MCP-1 protein levels were also elevated in the 
serum and BAL from animals with CHF (figure 6.6). It is not known whether 
SERCA2a gene therapy attenuates these changes. BMPR2 gene expression was not 
altered by either LCA ligation or SERCA2a therapy (figure 6.15). Human SERCA2a 
gene expression could not be reliably detected in the lungs of any of the animals and 
Figure 6.16 Effects of left coronary artery ligation with or without SERCA2a gene therapy on rat 
whole lung bone morphogenetic protein receptor (BMPR)-2 gene expression. 
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neither could BMP-9 expression. ERK1/2 phosphorylation was increased in lungs of 
CHF animals (figure 6.8). 
Measures of lung “dynamics” also differed between AMC post LCA ligation 
animals. These changes might reflect differences in lung compliance. Parameters 
returned towards normal levels with SERCA2a gene therapy (figures 6.10, 6.15). 
 
6.4.2. Effect of chronic heart failure on lung weights and histology 
At 16 weeks post LCA there was an increase in LVEDP, HW:BW and LW:BW 
without an increase in wet:dry lung weight . The lungs of CHF rodents are heavier 
but not wetter than control animals. A possible explanation is that the lungs have 
remodelled by laying down excess extracellular matrix in response to a higher 
LVEDP. Unfortunately, in initial animal cohorts the amount of lung homogenised for 
wet:dry weight was not standardised and consequently the dry weight could not be 
compared between animals or groups. Latterly this was addressed by taking the left 
lung for dry weight analysis, allowing a dry weight to body weight (DW:BW) ratio 
to be compared between animals. No differences were seen in the DW:BW ratio 
between the groups, but further numbers are required to confirm this.  
These findings are consistent with previously published data. CHF lungs are 
heavier and stiffer due to structural remodelling with increased collagen content 
(Jasmin et al. 2003; Da Silva et al. 2006; Dixon et al. 2009; Jiang et al. 2010). It is 
likely these changes underlie the differences seen here, but should be confirmed by 
histological analysis and more sensitive measurements of collagen content because 
collagen or fibrotic changes may not be evident under light microscopy alone (Dixon 
et al. 2009).  
Closer inspection of the wet:dry weights identified a potential increase in the 
SERCA2a treated group. This highlights an important potential hazard of reversal of 
structural remodelling in the lung in CHF. A physiological benefit of structural 
remodelling of the lung in CHF is that the ACM is able to endure a higher LAP 
before pulmonary oedema occurs. Reversing these changes, particularly if they occur 
more rapidly that improvements in cardiac hemodynamics, may restore susceptibility 
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to pulmonary oedema (reflected by an increased wet:dry weight ratio) and be 
detrimental. 
6.4.3. Differences in gene expression are seen at 16 weeks of heart failure 
Analysis of whole lung gene expression reveal differences in expression of 
ET1, ETAR, ETBR and MCP-1. Increases in ET-1 gene expression has been shown in 
several different models of CHF (table A.2, Appendix A). A decrease in ETBR 
expression also occurred at 3 and 12 weeks post LCA, but neither group showed any 
alterations in ETAR expression (Kobayshi et al. 1998; Lepailleur-Enouf et al. 2001). 
Twelve weeks of tachycardia induced heart failure in dogs did not alter ETBR gene 
expression, but did decrease the affinity of ETBR for ET-1, resulting in an increase in 
circulating levels of ET-1 (Dupuis et al. 1998). The differences in ETAR expression 
between this work and others might be due to the later 16 week time point and also 
the model used. Increases in MCP-1 gene and protein, and IL-6 gene expression seen 
confirm previous findings (Gaertner et al. 2003; Tonnessen et al. 2003). 
Measurement of ET-1 protein levels in serum and BAL should be addressed in future 
work. 
These changes are important for a number of reasons. Firstly, regarding the 
difference in MCP-1 and IL-6 expression, they confirm the lung as a potential source 
of inflammatory mediators in CHF, and not simply a passive bystander. Secondly, 
the changes in ET-1, ETAR and ETBR may shed light on the disappointing outcome 
of clinical trials applying ETRAs to CHF. The pulmonary vasculature is understood 
to be the primary source of clearance of circulating ET-1, predominantly via the 
ETBR. Reduction in ETBR therefore is likely to result in an increase in circulating 
ET-1, with detrimental effects, such as vasoconstriction and cellular proliferation. 
These consequences of increased ET-1 activity would be compounded by blockade 
of the receptor by mixed ETRAs (e.g. Bosentan). In theory, selective ETAR 
antagonists should be a more attractive therapy, but again outcomes in clinical trials 
have not mirrorred haemodynamic benefits (table 1.1). This implies that blocking the 
ETAR in the presence of decreased ETBR expression is not sufficient for clinical 
improvement, and hence ET-1 confers some benefit via the ETAR, or ET-1 levels are 
simply a marker of disease rather than a causative agent. Bosentan does not attenuate 
PAH, right ventricular hypertrophy or lung remodelling at 5 weeks post LCA 
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ligation. It would be interesting to see if the same is true for a selective ETAR 
antagonist (Jiang et al. 2010). 
6.4.4. Measures of lung dynamics are altered in animals with chronic heart 
failure 
Lung remodelling is present in animals post MI with a decrease in lung 
compliance (Ben Driss et al. 2000; Dixon et al. 2009; Jiang et al. 2010). In the 
absence of previous experience or available techniques to measure lung compliance, 
a simplified method to measure lung dynamics was applied here. The initial volume 
of normal saline required to produce a recordable pressure in a manometer in an 
intubated single lung was taken as a approximation of lung stiffness: i.e. the more 
volume required to open a lung the stiffer it was. CHF animals required more volume 
and were deemed to have “stiffer” lungs, an effect that appeared to be restored to 
normal after SERCA2a gene therapy. This method is far from a “gold standard”, but 
did allow a comparison between groups. It is accepted that it may also not be purely 
measuring lung stiffness or compliance. In addition, subsequent volume pressure 
measurements were recorded. A blunting of the response was seen in animals with 
CHF, with some restoration of normality by SERCA2a gene delivery. The exact 
meaning of these data is uncertain. The opening volume may not simply reflect lung 
stiffness, but also may represent the lung’s ability to absorb or accommodate fluid, 
there being a greater ability in the CHF lungs. Furthermore, the “dynamic” curves 
may also reflect that CHF lungs are able to absorb or accommodate fluid in the 
ECM/alveolar space, hence showing a blunting of the dynamic curve with a shift 
down and to the right. Changes in pulmonary surfactant levels are seen post MI and 
might alter fluid handling by the lung (Dixon et al. 2009). 
An alternative interpretation of these data is that they represent a difference in 
elasticity or elastic recoil- AMC lungs recoil more effectively and produce a higher 
pressure for the given volume. It could also be argued to show that the CHF lungs are 
less stiff because they recoil less forcibly to produce less pressure for a given 
volume, but these lungs are also more difficult to expand, requiring higher volumes 
per cmH20. Whatever the true physiology underlying the changes seen, these data 
indicate a difference in the fluid-measured dynamics of the lungs and that SERCA2a 
gene therapy may influence these changes. This system does not measure true 
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compliance, to do so would require a measure of lung volume for a given pressure 
and such systems were not available here. Collaboration with groups able to do this 
would be beneficial to future work. 
6.4.5. ERK 1/2  pathway activation in whole lung after myocardial infarction 
The MAPK signalling pathways are involved in cardiac hypertrophy, fibrosis 
and cellular apoptosis (chapter 1.10.5) (Muslin 2008). To date, the involvement of 
these pathways in the lung in CHF has not been determined. EC subjected to 
mechanical strain activate the MAPK pathways and release MCP-1 in an ERK 
dependent manner (chapter 4) (Wang et al. 1993; Kito et al. 2000). If the hypothesis 
that MCP-1 release in the lung in CHF is stimulated by mechanical strain at the 
pulmonary microvasculature is true, then activation of the MAPK pathways, 
specifically ERK, is likely. The data here are inconclusive regarding an increase in 
MAPK phosphorylation in CHF animals. There was a significant increase in p44 
ERK, but an insignificant increase in p42 MAPK phosphorylation in four animals 
studied. It is noticeable that in two of the AMC animals the baseline ERK 
phosphorylation was relatively high. This highlights a methodological problem with 
this study. The lungs in these experiments are a bi-product of ongoing work into the 
effect of SERCA2a gene therapy on cardiac function and biology and as such this 
lung work is entirely observational. During sacrifice the lungs are intubated and 
ventilated during which time the heart is accessed via the diaphragm, with an 
abdominal incision, in order to ensure that any chest wall- pericardial adhesions can 
be dissected to prevent cardiac rupture. As a result, two potential confounding factors 
may have affected the results independent of the hemodynamic effects of the MI. 
The duration of intubation can vary and the tidal volume delivered to the lungs by 
mechanical ventilation is not standardised (it was not possible to do so accurately 
with the equipment available). Both mechanical ventilation and injurious mechanical 
ventilation stimulate MAPK activation in animal models of ventilator induced lung 
injury (VILI) (Nakamura et al. 2001; Pinhu et al. 2003). In order to accurately 
determine if MAPK are activated in the lungs of CHF animals these parameters need 
to be standardised. Furthermore, the role of ERK1/2 activation should ideally be 
further addressed by the use of MEK 1/2 pharmacological inhibitors in AMC and 
LCA ligation animals. In addition, if possible, the expression of MCP-1 should be 
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analysed post LCA ligation in lungs of mice with genetically manipulated ERK 
signalling (Purcell et al. 2007). 
6.4.6. SERCA2A gene therapy partially reverses the changes seen in gene 
expression and lung “dynamics” in animals with chronic heart failure 
The SERCA2a gene is a promising therapeutic target in the treatment of heart 
failure, improving haemodynamic parameters and mortality in animal models (del 
Monte et al. 2001). It is not known how these improvements affect the lung, but an 
understanding of this will be important in the clinical setting. Dyspnoea is the 
predominant symptom in CHF and PAH imparts a poor prognosisc (Kirklin et al. 
1988; Lewis et al. 2001). Consequently even if cardiac haemodynamic parameters 
are improved, if pulmonary remodelling (both vascular and structural) are fixed, then 
symptoms and outcome will remain poor. 
This work shows that SERCA2a gene therapy is able to reverse gene 
expression in the lungs of animals with CHF and potentially reverse changes 
representing structural remodelling (i.e. LW:BW), although these findings require 
confirmation. SERCA2a gene expression was not found in the lungs of animals in 
this study. Systemically delivered SERCA2a via adenoviral vector in pigs leads to 
expression of the gene in the lung at 5 days post injection and in the RV and 
pulmonary arteries at 90 days (Hajjar et al. 2008). SERCA2a gene therapy reduces 
VSMC proliferation and angioplasty associated re-stenosis in rat carotid arteries 
(Lipskaia et al. 2005). VSMC proliferation is believed to be important in the 
pathophysiology of vascular remodelling in PAH. Thus, if SERCA2a were to be 
incorporated into the lung, such anti-proliferative effects would be of potential 
benefit in this remodelling process. It is therefore possible that protein expression 
will be evident in the lungs in these experiments, and if so the SERCA2a could be 
having direct effects on pulmonary physiology.  
Further work is therefore required to determine more accurately the 
expression of SERCA2a in the lung after gene therapy, initially by western blotting, 
but also using fluorescence labelling and measurements of the transfected gene. This 
will also enable effectiveness of the gene therapy to be determined and correlation of 
subsequent changes to this. If SERCA2a protein is not seen in whole lung lysates 
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then it is unlikely that SERCA2a is having a direct effect on the lung and 
consequently changes are presumably due to effects on hemodynamic parameters.  
6.4.7. Bone morphogenetic Protein (BMP)-9 and BMP receptor (BMPR) 2 
Abnormalities in expression of members of the BMPR family occur in 
acquired forms of PAH (Eddahibi et al. 2002; Du et al. 2003). The consequence of a 
reduction in BMPR signalling is a postulated release of inhibition of TGF- 
signalling (through loss of Smads 1/5/8 activity) and an increase in BMP Smad 
independent signalling. BMP-9 increases ET-1 release by PAEC via a Smad 
independent pathway and hence could lead to increase in ET-1 levels in the absence 
of BMPR signalling. Gene expression of BMPR2 was not altered in CHF animals 
(figure 6.15). Protein levels were not assayed and should be determined by Western 
blotting because BMPR2 gene expression may not accurately represent protein levels 
(personal communication with P. Upton, Cambridge, UK). This does not exclude 
abnormalities in BMPR signalling in this system, which will require analysis of other 
receptors (BMPR1s) and signalling pathway components (Smads 1/5 and Smads 
2/3).  
Attempts to determine levels of BMP-9 were unsuccessful. PCR CT values for 
gene expression were high, suggesting very low levels of expression, and primer 
efficiency was poor. A commercially available primer was used to avoid problems 
with primer design. ELISA assays for protein level are not yet commercially 
available, although functional assays have been reported (Herrera and Inman 2009). 
The effect on CHF on BMP-9 expression in the lung therefore remains unknown. 
6.5. Further Work 
6.5.1. Lung histology, dry weights and collagen content 
Histological analysis of lungs post LCA have revealed a spectrum of 
remodelling related changes, ranging from visible increased collagen to only 
thickening of the ACM (Ben Driss et al. 2000; Jasmin et al. 2003; Kingsbury et al. 
2003; Dixon et al. 2009). Preliminary work on these experiments (one animal in each 
group; not shown) suggest only increased ACM thickening, without evidence of 
increased collagen staining. These samples need to be repeated and morphometric 
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analysis made to assess ACM changes and the effect of SERCA upon this. 
Furthermore, DW:BW sample numbers need to be increased as animals become 
available to determine the effect of CHF and SERCA2a.  
High phase liquid chromatography provides a more sensitive measure of tissue 
collagen content and it is planned to measure this in subsequent experiments. This, 
coupled with histological assessment, will also determine if the increased lung 
weights seen are due to increases in structural components of the lung or increased 
inflammatory infiltrates. 
6.5.2. Bronchoalveolar lavage white blood cell counts 
Total white cell count is raised in BAL from CHF animals without an increase in any 
one cell type (Dixon et al. 2009). Increases in WBC numbers suggest active 
inflammation in the pulmonary system and supports a hypothesis that the lung is a 
source of these mediators in CHF. A protocol for measurement of total and 
proportional white blood cell (WBC) numbers in BAL has recently been established 
and future work will investigate this. 
 
6.5.3. Cytokine and chemokine modulation 
Treatment with mixed ETRA has been unsuccessful in CHF animals (Jiang et 
al. 2010). In addition to the effect of gene therapy, studying the effect of MCP-1 or 
IL-6 inhibition on pulmonary remodelling post LCA ligation would be important in 
determining the functional importance of these mediators in the pathophysiology of 
pulmonary remodelling in CHF. Furthermore the effect of MEK 1/2 inhibition in 
animal experiments would also determine the importance of this signalling pathway 
in CHF induced pulmonary remodelling and inflammation. 
6.6. Summary 
The lungs of rats post LCA ligation (MI) are heavier, but not wetter, than those 
of AMC animals suggesting pulmonary remodelling has occurred. Gene expression 
of ET-1 and its receptors altered, potentially increasing levels of ET-1 (increased 
transcription and decreased clearance) and increasing the more proliferative and 
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fibrogenic actions via the ETAR. MCP-1 lung gene expression, and BAL and serum 
levels are also increased in post MI animals, but SERCA2a gene therapy attenuated 
both these changes and the changes seen in the endothelin system. ERK 1/2 activity 
is non-significantly increased in rat lungs after MI, supporting the possibility that 
mechanical strain sensed by the EC in response to PVH is stimulating this signalling 
pathway. 
Further work is required to confirm and more rigorously test these findings but, 
thus far, they identify the lung as a contributor to inflammation in CHF and that gene 
therapy may alter pulmonary changes seen in CHF. 
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7. Chapter 7: General Discussions 
 
7.1. Summary of important results 
7.1.1. Establishment of a robust model of strain induced endothelial cell mediator 
release 
Initially, HLMVEC subjected to static mechanical strain released IL-8 and ET-1 
and supernatants increased fibroblast proliferation and differentiation in an ET-1 
dependent manner. This effect did not persist across cell donors and so alternative 
mediators were investigated using both primary HLMVEC and Ea.hy 926 cells (an EC 
cell line). MCP-1 was robustly upregulated by both HLMVEC and Ea.hy 926 cells by 
CMS (4 hours; 30%; 0.3Hz). There was no effect on cell viability or LDH release by 
cells in response to either SMS or CMS. 
7.1.2. Mechanotransduction signalling pathway of cyclic mechanical strain 
induced monocyte chemoattractant protein (MCP)-1 release 
CMS induced activation of ERK 1/2, JNK 1/2 and p38 MAPK, with peak 
activation at 10 minutes for JNK and p38 and at 30 minutes for ERK 1/2 in Ea.hy 926 
cells. HLMVEC phosphorylated ERK 1/2 in response to CMS with a peak at 5-10 
minutes. Pharmacological inhibitors of the three MAPK pathways showed that only 
UO126 and PD98059 (MEK1/2 inhibitors) attenuated CMS induced MCP-1 protein 
release and gene expression by EC. Nuclear extracts identified p90RSK as a downstream 
component of CMS induced signalling, entering the nucleus with phosphorylated ERK 
after 30 minutes of CMS. Attempts to determine the upstream components of the 
pathway, specifically Ras, were unsuccessful: dominant negative (dn) Ras transfection 
did not abolish MCP-1 protein expression, mRNA upregulation or ERK 1/2 
phosphorylation. The continued phosphorylation of ERK 1/2 in the presence of dnRAS 
suggests either the dnRas was not functioning as intended or that ERK1/2 is 
phopshorylated via an alternative mechanism.  
Induction of MCP-1 in other systems commonly involves the NFB signalling 
pathway. Both pharmacological inhibition of this pathway (SC514) and dominant 
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negative I transfection failed to attenuate MCP-1 protein release by Ea.hy 926 cells, 
suggesting that NFB signalling was not important in this system. 
Supernatants from stretched Ea.hy 926 cells increased fibroblast differentiation 
and proliferation of PASMC. Experiments using antibody inhibition of MCP-1 are 
required to determine the role of MCP-1 in this system. In preliminary experiments 
monocyte migration was also increased in the presence of conditioned media from cells 
subjected to stretch. Further experiments, again including the use of MCP-1 blocking 
antibody, are required to confirm these results and the role of MCP-1 in both the cell 
line and in the primary HLMVEC. 
7.1.3. Bone morphogenetic protein (BMP)-9 increased endothelin-1 (ET-1) release 
by pulmonary artery endothelial cells (PAEC) in a Smad independent, p38 MAPK 
dependent manner 
Vascular remodelling analogous to that seen in PAH occurs in CHF. BMPR2 
mutations are believed to underlie the pathophysiology of primary idiopathic PAH. 
Decreased BMPR2 and BMPR1a expression are seen in secondary forms of PAH in 
addition. BMP-9, a member of the TGF- superfamily, stimulates PAEC to produce IL-
8, E-selectin and IL-6 through Smad 1/5 signalling. It is also able to signal through 
Smad-2/3, the usual pathway through which TGF- signals. We investigated the ability 
of BMPs to stimulate ET-1 release by PAEC to determine whether this molecule has a 
potentially important role in pulmonary remodelling in CHF. BMP-9 increased ET-1 
release and gene expression by PAEC at physiological concentrations (0.1-3ng.ml). An 
increase in gene expression was seen at 2 and 24 hours. In addition BMP-9 decreased 
MCP-1 gene expression and release by PAEC. BMP-9 stimulated ET-1 release occurred 
independent of Smad signalling as shown by the failure of siRNA directed against 
Smad-4 to abolish this response. In light of these results we investigated the ability of 
BMP-9 to activate MAPK and the effect of pharmacological inhibition of MAPK on 
BMP-9 induced ET-1 release. As expected BMP-9 robustly activated Smad 1/5, but of 
the MAPKs only p38 was phosphorylated after 30 minutes of stimulation. Inhibition of 
p38 (SB203580) attenuated ET-1 protein release, but did not prevent increased gene 
expression at 2 or 24 hours. Co-incubation with ETAR or ETBR antagonists did not 
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attenuate the BMP-9 stimulated increase in ET-1 gene expression at 24 hours, 
suggesting that increase in gene expression at the later time point is not the result of ET-
1 autocrine feedback. Neither BMP-9 stimulation nor p38 inhibition altered ECE or 
ETBR gene expression, which is important in ET-1 synthesis and clearance respectively. 
Further work is necessary to determine the receptors and pathway through which 
BMP-9 increased ET-1 gene expression and how p38 potentiated this effect. Inhibition 
of NFB (SC514) attenuated ET-1 protein release in a dose-dependent manner 
suggesting a potential role for NFB signalling in BMP-9 induced ET-1 transcription. 
7.1.4. Left coronary artery (LCA) ligation animal model of chronic heart failure 
and the effect of SERCA2a gene therapy 
Lung specimens were available from a 16 week post LCA ligation model of 
CHF. The lungs of these animals were heavier but not wetter than AMC animals. 
Increased ET-1, ETAR, MCP-1 and IL-6 gene expression was identified in the lungs of 
CHF animals. ETBR expression was reduced in the lungs of animals with CHF and there 
was no change in ECE expression. MCP-1 protein levels were increased in the serum 
and BAL of animals with CHF and BAL levels correlating with a surrogate of infarct 
severity. A crude measure of lung mechanics revealed the heart failure lungs to be 
stiffer. There was a non-significant increase in ERK 1/2 phosphorylation in the lungs of 
CHF animals. 
A subsequent group of animals was treated with systemically delivered human 
SERCA2a gene therapy at 16 weeks post LCA ligation, and then sacrificed after a 
further 4-6 weeks. CHF animals had an increased LW: BW ratio, but SERCA2a treated 
animals did not. SERCA2a treatment also attenuated the changes in gene expression 
described above. There was no difference in BMPR2 expression in the three animal 
groups and BMP-9 gene expression was not detected in any of the cohorts. Human 
SERCA2a gene expression could not be detected in any of the cohorts. Further work 
will address lung histology and cellular composition of the BAL. 
This thesis therefore describes the CMS dependent induction of MCP-1 in EC 
via an ERK 1/2 dependent pathway. Conditioned media from cells subjected to 
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mechanical strain altered fibroblast and PASMC proliferation, fibroblast differentiation 
and monocyte migration.  
BMP-9, a member of the TGF- superfamily, increased ET-1 release by PAEC 
in a Smad dependent manner.  This effect may contribute to vascular remodelling of 
primary or acquired PAH. 
Our animal model of CHF showed evidence of pulmonary structural remodelling 
and induction of inflammatory and fibrogenic mediators, namely ET-1, MCP-1 and IL-
6. SERCA2a gene therapy attenuated these changes. 
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Figure 7.1 maps the results from this thesis onto the initial hypothesis. 
Results are shown in green boxes. Gree arrows from the boxes illustrates how the results map onto the 
original hypothesis. 
Abbreviations: PMVEC- pulmonary microvascular endothelial cells; ET-1– endothelin-1; ETAR- 
endothelin A receptor; ETBR- endothelin B Receptor;  MCP-1- Monocyte chemoattractant protein-1; 
ACM- alveolar capillary membrane; BMPR- bone morphogenetic receptor protein; TGF- transforming 
growth factor; BMP- bone morphogenetic protein; EC- endothelial cell; PASMC- pulmonary artery 
smooth muscle cells; LCA- left coronary artery; HFL-1- human fetal lung fibroblast-1 cells; PAEC- 
pulmonary artery endothelial cell; MI- myocardial infarction; AMC- age matched control. 
 
 
 
7.2. Experimental Models 
7.2.1. Flexercell™ Apparatus 
The Flexercell apparatus was used to apply mechanical strain to Ea.hy 926 and 
HLMVEC to model the effect of PV hypertension at the PMV. In vitro stretch systems 
have emerged as invaluable devices for the study of mechanical strain, which help to 
elucidate the molecular machinery regulating stretch-induced responses in cells. Among 
a variety of devices, the Flexercell Strain UnitTM (Flexercell International Corporation) 
has been widely used to deliver quantified mechanical stimuli to various cell or tissue 
Figure 7.1 Summary of the results of this thesis and how they map onto the initial hypothesis 
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culture systems (Edwards et al. 1999; Rose et al. 1999; Vlahakis et al. 1999; Waters et 
al. 1999; Edwards et al. 2000) It is a computer-controlled cell deformation apparatus 
that generates programmed stretch regimens of defined intensity, duration and 
frequency. At the higher amplitudes of stretch used in our experiments, it is not possible 
to administer equibiaxial stress so that there is considerable in homogeneity in the strain 
experienced by cells at different positions on the plate. Furthermore, the apparatus is 
quite cumbersome – for example it would not be possible without considerable 
modification to capture images of cells during CMS. For this type of experiment it 
would be useful to have a twisting cytometer which allows stimulation of cells by 
pulling micro-beads coated with integrin ligands attached to the cell surface.  
There are further limitations to this model. The ACM is comprised of epithelial 
and endothelial cells and interstitial cells. It is likely that all contribute to the 
pathophysiology of remodelling at the ACM and all are likely to be exposed to the 
mechanical forces. Co-culture experiments would therefore be preferable in 
investigating the effects of mechanical strain, but the Flexercell™ limits the application 
of strain to monolayers only. It is possible that our model has selected the wrong cell to 
stretch- are the AT2 cells or the resident fibrocytes more important? The EC are best 
placed to sense changes in pressure from the vasculature and the PMV is the direct 
upstream target of raised left atrial pressure. Furthermore, in vitro mediator release 
mirrors in vivo changes in gene expression, and relevant mediators (IL-6 and MCP-1) 
have been localised to the endothelium in CHF models (Gaertner et al. 2003; Tonnessen 
et al. 2003). We would consequently argue that if picking one cell, the EC is the best to 
study. 
A maximal 30% strain was applied to our cell monolayers. It is entirely 
unknown to what degree the pulmonary microvasculature is chronically stretched in 
heart failure, only that pressures can be raised to a level that is enough to cause stress 
failure and hence pulmonary oedema. It is therefore possible that this model over or 
underestimates the mechanical strain at the PMV. It is difficult to determine how the 
degree of mechanical stretch could be estimated and is a limitation that must be 
accepted. 
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7.2.2. Tissue myography 
An alternative to EC monolayer cell stretch, and a potential method of 
confirming our findings, would be to stretch directly segments of human or animal 
pulmonary veins. This would allow direct determination of gene expression and 
mediator release from the pulmonary veins and has the potential of allowing comparison 
of veins from AMC animals and CHF animals with and without SERCA2a gene 
therapy. 
7.2.3. Primary human lung microvascular endothelial cells and Ea.hy 926 
The availability, cost and limited life span of primary HLMVEC was a 
significant limitation to this work. The cells proved difficult to grow in enough numbers 
for stretch experiments before changing morphology or ceasing to divide. The cost of 
purchasing large numbers of cells was prohibitive and so an alternative was needed. The 
Ea.hy 926 cell provides a good working alternative, but does have obviously has 
limitations of its own. Firstly it is the fusion of A549 cells and HUVEC. The A549 a 
bronchoalveolar carcinoma cell line with some properties of alveolar epithelial cells but 
also has its own mechanosensitive properties that may have influenced results. HUVEC 
themselves were a viable alternative, but repeated attempts to grow these cells on 
BioFlex™ plates and to stretch them without cell detachment were unsuccessful. The 
component of the HUVEC in the Ea.hy 926 cell was felt to be appropriate because we 
wanted to investigate a venous endothelial cell. The limitations however, of using a cell 
line are accepted and we hope to extract HLMVEC from lung tissue samples available 
to our laboratory. 
It is not known why the initial batch of cells responded differently to mechanical 
strain in comparison to subsequent batches. Thoroughly working back through the 
experimental protocol did not identify any inadvertent methodological difference and 
cells were continually reviewed under light microscopy and did not take on an abnormal 
morphology. Possibilities for the difference are that the cells (and donor) were 
genetically different from subsequent ones, or that the cells had transformed or 
differentiated in vitro in a way that was not apparent under light microscopy. 
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7.2.4. Rat left coronary artery ligation model of chronic heart failure 
We were fortunate to have access to this model from our collaborators. It is well 
tested and considered to be a good representative model of CHF (Hearse and Sutherland 
2000). Investigation into the pulmonary responses to CHF was essentially a parallel 
experimental pathway alongside the collaborators primary work addressing the effect of 
SERCA2a gene therapy on cardiac cell biology. This arrangement was associated with 
limitations already described because the lungs were of secondary importance to the 
heart. Our ability to measure lung compliance was especially limited and future work 
would hope to improve upon this. This work, however, provides an important further 
insight into the pulmonary adaptation to CHF and responses to gene therapy induced 
haemodynamic changes. This is particularly vital if, as expected, clinical trials of 
SERCA2a gene therapy are to proceed (Lipskaia et al. 2010). 
7.3. Clinical Importance 
CHF is an increasingly common and severely debilitating disease with a poor 
prognosis (Croft et al. 1999; Hobbs et al. 2002; Lacey and Tabberer 2005). Dyspnoea is 
a major symptom and the majority of sufferers would swap an improvement in 
symptoms for life expectancy (Lewis et al. 2001; Hobbs et al. 2002). Shortness of 
breath is due, at least in part, to structural remodelling of the AMC, which, alongside 
pulmonary vascular remodelling, results in right heart failure and worsens prognosis 
(Agostoni et al. 2000; Kjaergaard et al. 2007). 
This work provides further insight into the pathophysiology underling CHF. 
Inflammation has been regarded as important in the disease progression of CHF, but the 
sources of the inflammatory mediators are not entirely clear. Here we have identiied the 
lung as a potential source of inflammatory mediators, including MCP-1 and IL-6, and 
that back pressure from raised LAP is a potential stimulus for their production. 
Mediators released by strained EC are able to recruit inflammatory cells and stimulate 
fibroproliferation. Consequently this work provides a mechanistic basis on which to 
advance prospective therapies, including for example, inhibitors of MCP-1 or IL-6. 
Such inhibitors are in the research domain and, in the case of MCP-1, are already being 
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considered in other cardiovascular disease states, notably atherosclerosis (Xia and Sui 
2009).  
The work identifying Smad independent release of ET-1 by PAEC in response to 
BMP-9 is important in advancing the understanding of pulmonary vascular remodelling 
in both primary and secondary PAH. BMPR1 or 2 deficiency is thought to be important 
in the pathophysiology of primary and secondary PAH. This may result in not only the 
loss of inhibition of the TGF-- Smad-2/3 signalling pathway, but an increase in Smad-
independent BMP signalling, with a resultant increased ET-1 levels and thereby 
worsening PAH. The role of p38 or NFB in this system is not yet fully identified, but 
once understood can potentially provide a novel therapeutic target for p38 or NKB 
inhibitors. 
Finally SERCA2a gene therapy illustrates the potential for plasticity in the 
response of the lung to raised LAP. SERCA2a replacement is an attractive therapeutic 
strategy, but the effects on pulmonary physiology are not known. This work provides 
the first insights into how the lung will respond to SERCA2a restoration delivered 
systemically. Knowing how the lung will change during or after improvements in 
cardiac function is vital. Lung remodelling in CHF on one hand provides a protection 
against pulmonary oedema in the face of raised LAP, but with this protection comes a 
loss of ACM diffusing capacity and dyspnoea. If these changes are irreversible then 
improvement in cardiac parameters in CHF may not improve symptoms in patients. 
Alternatively if the pulmonary remodelling is reversible but proceeds at a pace in 
advance of cardiac recovery then the lungs will become susceptible to pulmonary 
oedema again. The possibility of the lungs being able to “reverse remodel”, however, is 
an exciting one raising the possibility of improving symptoms and outcomes for the 
many sufferers of CHF. 
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Appendix A 
 
Mediators Source Comments Study 
ET-1 Serum Elevated ET-1 levels  Correlated with PHT Cody et al 1992 
ET-1  
Big ET-1 
Serum  
Heart 
Elevated serum ET-1 and big ET-1 in NHYA 3 & 4 patients 
No increase in cardiac tissue Wei et al 1994 
Big ET-1 Serum Elevated Big ET-1  Correlated with functional status and 1 year mortality Pacher et al 1996 
TNF-/ TNF- sR 
IL-6/IL-6sR 
IL-1/IL-1R 
Serum Increased cytokine and sR / Ra levels Cytokine levels correlated with NYHA  Testa et al 1996 
TNF- 
IL-6 Serum 
SOLVD patients (n=514) 
Levels correlated with functional status Torre-Amione et al 1996 
MCP-1 
MIP 1 Serum Levels inversely correlate with LV function Aukurst et al 1998 
IL-6 
TNF- 
TGF- 
Serum Elevated IL-6 and TNF- (relative to receptor levels) Decreased TGF- Aukrust et al 1999 
IL-8 
ENA-78 Serum IL-8 levels inversely correlated with LV function and CI Damas et al 2000 
TNF- / TNF- sR 
IL-6 Serum 
VAST patients (n=1200) 
Cytokines correlated with mortality Deswal et al 2001 
MCP-1, G-CSF, M-CSF Serum High MCP-1 levels correlated with mortality. M-CSF levels were associated with increased risk of death. G-CSF did not correlate with mortality Hohensinner et al 2010 
Table A.1 Summary of pertinent human data of fibrogenic and inflammatory mediators 
Abbreviations: ET-1- endothelin; TNF- – tumour necrosis factor alpha; IL-6 - interleukin-6; IL-6sR – interleukin-6 soluble receptor; IL-1 – interleukin -1 beta; IL-1 
R – IL-1 receptor; MCP-1 – monocyte chemoattractant protein -1; MIP – macrophage inflammatory protein; TGF – transforming growth factor; M-CSF – macrophage 
colony stimulating factor; G-CSF – granulocyte colony stimulating factor. 
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Reference Mediator Model Organ Time Comments 
Dupuis et al 1998 ET-1 Rapid Pacing Lung 3 weeks Increased plasma ET-1 
No change in receptors 
Decreased ETBR ET-1 binding affinity 
Kobayashi et al 1998 ET-1 / ETAR / ETBR LCA Lung 3 weeks Higher lung (protein & mRNA) & plasma ET-1 
Lower protein & mRNA ETBR 
Unchanged ETAR 
Tonnessen et al  1998 ET-1 LCA ung & Heart 1 week Increased mRNA lung 
Localised to epithelial cell and SMC 
Behr et al 2000 MCP-1 Aorto-caval fistula  1 -7 days ↑ MCP-1 mRNA 
Lepailler-Enouf et al 
2001 
ET-1, ETAR, ETBR, 
ECE 
LCA Lung 12 weeks 
 
↑ ET-1 
↓ ETBR 
No change ETAR and ECE 
Gaertner et al 20003 IL-6 
IL-6R 
gp130 
TNF- 
LCA Lung 3 months Increased IL-6 
Decreased IL-6R 
No change gp130 / TNF- 
IL-6 localised to Endothelium 
Tonnessen et al 2003 IL-6 
MCP-1 
CNTF 
LCA Lung One week 
6 weeks 
Increased lung MCP-1 at 6 weeks 
Non-significant increased IL-6 
Differential heart & lung expression 
von Leuder et al 2004 ET-1, ECE Rapid Pacing Lung 21 days ↑ ET-1 serum (step up across pulmonary 
circulation) 
↑ ECE expression 
Dai et a 2004l eNOS 
ET-1 
Aortic banding Lung 12 weeks ↑ ET-1 mRNA, lung protein & serum 
↑eNOS mRNA  
Tan et al 2006 eNOS  
ET-1 
Aortic banding Lung 1 day – 12 
weeks 
↑eNOS mRNA at 1 day and 12 weeks 
↑ ET-1 mRNA at 1day and 4 & 12 weeks 
Ahmed et al  2007 CTGF 
TGF- 
ET-1 
LCA Lung 1 week Increased lung CTGF protein & gene expression  
Increased lung TGF- and collagen I 
Increased macrophage ET-1 
Stumpf et al 2008 MCP-1, IL-6, TNF- LCA Serum 4 weeks Elevated serum levels 
Table A.2 Summary of data of inflammatory mediator expression principally in the lung in animal models of heart failure 
Abbreviations: LCA left coronary artery ligation; ET-1- endothelin; TNF- – tumour necrosis factor alpha; IL-6 - interleukin-6; IL-6R – interleukin-6 receptor; IL-1 – 
interleukin -1 beta; IL-1 R – IL-1 receptor; MCP-1 – monocyte chemoattractant protein -1; TGF – transforming growth factor; M-CSF – macrophage colony 
stimulating factor; G-CSF – granulocyte colony stimulating factor; eNOS- endothelial nitric oxide synthase; CTGF- connective tissue growth factor; SMC- smooth 
muscle cell 
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Appendix B 
Table B.1 Reference gene primers used for selection. The gene sequences of commonly used reference genes were obtained from the NCBI (National Centre for 
Biotechnology Information) database via the PubMed GenBank service. The primers were selected with the aid of Primer3 software. All primers were synthesized by the 
Life Technologies Company ACTB, beta actin; B2M, beta-2-microglobulin; GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; HMBS, hydroxymethylbilane 
synthase; HPRT1, hypoxanthine phosphoribosyltransferase 1; RPL13A, ribosomal protein L13a; SDHA, succinate dehydrogenase complex, subunit A,; UBC, ubiquitin 
C; YWHAZ, tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide; PPIB, peptidylprolyl isomerase B; TBP, TATA box binding 
protein; GUSB, glucuronidase, beta; TUBA1B, tubulin, alpha 1b; POLR2A, polymerase (RNA) II polypeptide A; IL-8, interleukin 8; Fw, forward; Rv, reverse; bp, base 
pairs  
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Gene Primer Pair Size Gene Sequence 
Human Genes    
IL-8 Fwd: TCAGGGAGGCTACCACTTC 
Rev: TACTCCAAACCTTTCCACCC 
157  
ET-1 Fwd: TCAGTTTGAACGGGAGGTTT 
Rev: CAAGCCACAAACAGCAGAGA 
83 NM_001955 
IL-6 Quantitect (Qiagen )  NM_000600 
MCP-1 Fwd: GATCTCAGTGCAGAGGCTCG 
Rev: TGCTTGTCCAGGTGGTCCAT 
73 NM_0002982 
ETAR Fwd: CTCCCACACCCAAGAAGAAA 
Rev: TCGTAGATGTTGTGGGTGGA 
72 NM_001957 
ETBR Fwd: AAGAACAAGTGCATGCGAAA 
Rev: GGATGTCAATGACGATGTGC 
85 NM_000115 
ECE Fwd: ATACTACCGTGCGTGCATGA 
Rev: CGAGCCTCTCAATCAACTCC 
80 NM_001397 
SMA Fwd: AGCCAAGCACTGTCAGGAAT 
Rev: AGAGCCATTGTCACACACCA 
88 NM_001613 
PC1 Fwd: AGCCAGCAGATCGAGAACAT 
Rev: CAGAGTGGCACATCTTGAGG 
88 NM_000302 
Desmin Fwd: CAGGTGGAGGTGCTCACTAAC 
Rev: TGTTCTCTGCTTCTTCCTTCAAC 
127 NM_001927 
Vimentin Fwd: CAGGACTCGGTGGACTTCTC 
Rev: CAGCTCCACCTTCTCGTTG 
81 NM_003380 
vWF Quantitect (Qiagen )  NM_000552 
PECAM Quantitect (Qiagen )  NM_000442 
Rat Genes    
MCP-1 Fwd: CCCAGAAACCAGCCAACT 
Rev: TGCTGCTGGTGATTCTCTTG
88 NM_031530 
ET-1 Fwd: ACCACAGACCAAGGGAACAG 
Rev: GCTCGGAGTTCTTTGTCTGC 
89 NM_012548 
ETAR Fwd: GCCATTGAAATTGTCTCCATCTGG 
Rev: GAACTTGGTCGTGGCGTTGA 
93 NM_012550 
ETBR Fwd: AAGTCGTGTTTGTGCTGCTG 
Rev: TTTATTGCTGGAGCGGAAGT 
123 NM_017333 
 
ECE Fwd: ATCAACAGCACCGACAAATG 
Rev: CTGGTCGAGAAAGGAGCTTG  
81 NM_053596 
 
BMPR2 Quantitect (Qiagen )   
BMP-9 Quantitect (Qiagen )   
Table B.2 Human and Rat gene primers. IL-8- interleukin-8; ET-1- endothelin-1; IL-6- interleukin-6; 
MCP-1- monocyte chemoattractant protein-1; ETAR- endothelin A receptor; ETBR- endothelin B receptor; 
ECE- endothelin converting enzyme; SMA- alpha smooth muscle actin; PC1- procollagen 1; vWF- von 
Willibrand Factor; PECAM- platelet endothelial cell adhesion factor; BMPR- bone morphogenetic protein 
receptor; BMP- bone morphogenetic protein 
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Target Cat No. Host Label Concentration Source 
Phospho-p44/42 MAP Kinase (Thr202/Tyr204)  
Total p42/44 MAP Kinase  
9101 
9102 Rabbit polyclonal None 1 in 1000 
Cell signaling  
(New England Biolabs) 
Phospho-SAPK/JNK (Thr183/Tyr185) 
Total SAPK/JNK  
9251 
9252 Rabbit polyclonal None 1 in 1000 
Cell signaling  
(New England Biolabs) 
Phospho-p38 MAP Kinase (Thr180/Tyr182) 
Total p38 MAP Kinase 
9211 
9212 Rabbit polyclonal None 1 in 1000 
Cell signaling  
(New England Biolabs) 
Phospho-p90RSK (Ser380) Antibody 9341 Rabbit polyclonal None 1 in 1000 Cell signaling  (New England Biolabs) 
Phospho-smad 1/5 9516 Rabbit polyclonal None 1 in 1000 Cell signaling  (New England Biolabs) 
Phospho-smad 2 3108 Mouse monoclonal  None 1 in 1000 Cell signaling  (New England Biolabs) 
Lamin A/C 2032 Rabbit polyclonal None 1 in 1000 Cell signaling  (New England Biolabs) 
Human -actin A5441 Mouse polyclonal None 1 in 4000 Sigma-Aldrich 
Anti-Rabbit IgG (secondary) 7074 Goat polyclonal HRP 1 in 2000 Cell signaling  (New England Biolabs) 
Table B.3 Antibodies used in western blotting
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Appendix C 
Abbreviations: ACTB, beta actin; B2M, beta-2-microglobulin; GAPDH, Glyceraldehyde-3-phosphate 
dehydrogenase; HMBS, hydroxymethylbilane synthase; HPRT1, hypoxanthine phosphoribosyltransferase 1; 
RPL13A, ribosomal protein L13a; SDHA, succinate dehydrogenase complex, subunit A,; UBC, ubiquitin C; 
YWHAZ, tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide; 
PPIB, peptidylprolyl isomerase B; TBP, TATA box binding protein; GUSB, glucuronidase, beta; TUBA1B, 
tubulin, alpha 1b; POLR2A, polymerase (RNA) II polypeptide A; 
 
 
 
 
 
 
 
 
Figure C.1 GeNorm output graphs for (A) human lung microvascular endothelial cells and (B) Ea.hy 926 cells 
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Abbreviations: ACTB, beta actin; B2M, beta-2-microglobulin; GAPDH, Glyceraldehyde-3-phosphate 
dehydrogenase; HMBS, hydroxymethylbilane synthase; HPRT1, hypoxanthine phosphoribosyltransferase 1; 
RPL13A, ribosomal protein L13a; SDHA, succinate dehydrogenase complex, subunit A,; UBC, ubiquitin C; 
YWHAZ, tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide; 
PPIB, peptidylprolyl isomerase B; TBP, TATA box binding protein; GUSB, glucuronidase, beta; TUBA1B, 
tubulin, alpha 1b; POLR2A, polymerase (RNA) II polypeptide A 
Figure C.2 GeNorm output graphs for (C) human fetal lung fibroblast-1 cells and (D) whole rat lung 
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